Bacterial therapy
Through culture and whole genome sequencing technology, bacteria in the human intestinal microbiota are identified and isolated to form therapeutic compositions, which solves the problems that are difficult to isolate and identify in the prior art, and achieves effective treatment and treatment results for dysbiosis. Predictive.
Patent Information
- Application Number
- CN202411270944.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-04-19
- Filing Date
- 2017-04-19
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to isolate and identify specific bacteria for the treatment of dysbiosis, and most of the bacteria in the gut microbiota are considered unculturable, making it difficult to develop effective therapeutic compositions.
Drugs for the treatment of dysbiosis are prepared by culture and whole-genome sequencing, multiple bacteria in the human gut microbiota are identified and isolated, forming therapeutic compositions, and mixed with pharmaceutically acceptable excipients.
Effective identification and isolation of dysbiosis bacteria is achieved, the safety and efficacy of the therapeutic composition is improved, the standardization and predictability of treatment results are ensured, and the uncertainty brought about by the use of fecal materials is avoided.
Smart Images

Figure BDA0005038677110000541 
Figure BDA0005038677110000551 
Figure BDA0005038677110000561
Abstract
Description
[0001] This application is a divisional application of the application with international application date of April 19, 2017, international application number PCT / GB2017 / 051083, entering the Chinese national phase, application number 201780037779.6, and invention name “Bacterial Therapy”. Field of the Invention
[0002] The present invention relates to therapeutic compositions comprising at least one isolated bacterium as defined herein and a pharmaceutically acceptable excipient, as well as methods for preparing such therapeutic compositions. The therapeutic compositions are useful for treating dysbiosis, particularly dysbiosis of the gastrointestinal tract. The dysbiosis may be dysbiosis associated with enterobacterial infection, inflammatory bowel disease, dermatitis, irritable bowel syndrome, metabolic disease, neuropsychiatric disorder, autoimmune disease, allergic disease, cancer, or hepatic encephalopathy. Background Art
[0003] The typical human gut microbiome contains 100–1000 bacterial species. There is extensive compositional diversity between individuals, making each individual's microbiome as unique as a fingerprint (Qin, Li et al. 2010; Nielsen, Almeida et al. 2014). Most bacterial species in the adult microbiome come from four high-level taxonomic groups or phyla: Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. These groups vary in abundance from birth to adulthood and into old age, reflecting changes in environmental influences such as initial delivery mode, diet, invasions such as pathogen infection, and, in many cases, antibiotic use (Dominguez-Bello, Costello et al. 2010; Koenig, Spor et al. 2011; Ottman, Smidt et al. 2012). In adulthood, the gut microbiome is dominated by Firmicutes and Bacteroidetes, both of which are strict anaerobes.
[0004] The gut microbiota plays a key role in digesting foods that are difficult for the human gastrointestinal tract to access, such as metabolizing carbohydrates into short-chain fatty acids (Sekirov, Russell, et al. 2010), interacting with the immune system to maintain homeostasis (Hooper, Littman, et al. 2012), and promoting intestinal maturation (Hooper, Wong, et al. 2001) and immune system development. The gut microbiota also plays an important role in resisting pathogen invasion, a process known as colonization resistance. This is achieved through the diversity and abundance of commensal species, occupation of key ecological niches, and utilization of nutrients (Lawley and Walker 2013; Britton and Young 2014). If microbial homeostasis is disturbed, for example through the use of antibiotics, a shift toward dysbiosis can occur.
[0005] Dysbiosis provides pathogens with the opportunity to establish themselves and cause the individual's disease. It is best studied with respect to single implicated pathogens such as Clostridium difficile (Lawley et al. 2012; Britton and Young 2014; Buffie et al. 2015), but dysbiosis has also been associated with other more complex multifactorial diseases such as inflammatory bowel disease (IBD), impetigo (Angeriman et al. 2014), irritable bowel syndrome (IBS), hepatic encephalopathy (Bajaj 2014; Bajaj et al. 2012), metabolic diseases (including metabolic syndrome, malnutrition and obesity), neuropsychiatric disorders such as Parkinson's disease and Alzheimer's disease, autoimmune diseases, allergic diseases and cancer (Jostins, Ripke et al. 2012, Collins 2014, Hold, Smith et al. 2014, Perez et al. 2015). Martinez, Bauerl et al. 2014, Scheperjans, Aho et al. 2015; Blanton et al. 2016, Xu et al. 2015).
[0006] Fecal microbiota transplantation (FMT) has successfully addressed Clostridium difficile-associated dysbiosis (Petrof et al. 2013, van Nood et al. 2013), and administration of specific bacteria has also been shown to be effective (Lawley et al. 2012, Buffie et al. 2015). FMT has also shown promising results in the treatment of other intestinal diseases and in the management of extraintestinal diseases associated with the gut microbiota, including metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic diseases, and tumors (Xu et al. 2015).
[0007] In recent years, great progress has been made in understanding the role of the gut microbiome in health and disease and how it can be manipulated for the benefit of the host. To date, much of our understanding has been derived through culture-independent studies, using molecular and genomic techniques to investigate the composition of the microbiome and how it changes during disease. This process has allowed the identification of potential therapeutic candidates that could address disease. However, isolating, purifying, and obtaining such candidate therapeutic bacteria has proven difficult.
[0008] Therefore, there is a need in the art to identify and isolate specific bacteria and bacterial combinations that can be used to treat dysbiosis. Therapeutic compositions based on known, defined bacteria or bacterial mixtures are advantageous because they improve patient safety, as they contain only defined and well-characterized bacteria known to promote and not harm human health, and eliminate the possibility of inadvertent transfer of pathogenic agents to recipients via FMT. Furthermore, such therapeutic compositions can be prepared in vitro on a large scale using standardized, reproducible procedures, thereby providing batch consistency and not relying on regular donations from healthy human donors. Therapeutic compositions containing known, defined bacteria or bacterial mixtures can also be delivered therapeutically (e.g., in capsules, tablets, or enemas), which is more readily accepted by patients and healthcare professionals than the fecal material suspensions used in FMT. The bacteria contained in such therapeutic compositions can be further tailored to treat specific ecological conditions and their associated diseases by specifically altering the bacterial composition to optimally address the ecological condition in question and thereby improve efficacy.
[0009] However, in order to isolate such candidate therapeutic bacteria for the treatment of dysbiosis, a thorough understanding of the biology of the candidate in question is required, as well as a large number of preliminary candidates from which to choose. This poses a problem because most bacteria in the gut microbiota are considered unculturable and have never been isolated in the laboratory (Eckburg, Bik et al. 2005, Hattori and Taylor 2009, Stewart 2012). Therefore, gaining a fundamental understanding of the functional properties of the microbiota and developing multispecies bacterial therapeutics with difficult-to-cultivate anaerobic commensal strains is a daunting challenge. Although recent efforts have made progress in addressing this problem (Goodman, Kallstrom et al. 2011, Lagier, Hugon et al. 2015), there remains a need in the art to identify and isolate bacteria capable of treating dysbiosis.
[0010] Description of the Invention
[0011] The present invention relates to therapeutic compositions, particularly therapeutic compositions for treating dysbiosis in an individual. Dysbiosis can occur in any part of the human or animal body that is typically colonized by bacteria and other microorganisms. The present invention particularly relates to dysbiosis in the human gastrointestinal tract.
[0012] The inventors unexpectedly discovered that the majority of bacteria present in the human gut microbiome can be cultured, contrary to the prevailing belief in the field that most human gut microbiota are unculturable. This significant breakthrough now makes it possible to isolate and characterize the majority of bacteria present in the human microbiome and evaluate their activity in treating dysbiosis. This can be applied not only to individual bacterial isolates, but also to combinations of bacteria isolated from the gut microbiome. Furthermore, the isolation of these bacteria allows them to be screened (e.g., for the absence of virulence factors and antibiotic resistance) before inclusion in therapeutic compositions, thereby improving safety. Furthermore, the bacteria included in therapeutic compositions can be tailored to treat specific probiotic conditions and / or diseases associated therewith by optimizing the bacterial composition to address the dysbiosis in question, thereby improving efficacy. This is not possible with FMT, which uses undefined bacterial mixtures (typically obtained from fecal samples of healthy human donors). Another advantage of using isolated bacteria to treat dysbiosis is that it can standardize bacteriotherapy treatments, making patient outcomes more predictable and facilitating the evaluation of bacteriotherapy therapeutic potential by eliminating the variability in bacterial composition associated with the use of FMT in the context of a specific disease.
[0013] By unexpectedly being able to culture the majority of bacteria present in the human gut microbiome, the inventors were able to prepare libraries of enteric bacteria, which they then subjected to whole-genome sequencing and screened using in silico analysis and in vitro assays to identify bacteria potentially useful for treating dysbiosis, particularly dysbiosis of the gastrointestinal tract. Using this approach, the inventors identified 51 bacteria potentially useful for this purpose, including several families, genera, and species of bacteria that had not previously been described, let alone isolated or used to treat dysbiosis. As noted above, the human microbiome was considered unculturable in the art, and therefore the mere disclosure of the 16S ribosomal RNA sequence of one of these bacteria does not, by itself, isolate this bacterium from its natural environment. The disclosure of this 16S ribosomal RNA sequence also does not indicate that a bacterium with this sequence has previously been isolated, as 16S ribosomal RNA sequence information can be obtained from bacterial populations (including fecal samples) without the need to isolate individual bacteria. However, the ability to isolate bacteria in pure form from their natural environment is a prerequisite for their inclusion in therapeutic compositions according to the present invention.
[0014] Thus, in a first aspect, the present invention provides a therapeutic composition comprising at least one isolated bacterium and a pharmaceutically acceptable excipient. The bacterium preferably comprises a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs 1 to 51.
[0015] In addition to a pharmaceutically acceptable excipient, the therapeutic composition may further comprise more than one isolated bacterium. When more than one bacterium is included in the therapeutic composition, the bacterium is preferably different, wherein each bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs 1 to 51. Thus, for example, a therapeutic composition may comprise two different isolated bacteria, wherein the first bacterium preferably comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO 1, and the second bacterium preferably comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO 2.
[0016] As described above, the therapeutic compositions of the present invention can be used to treat dysbiosis, particularly intestinal dysbiosis. Thus, in a second aspect, the present invention provides a therapeutic composition according to the present invention for use in a method of treating dysbiosis, preferably gastrointestinal dysbiosis, in a subject. Also provided are methods of treating dysbiosis in a subject, comprising administering a therapeutically effective amount of the therapeutic composition of the present invention to a subject in need thereof, as well as the use of a therapeutic composition according to the present invention for the preparation of a medicament for treating dysbiosis in a subject. Also provided are the use of at least one isolated bacterium as described herein, preferably comprising a gene encoding 16S rRNA and comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs 1 to 51, and optionally a pharmaceutically acceptable excipient, for the preparation of a medicament for treating dysbiosis in a subject.
[0017] Methods for preparing or manufacturing a therapeutic composition according to the invention also form part of the present invention. Thus, in a third aspect, the present invention provides a method for preparing or manufacturing a therapeutic composition according to the invention, wherein said method preferably comprises the following steps:
[0018] (i) cultivating the isolated bacteria as described herein; and
[0019] (ii) mixing the bacteria obtained in (i) with a pharmaceutically acceptable excipient.
[0020] As described above, the therapeutic composition of the present invention may comprise at least two different isolated bacteria as described herein. When the therapeutic composition comprises more than one different isolated bacteria, the method of preparing or manufacturing the therapeutic composition preferably comprises the following steps:
[0021] (i) cultivating a first isolated bacterium as described herein;
[0022] (ii) cultivating a second isolated bacterium as described herein; and
[0023] (ii) mixing the bacteria obtained in (i) and (ii) with a pharmaceutically acceptable excipient. The bacteria cultured in steps (i) and (ii) preferably have different 16S rRNA sequences. Steps (i) and (ii) are preferably performed independently. By including one or more additional steps for culturing a third or additional isolated bacteria as disclosed herein, the above method can be adapted to include additional steps allowing the cultivation of two or more different isolated bacteria (preferably bacteria with different 16S rRNA sequences). In this case, all bacteria cultured in the method are mixed with a pharmaceutically acceptable excipient.
[0024] Therapeutic compositions obtainable by the methods of preparing or manufacturing therapeutic compositions as disclosed herein also form part of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 A schematic diagram of the workflow for culturing, archiving, and characterizing the gut microbiome is shown. The process includes the following steps: culturing, restreaking, archiving, and phenotyping. (A) Fresh fecal samples are either left untreated or treated to select bacteria with desired phenotypes (such as spore formation). The feces are homogenized and then serially diluted, and aliquots of the homogenate are then plated on YCFA agar to culture the bacteria present in the fecal sample. (B) Bacterial isolates are identified by selecting single colonies, which are then streaked to purity, followed by full-length 16S rRNA gene amplification and sequencing. (C) Each unique, novel, and desirable bacterial isolate is frozen and archived in a culture collection, and a whole genome sequence is generated for each bacterial isolate. (D) Phenotypic characterization and functional validation for metagenomic studies are then performed using in vitro and in vivo methods.
[0027] Figure 2 Targeted phenotypic culture facilitates bacterial discovery from the healthy human fecal microbiome. Figure 2The relative abundance of bacteria in stool samples determined by metagenomic sequencing (x-axis) is compared to the relative abundance of bacteria grown on YCFA agar plates (y-axis). The results show that bacteria grown on YCFA agar are representative of the bacteria present in intact stool samples, as shown by Spearman Rho = 0.75.
[0028] Figure 3 Shown are principal component analysis (PCoA) plots of 16S rRNA gene sequences detected in stool samples from six donors representing bacteria in intact stool samples (open circles), fecal bacterial colonies recovered from YCFA agar plates without ethanol pretreatment (black squares), or from YCFA agar plates pretreated with ethanol (to select for bacteria that form ethanol-resistant spores) (black circles). These results indicate that cultures without ethanol selection represent intact stool samples, while ethanol treatment alters the distribution, enriching for bacteria that form ethanol-resistant spores and allowing their subsequent isolation.
[0029] Figure 4 : Archiving bacterial diversity and novelty through anaerobic cultivation. Figure 4 Figure A shows that the culture conditions employed by the inventors were able to isolate representatives from 21 of the 25 most abundant fecal bacterial genera identified by metagenomic sequencing. Black dots indicate the number of species cultured and archived from each genus. Lachnospiraceae incertae sedis, the unclassified Lachnospiraceae, Clostridium IV, and Clostridium XI are not strict genera and represent currently unclassified species. Figure 4 B shows the 24 most abundant bacterial species (accounting for 90% of the total bacterial abundance at the species level) identified by metagenomic sequencing. All except Odoribacter splanchnicus have been cultured and archived. Figure 4 C shows that members of the gut microbiota present at low abundance were also cultured. At least one representative species from each genus was cultured. Genera are listed in order of decreasing abundance.
[0030] Figure 5 :Phylogeny of cultured and archived bacteria from the fecal microbiota of healthy humans. Figure 5 Shown is a phylogenetic tree of cultured bacteria from six donors constructed from full-length 16S rRNA gene sequences. New candidate species (black circles), genera (grey circles), and families (solid stars) are indicated by point color. Major phyla and families are indicated. Proteobacteria are not cultured but are included for context.
[0031] Figure 6Fecal microbiota transplant (FMT) restores the gut microbiota to a healthy state in patients with recurrent Clostridium difficile (C. difficile) infection. Figure 6 Results of principal component analysis of donors, recipients, and controls 2-3 months after FMT are shown. Clustering of fecal samples indicated similar microbial community structure. Antibiotic use and exposure to C. difficile may have led to a shift from a healthy state, as seen in metronidazole-treated control samples. Treatment of C. difficile infection (CDI) with vancomycin, an antibiotic targeting Gram-positive organisms, may have caused further disruption of the gut microbiota. FMT resulted in a shift from a diseased to a healthy microbiota, with the majority of post-FMT samples clustering with the donor and healthy control samples.
[0032] Figure 7 Taxonomic summary of bacteria isolated from fecal samples of donors, recipients, and controls in a study using FMT for the treatment of Clostridium difficile. These bacterial isolates represent a large cross-section of gut microbiota diversity.
[0033] Figure 8 : Average relative abundance of bacteriotherapy candidate bacteria in healthy individuals. The average abundance of bacteriotherapy candidate bacteria in the gastrointestinal microbiota of 1883 healthy individuals (3218 samples) was greater than 0.001%.
[0034] Figure 9 : Bacteriotherapy candidates are depleted in anemia and disease states.
[0035] The average fold change in the relative abundance of each bacterial therapy candidate in disease and dysbiosis states is plotted compared to its relative abundance in the healthy microbiome. Escherichia coli (a marker of dysbiosis) is also included for comparison. The relative abundance of a bacterium refers to the proportion of the total microbiome represented by the bacterium in question.
[0036] Figure 10 Demonstrates how to measure the clearance zone around bacterial therapy candidates in an overlay assay. Figure 10 A portion of a YCFA agar plate is shown on which a bacteriotherapy candidate bacteria is streaked in an X shape and allowed to grow. After the bacteriotherapy candidate bacteria have grown, the plate is coated with overlay agar containing Clostridium difficile and E. coli. Inhibition of the growth of Clostridium difficile and E. coli by the bacteriotherapy candidate bacteria is measured by determining the width of the clearance zone surrounding the bacteriotherapy candidate bacteria grown on the plate. Figure 10 The black diagonal line in the figure represents the distance measured and recorded as the width of the clearance zone for the exemplary bacteriotherapy candidate. Four such measurements were performed for each plate.
[0037] Figure 11 Results are shown for Clostridium difficile and Escherichia coli growth overlay assays to determine the antipathogen activity of bacteriotherapy candidates. Figure 10 Measure the cleared area with a ruler as shown. Make measurements in millimeters (mm). Figure 11 Mean measurements ± standard deviation of a representative experiment are shown.
[0038] Figure 12 Results of Clostridium difficile and Escherichia coli growth inhibition assays are shown to determine the antipathogen activity of bacteriotherapy candidates. Figure 12 A shows the reduced relative growth of C. difficile in the cell-free supernatant (CFS) of the bacteriotherapy candidate culture at the 18.17 h time point, while Figure 12 B shows reduced relative E. coli growth in CFS from candidate bacteriotherapy isolates. The relative growth of either pathogen in the control YCFA medium was high (C. difficile = 8.96 ± 0.39 relative growth units; E. coli 11.61 ± 2.55 relative growth units at the 18.17 hour time point). Pathogen growth was considered inhibited when the mean and two standard deviations of the relative growth of any pathogen in the CFS from the bacteriotherapy candidate culture were more than two standard deviations lower than the mean growth in YCFA at the 18.17h time point. Only one relative growth value was available for a specific CFS (compared to C. difficile, Figure 12 A: HMI 15, HMI 26, HMI 27, HMI 28), bacteriotherapy candidates were considered inhibitory if the relative growth of C. difficile was two standard deviations below the mean growth of C. difficile in YCFA broth. Only results for inhibitory CFS are shown.
[0039] Figure 13 A summary of the results obtained in the growth overlay and growth inhibition assays is shown. Bacterial isolates showed inhibitory activity in the E. coli (AIEC) overlay assay, the C. difficile overlay assay, and the C. difficile and E. coli growth assay. Bacterial isolates that showed inhibitory activity in two or more assays are shown in the overlapping regions. Bacterial isolates are indicated by their isolate number. For detailed information on the listed bacterial isolates, see Table 1.
[0040] Figure 14 : Treemap and bar chart, which show Figure 14 The relative abundance of each genus is shown in the figure in donors and recipients 3 months after FMT. The dendrogram clusters the samples according to the phylogenetic relationships of the microbial communities present in them. When evaluated at the genus level after FMT, the composition of the donor and recipient profiles was similar. Detailed description
[0042] Bacteria disclosed herein are obtained from human fecal samples and are therefore naturally present in the gastrointestinal tract of at least some healthy human individuals. However, the inventors have cultured these bacteria in vitro for the first time, thereby separating them from their environment in pure form and allowing them to be included in therapeutic compositions as definite active ingredients. Therefore, the bacteria present in the therapeutic compositions of the present invention have been separated. In other words, the bacteria present in the therapeutic compositions are provided in a separated and / or purified form, for example, from its normally present environment such as gastrointestinal tract and / or fecal sample, separated and / or purified. The separated bacteria present in the therapeutic compositions can be substantially pure or uniform form. For example, bacteria can be free of or substantially free of the material found together with its normally present environment (such as gastrointestinal tract and / or fecal sample).
[0043] The bacteria present in the therapeutic composition of the present invention are preferably human enteric bacteria, ie bacteria found in the human intestine. Bacteria whose 16S rRNA gene sequences are shown in SEQ ID NOs 1 to 51 are all enteric bacteria.
[0044] The bacteria are preferably non-pathogenic. In other words, the bacteria preferably do not cause disease in healthy human subjects when administered to the individual, particularly to the gastrointestinal tract of the individual. As described in more detail elsewhere herein, the therapeutic composition can be administered to the individual in a variety of ways, including in the form of a tablet or enema.
[0045] The bacteria present in the therapeutic composition of the present invention are preferably susceptible to one or more antibiotic treatments. In other words, the bacteria are preferably intolerant to treatment with at least one antibiotic. This allows for antibiotic treatment of the individual in the event that one or more bacteria contained in the therapeutic composition administered to the individual cause an individual disease contrary to expectations. All 51 bacteria disclosed herein were not found to carry known genes that confer resistance to the following antibiotics: β-lactams, fusidic acid, elfamycin, aminoglycosides, fosfomycin, and tunicamycin. Therefore, in a preferred embodiment, the bacteria are susceptible to treatment with one or more antibiotics selected from the group consisting of: β-lactams, fusidic acid, elfamycin, aminoglycosides, fosfomycin, and tunicamycin. In vitro and computer simulation methods for screening for antibiotic-resistant bacteria are known in the art. Exemplary computer simulation methods are also described in Example 1.
[0046] The bacterium included in the therapeutic composition of the present invention preferably does not include one or more genes encoding one or more virulence factors and / or preferably does not produce one or more virulence factors. In this case, virulence factors are characteristics that enhance the likelihood of bacterium causing disease in an individual. Virulence factors include the production of bacterial toxins (such as endotoxins and exotoxins of bacteria), and the production of hydrolytic enzymes that may contribute to bacterial pathogenicity. Methods for screening bacteria for genes encoding virulence factors are known in the art, and include the computer simulation methods described in Example 1. Use computer simulation analysis to find that 51 kinds of bacterium disclosed herein do not carry any known virulence factors. Methods for screening bacteria for the production of virulence factors are similarly known in the art.
[0047] Bacteria can be taxonomically classified based on the sequence of the gene encoding the 16S ribosomal RNA (rRNA) in the bacteria. This gene sequence is also referred to as the ribosomal DNA sequence (rDNA). The bacteria comprising the gene encoding 16S rRNA belong to the same family as the second bacteria, and the 16S rRNA has 90% or more sequence identity with the 16S rRNA encoded by the second bacteria. The bacteria comprising the gene encoding 16S rRNA belong to the same genus as the second bacteria, and the 16S rRNA has 95% or more sequence identity with the 16S rRNA encoded by the second bacteria. The bacteria comprising the gene encoding 16S rRNA belong to the same species as the second bacteria, and the 16S rRNA has 97% or more, or 98.7% or more sequence identity with the 16S rRNA encoded by the second bacteria. The bacteria contained in the therapeutic composition of the present invention can be bacteria belonging to the same family, genus and / or species as the bacteria disclosed herein.
[0048] It is expected that bacteria belonging to the same family, genus, and / or species as the bacteria disclosed herein retain one or more properties of the disclosed bacteria. Thus, in preferred embodiments, the bacteria present in the therapeutic compositions of the present invention belong to the same family, genus, and / or species as the bacteria disclosed herein and retain at least one property of the bacteria disclosed herein. Various properties of the bacteria disclosed herein have been described, including, for example, lack of production of one or more virulence factors, susceptibility to treatment with one or more antibiotics, and lack of pathogenicity.
[0049] The therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 1 to 51.
[0050] For example, the therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in any one of SEQ ID NOs 1 to 51. In a preferred embodiment, the therapeutic composition comprises an isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, and wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 1. Additionally, or alternatively, the therapeutic composition may comprise an isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, and wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 21.
[0051] Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 1 to 51. In a preferred embodiment, the therapeutic composition comprises at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, and wherein the gene comprises a sequence having at least 95% sequence identity to any one of SEQ ID NOs 2 to 20, or 22 to 51, more preferably to any one of SEQ ID NOs 5, 6, 11, 13, 14, 15, 17, 18, 19, 20, 22, 23, 24, 26, 29, 33, 35, 41, 43, 45, 46, 47, 49, or 50, yet more preferably to any one of SEQ ID NOs 5, 6, 11, 13, 15, 19, 22, 23, 29, 33, 35, 41, 43, 45, 46, or 50.
[0052] Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 97% or at least 98.7% sequence identity to the sequence shown in any one of SEQ ID NOs 1 to 51. In a preferred embodiment, the therapeutic composition comprises at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, and wherein the gene comprises a sequence having at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 2 to 20, or 22 to 51, more preferably to the sequence shown in any one of SEQ ID NOs 2 to 3, 5 to 8, 10 to 20, 22 to 26, 29 to 37, or 39 to 50, yet more preferably to the sequence shown in any one of SEQ ID NOs 3, 5 to 8, 10 to 13, 15, 16, 19, 22, 23, 29, 32 to 37, 39 to 46, or 48 to 50. In an alternative preferred embodiment, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, and wherein the gene comprises a sequence having at least 98.7% sequence identity to any one of SEQ ID NOs 2 to 20, or 22 to 51, more preferably to any one of SEQ ID NOs 2 to 4, 5 to 20, 22 to 26, 29 to 37 to 51, and still more preferably to any one of SEQ ID NOs 2 to 8, 10 to 13, 15, 16, 17, 19, 20, 22, 23, 29, 31, 32 to 37 to 46, or 48 to 51.
[0053] As described above, in preferred embodiments, the therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 21. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 91% sequence identity to the sequence set forth in SEQ ID NO: 29. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 92% sequence identity to the sequence set forth in any one of SEQ ID NOs 6, 11, 19, or 24. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 93% sequence identity to the sequence set forth in any one of SEQ ID NOs 13, 22, 26, or 35. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs 5, 14, 15, 17, 18, 23, or 50. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 20, 33, 41, 43, 45, 46, 47, or 49. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 7, 8, 10, 12, 30, 32, 39, 42, 44, or 48. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 97% sequence identity to the sequence set forth in any one of SEQ ID NOs 3, 16, 25, 31, 34, 36, 37, or 40. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 98% sequence identity to the sequence set forth in any one of SEQ ID NOs 4 or 9.Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 27, 28, 38 or 51.
[0054] More preferably, the therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 21. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 92% sequence identity to the sequence shown in either SEQ ID NO: 6 or 11. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 93% sequence identity to the sequence shown in SEQ ID NO: 35. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 94% sequence identity to the sequence shown in any one of SEQ ID NO: 5, 19, 22, 23, or 50. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 13, 15, 29, 33, 41, 43, 45, or 46. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 7, 12, 32, 39, 42, or 44, and at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 3, 8, 10, 16, 34, 36, 37, 40, 48, or 49. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 98% sequence identity to the sequence shown in any one of SEQ ID NOs 4, 9, 17, or 31. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 20, 38, or 51. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having 100% sequence identity to the sequence shown in any one of SEQ ID NOs 14, 18, 24, 25, 26, 27, 28, 30, or 47.
[0055] Sequence identity is usually defined with reference to the algorithm GAP (Wisconsin GCG package, Accelerys Inc, San Diego USA). GAP uses the Needleman and Wunsch algorithm to align two complete sequences to maximize the number of matches and minimize the number of gaps. Typically, default parameters are used, with a gap creation penalty of 12 and a gap extension penalty of 4. Other algorithms suitable for nucleotide sequence alignment (e.g., BLAST (Basic Local Alignment Search Tool) (which uses the method of Altschul et al. (1990) J. Mol. Biol. 215: 405-410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85: 2444-2448), the Smith-Waterman algorithm (Smith and Waterman (1981) J. Mol Biol. 147: 195-197), the TBLASTN program (Altschul et al. (1990) supra), or the psi-Blast algorithm (Nucl. Acids Res. (1997) 25 3389-3402), which are generally employed with default parameters) may be used instead of GAP. In particular, BLAST may be used, preferably with default parameters.
[0056] A sequence alignment algorithm, such as BLAST, calculates a similarity score between a query sequence and a subject sequence. The sequence identity of a query sequence to a subject sequence can depend on the percentage of the query sequence required to overlap with the subject sequence. This is also referred to as query coverage. In a preferred embodiment, the isolated bacteria present in the therapeutic composition of the present invention comprise a gene encoding 16S rRNA, wherein the gene comprises a sequence that (in addition to the specified sequence identity) has a query coverage of at least 98%, at least 99%, or 100%, preferably at least 98%. Query coverage refers to the percentage of the sequence that overlaps with a sequence having a specified sequence identity, such as SEQ ID NO: 1. For example, the bacteria present in the therapeutic composition may comprise a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90% sequence identity to a sequence shown in any one of SEQ ID NOs 1 to 51 and having a query coverage of at least 98%.
[0057] More preferably, the therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium is deposited with the German Collection of Microorganisms and Cell Cultures (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) (DSMZ) (Inhoffenstr. 7B, 38124 Braunschweig, Genome Research Limited) under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and the accession numbers are listed in Table 1 below. Specifically, the therapeutic composition of the present invention may comprise at least one isolated bacterium, wherein the bacterium is a bacterium deposited in DSMZ under the Budapest Treaty and has one of the following accession numbers (the DSMZ deposit date of each deposited bacterium is indicated in brackets after the accession number): DSM32191 (October 27, 2015), DSM32147 (September 23, 2015), DSM32149 (September 23, 2015), DSM32150 (September 24, 2015), DSM32151 (September 25, 2015), DSM32152 (September 26, 2015), DSM32153 (September 27, 2015), DSM32154 (September 26, 2015), DSM32155 (September 27, 2015), DSM32156 (September 27, 2015), DSM32157 (September 27, 2015), DSM32158 (September 27, 2015), DSM32159 (September 28, 2015), DSM32160 (September 29, 2015), DSM32161 (September 29, 2015), DSM32162 (September 29, 2015), DSM32163 (September 29, 2015), DSM32164 (September 29, 2015), DSM32165 (September 29, 2015), DSM32166 (September ), DSM32175 (October 6, 2015), DSM32153 (October 27, 2015), DSM32152 (September 23, 2015), DSM32158 (September 23, 2015), DSM32192 (October 27, 2015), DSM32148 (September 23, 2015), DSM32166 (October 6, 2015), DSM32 151 (September 23, 2015), DSM 32150 (September 23, 2015), DSM 32193 (October 27, 2015), DSM 32162 (October 6, 2015), DSM 32194 (October 27, 2015), DSM 32163 (October 6, 2015), DSM 32205 (March 1, 2016), DSM 32195 (2015 October 27), DSM 32164 (October 6, 2015), DSM 32177 (October 13, 2015), DSM 32167 (October 6, 2015), DSM 32165 (October 6, 2015), DSM 32169 (October 6, 2015), DSM 32168 (October 6, 2015), DSM 32178 (October 13, 2015),DSM 32182 (October 13, 2015), DSM 32179 (October 13, 2015), DSM 32180 (October 13, 2015), DSM 32184 (October 13, 2015), DSM 32181 (October 13, 2015), DSM 32183 (October 13, 2015), DSM 32262 (February 2, 2016), DSM 32211 (December 2, 2015), DSM 32219 (December 8, 2015), DSM 32222 (December 8, 2015), DSM 32261 (February 2, 2016), DSM 32212 (December 2, 2015), DSM 32220 (December 8, 2015), DSM 32213 (December 2, 2015), DSM 32226 (December 8, 2015), DSM 32215 (December 2, 2015), DSM 32216 (December 2, 2015), DSM 32217 (February 2, 2016), DSM 32221 (December 8, 2015), DSM 32218 (December 2, 2015), DSM 32224 (December 8, 2015), DSM 32214 (December 2, 2015), DSM 32263 (February 2, 2016), DSM 32223 (December 8, 2015), DSM 32225 (December 8, 2015) and DSM 32265 (February 10, 2016). The putative genus and species names of the deposited bacteria and their known characteristics are listed in Table 1 below.
[0058] More preferably, the therapeutic composition of the present invention comprises at least one isolated bacterium, wherein the bacterium is a bacterium deposited at DSMZ under the Budapest Treaty with one of the following accession numbers: DSM 32191 and DSM 32177. Additionally or alternatively, the therapeutic composition may comprise at least one isolated bacterium, wherein the bacterium is a bacterium deposited at DSMZ under the Budapest Treaty with one of the following accession numbers: DSM 32153, DSM 32152, DSM 32151, DSM 32193, DSM 32162, DSM 32194, DSM 32205, DSM 32195, DSM 32164, DSM 32177, DSM 32165, DSM 32169, DSM 32168, DSM 32182, DSM 32184, DSM 32211, DSM 32222, DSM 3221 5, DSM32217, DSM32218, DSM32224, DSM32214, DSM32223, and DSM32225; more preferably, a bacterium having one of the following accession numbers: DSM32153, DSM32152, DSM32151, DSM32193, DSM32194, DSM32164, DSM32165, DSM32169, DSM32184, DSM32211, DSM32222, DSM32215, DSM32217, DSM32218, DSM32224, and DSM32225.
[0059] Alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium comprising a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-mentioned deposited bacteria.
[0060] The therapeutic compositions of the present invention can comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty, at least thirty-one, at least thirty-two, at least thirty-three, at least thirty-four, at least thirty-five, at least thirty-six, at least thirty-seven, at least thirty-eight, at least thirty-nine, at least forty, at least forty-one, at least forty-two, at least forty-three, at least forty-four, at least forty-five, at least forty-six, at least forty-seven, at least forty-eight, at least forty-nine, at least fifty, or at least fifty-one bacteria as disclosed herein.
[0061] The therapeutic compositions of the present invention may comprise one, up to two, up to three, up to four, up to five, up to six, up to seven, up to eight, up to nine, up to ten, up to eleven, up to twelve, up to thirteen, up to fourteen, up to fifteen, up to sixteen, up to seventeen, up to eighteen, up to nineteen, up to nineteen, up to twenty, up to twenty-one, up to twenty-two, up to twenty-three, up to twenty-four, up to twenty-five, up to twenty-six, up to twenty-seven, up to twenty-eight, up to twenty-nine, up to thirty, up to thirty-one, up to thirty-two, up to thirty-three, up to thirty-four, up to thirty-five, up to thirty-six, up to thirty-seven, up to thirty-eight, up to thirty-nine, up to forty, up to forty-one, up to forty-two, up to forty-three, up to forty-four, up to forty-five, up to forty-six, up to forty-seven, up to forty-seven, up to forty-eight, up to forty-nine, up to fifty, or up to fifty-one bacteria as disclosed herein. Preferably, the therapeutic composition of the present invention comprises up to 20, preferably up to 10, bacteria as disclosed herein.
[0062] When the therapeutic composition comprises more than one isolated bacterium, the isolated bacteria are preferably different. "Different" may refer to isolated bacteria that encode different 16S rRNA sequences.
[0063] The therapeutic composition of the present invention may include at least one isolated bacterium that forms spores. Such bacteria are also referred to as spore-forming bacteria. Spores are metabolically dormant structures that are resilient to environmental damage and are used as a survival strategy by some bacteria when faced with adverse conditions. Bacteriotherapy candidate bacteria HMI_1, HMI_2, HMI_4, HMI_6, HMI_10, HMI_15, HMI_17, HMI_21, HMI_22, HMI_33, HMI_36, HMI_37, HMI_38, HMI_44, HMI_47, HMI_48, HMI_50, HMI_51, and HMI_52 were isolated from ethanol-treated samples and are therefore expected to be capable of forming spores. In addition, HMI_3, HMI_7, HMI_8, HMI_16, HMI_18, HMI_19, HMI_24, HMI_25, HMI_26, HMI_27, HMI_28, HMI_29, HMI_30, HMI_34, HMI_41, and HMI_46 were expected to be spore formers based on phylogenetic analysis.
[0064] Thus, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty, at least thirty-one, at least thirty-two, at least thirty-three, at least thirty-four, or at least thirty-five isolated spore-forming bacteria. In one embodiment, the bacteria in the therapeutic composition may consist of spore-forming bacteria.
[0065] Thus, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in any one of SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 10, 14, 15, 16, 17, 18, 20, 21, 23, 24, 25, 26, 27, 28, 29, 32, 33, 35, 36, 37, 40, 43, 45, 46, 47, 49, 50, or 51. Alternatively, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in any one of SEQ ID NOs 1, 2, 4, 6, 10, 14, 16, 20, 21, 32, 35, 36, 37, 43, 46, 47, 49, 50, or 51.
[0066] The spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 10, 14, 15, 16, 17, 18, 20, 21, 23, 24, 25, 26, 27, 28, 29, 32, 33, 35, 36, 37, 40, 43, 45, 46, 47, 49, 50, or 51. Alternatively, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 1, 2, 4, 6, 10, 14, 16, 20, 21, 32, 35, 36, 37, 43, 46, 47, 49, 50, or 51.
[0067] Preferably, the spore-forming bacterium is a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO 1 or SEQ ID NO 21 and / or a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 3, 4, 6, 7, 8, 10, 14, 15, 16, 17, 18, 20, 23, 24, 25, 26, 27, 28, 29, 32, 33, 35, 36, 37, 40, 43, 45, 46, 47, 49, 50, or 51. More preferably, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO 1 or SEQ ID NO 21 and / or a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 4, 6, 10, 14, 16, 20, 32, 35, 36, 37, 43, 46, 47, 49, 50, or 51.
[0068] More preferably, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 21, at least 92% sequence identity to the sequence shown in SEQ ID NO: 29, at least 92% sequence identity to the sequence shown in SEQ ID NO: 6 or 24, at least 93% sequence identity to the sequence shown in SEQ ID NO: 35 or 26, at least 94% sequence identity to the sequence shown in any one of SEQ ID NO: 14, 15, 17, 18, 23, or 50, at least 95% sequence identity to the sequence shown in any one of SEQ ID NO: 20, 33, 43, 45, 46, 47, or 49, at least 96% sequence identity to the sequence shown in any one of SEQ ID NO: 2, 7, 8, 10, or 32, at least 97% sequence identity to the sequence shown in SEQ ID NO: 33, 3, 16, 25, 36, 37 or 40, a sequence having at least 97% sequence identity with the sequence shown in SEQ ID NO 4, or a sequence having at least 98% sequence identity with the sequence shown in SEQ ID NO 27, 28, or 51. Still more preferably, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 21, at least 92% sequence identity to the sequence shown in SEQ ID NO: 6, at least 93% sequence identity to the sequence shown in SEQ ID NO: 35, at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs 14 or 50, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 20, 43, 46, 47, or 49, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 10, or 32, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 16, 36, or 37, at least 98% sequence identity to the sequence shown in SEQ ID NO: 4, or at least 99% sequence identity to the sequence shown in SEQ ID NO: 51.
[0069] More preferably, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 21, at least 92% sequence identity to the sequence shown in SEQ ID NO: 6, at least 93% sequence identity to the sequence shown in SEQ ID NO: 35, at least 94% sequence identity to the sequence shown in SEQ ID NO: 23 or 50, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 15, 29, 33, 43, 45, or 46, at least 96% sequence identity to the sequence shown in SEQ ID NO 7 or 32, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 3, 10, 16, 36, 37, 40 or 49, at least 98% sequence identity to the sequence shown in SEQ ID NO 4, 8 or 17, at least 99% sequence identity to the sequence shown in SEQ ID NO 50. 2, 20, or 51, or a sequence having at least 99% sequence identity with the sequence set forth in any one of SEQ ID NOs 14, 18, 25, 26, 27, 28, or 47, or a sequence having 100% sequence identity with the sequence set forth in any one of SEQ ID NOs 14, 18, 25, 26, 27, 28, or 47. Even more preferably, the spore-forming bacterium may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 21, at least 92% sequence identity to the sequence shown in SEQ ID NO: 6, at least 93% sequence identity to the sequence shown in SEQ ID NO: 35, at least 94% sequence identity to the sequence shown in SEQ ID NO: 50, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 43 or 46, at least 96% sequence identity to the sequence shown in SEQ ID NO 32, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 10, 16, 36, 37 or 49, at least 98% sequence identity to the sequence shown in SEQ ID NO 4, at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 20 or 51, or at least 99% sequence identity to the sequence shown in SEQ ID NO: 53. 14 or 47 have 100% sequence identity.
[0070] More preferably, the spore-forming bacteria may be the bacteria deposited in DSMZ under the following accession numbers: DSM 32191, DSM 32147, DSM 32175, DSM 32152, DSM 32166, DSM 32162, DSM 32163, DSM 32177, DSM 32167, DSM 32262, DSM 32222, DSM 32261, DSM32212, DSM32217, DSM32224, DSM32214, DSM32223, DSM32225, DSM32265, DSM32149, DSM32158, DSM32192, DSM321 94, DSM32205, DSM32195, DSM32169, DSM32168, DSM32178, DSM32182, DSM32179, DSM32180, DSM32211, DSM32226, or DSM32218. Most preferably, the spore-forming bacterium may be the bacterium deposited at DSMZ under the following accession numbers: DSM 32191, DSM 32147, DSM 32175, DSM 32152, DSM 32166, DSM 32162, DSM 32163, DSM 32177, DSM 32167, DSM 32262, DSM 32222, DSM 32261, DSM 32212, DSM 32217, DSM 32224, DSM 32214, DSM 32223, DSM 32225, or DSM 32265. Alternatively, the therapeutic composition of the present invention may comprise at least one isolated spore-forming bacterium comprising a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the deposited bacterium described above.
[0071] The isolated bacteria present in the therapeutic composition can antagonize intestinal bacteria, inhibit or prevent the growth or sporulation of intestinal bacteria, and / or neutralize or protect against toxins produced by intestinal bacteria. Preferably, the bacteria inhibit or prevent the growth of intestinal bacteria. The intestinal bacteria can be pathogenic or non-pathogenic. Preferably, the intestinal bacteria are pathogenic. This is particularly preferred in the context of therapeutic compositions for treating dysbiosis associated with intestinal bacterial infection. However, other diseases are also known to be characterized by an increase in certain types of bacteria in the gastrointestinal tract. For example, inflammatory bowel disease is known to be characterized by an increase in bacteria from the Proteobacteria phylum, such as Escherichia coli, in the intestinal microbiota. Similarly, irritable bowel syndrome, obesity, and malnutrition are known to be characterized by an increase in certain types of bacteria in the gastrointestinal tract. Bacterial compositions comprising at least one bacterium that antagonizes intestinal bacteria, inhibits or prevents the growth or sporulation of intestinal bacteria, and / or neutralizes or protects against toxins produced by intestinal bacteria can therefore also be used to treat dysbiosis associated with inflammatory bowel disease, irritable bowel syndrome, obesity, or malnutrition.
[0072] Pathogenic bacteria can be gram-positive bacteria or gram-negative bacteria.Exemplary pathogenic bacteria include pathogenic bacteria of the genus: Clostridium, Escherichia, Enterococcus, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Staphylococcus, Vibrio, Aeromonas, Campylobacter, Bacillus, Helicobacter, Listeria, Plesiomonas, or Yersinia. In a preferred embodiment, the pathogenic bacterium is a pathogenic bacterium of the genus Clostridium or Escherichia, such as Clostridium difficile or Escherichia coli.
[0073] Examples of pathogenic E. coli include adherent-invasive E. coli (AIEC), enteroaggregative E. coli, enterohemorrhagic E. coli, enteroinvasive E. coli, enterotoxigenic E. coli, and E. coli 0157:H7. Enterotoxigenic E. coli may produce heat-labile enterotoxins or heat-stable enterotoxins.
[0074] For example, the pathogenic bacteria may be Clostridium difficile or adherent-invasive Escherichia coli (AIEC).
[0075] Bacteriotherapy candidates HMI_14, HMI_25, HMI_42, HMI_26, HMI_28, HMI_35 and HMI_46 have been shown to inhibit the growth of C. difficile in an overlay assay. In addition, HMI_2, HMI_4, HMI_5, HMI_6, HMI_15, HMI_26, HMI_27, HMI_28, HMI_34, HMI_35, HMI_39, HMI_40, HMI_43, HMI_44, HMI_46 and HMI_47 have been shown to inhibit the growth of C. difficile in a CFS relative growth inhibition assay (see Example 2, Figure 13 and Table 1 ).
[0076] Bacteriotherapy candidates HMI_4, HMI_10, HMI_11, HMI_14, HMI_26, HMI_28, HMI_33, HMI_35, HMI_42 and HMI_46 have been shown to inhibit the growth of E. coli in the overlay assay. In addition, HMI_46 and HMI_28 have been shown to inhibit the growth of E. coli in the CFS relative growth inhibition assay (see Example 2, Figure 13 and Table 1 ).
[0077] It is expected that bacteria that inhibit the growth of E. coli will also inhibit the growth of other Proteobacteria. Thus, pathogenic bacteria can be Proteobacteria. Proteobacteria (in addition to Escherichia species) also include Salmonella species, Campylobacter species, Vibrio species, Helicobacter species and Yersinia species.
[0078] Bacteria that inhibit the growth of C. difficile are expected to also inhibit the growth of other bacteria of the genus Clostridium. Thus, the pathogenic bacteria may be bacteria of the genus Clostridium. Pathogenic bacteria of the genus Clostridium (in addition to C. difficile) also include Clostridium perfringens, Clostridium botulinum, and Clostridium tetani.
[0079] Thus, the therapeutic composition may comprise at least one isolated bacterium that inhibits the growth of Clostridium difficile and / or E. coli. For example, the therapeutic composition of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, or at least twenty-two isolated bacteria that inhibit the growth of Clostridium difficile and / or E. coli. In one embodiment, the bacteria in the therapeutic composition may consist of one or more isolated bacteria that have been shown to inhibit Clostridium difficile and / or E. coli.
[0080] In a preferred embodiment, the therapeutic composition may comprise at least one isolated bacterium that has been shown to inhibit the growth of Clostridium difficile. This is preferred in the context of a therapeutic composition for treating dysbiosis associated with intestinal infection, particularly dysbiosis associated with infection with pathogenic Clostridium-related species (e.g., Clostridium difficile, Clostridium perfringens, Clostridium botulinum, or Clostridium tetani, most preferably Clostridium difficile).
[0081] For example, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, or at least nineteen isolated bacteria that inhibit the growth of Clostridium difficile. In one embodiment, the bacteria in the therapeutic composition may consist of bacteria that inhibit the growth of Clostridium difficile.
[0082] The bacterium that inhibits the growth of Clostridium difficile may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity with the sequence shown in any one of SEQ ID NOs 2, 4, 5, 6, 13, 14, 24, 25, 26, 27, 33, 34, 38, 39, 41, 42, 43, 45 and 46.
[0083] Alternatively, the bacterium that inhibits the growth of Clostridium difficile can be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 4, 5, 6, 13, 14, 24, 25, 26, 27, 33, 34, 38, 39, 41, 42, 43, 45 and 46.
[0084] More preferably, the bacterium that inhibits the growth of Clostridium difficile may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 92% sequence identity to the sequence shown in any one of SEQ ID NO: 6 or 24, at least 93% sequence identity to the sequence shown in any one of SEQ ID NO 13 or 26, at least 94% sequence identity to the sequence shown in any one of SEQ ID NO 5 or 14, at least 95% sequence identity to the sequence shown in any one of SEQ ID NO 33, 41, 43, 45 or 46, at least 96% sequence identity to the sequence shown in any one of SEQ ID NO 2, 39, or 42, at least 97% sequence identity to the sequence shown in any one of SEQ ID NO 25 or 34, at least 98% sequence identity to the sequence shown in SEQ ID NO 4, or at least 99% sequence identity to the sequence shown in any one of SEQ ID NO 27 or 38.
[0085] Even more preferably, the bacterium that inhibits the growth of Clostridium difficile may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 92% sequence identity to the sequence shown in SEQ ID NO: 6, at least 94% sequence identity to the sequence shown in SEQ ID NO 5, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 13, 33, 41, 43, 45, or 46, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 39 or 42, at least 97% sequence identity to the sequence shown in SEQ ID NO 34, at least 98% sequence identity to the sequence shown in SEQ ID NO 4, at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 2 or 38, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 14, 24, 25, 26, or 27.
[0086] Most preferably, the bacteria that inhibit the growth of Clostridium difficile may be the bacteria deposited in DSMZ under the following accession numbers: DSM32147, DSM32175, DSM32153, DSM32152, DSM32193, DSM32162, DSM32168, DSM32178, DSM32182, DSM32179, DSM32211, DSM 32219, DSM32220, DSM32213, DSM32215, DSM32216, DSM32217, DSM32218, DSM 32224. Alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium that inhibits the growth of Clostridium difficile, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-mentioned deposited bacteria.
[0087] In an alternative preferred embodiment, the therapeutic composition may comprise at least one isolated bacterium that inhibits the growth of Escherichia coli. This is preferred in the context of a therapeutic composition for treating dysbiosis associated with intestinal infections, particularly dysbiosis associated with Proteobacteria, such as Escherichia species, Salmonella species, Campylobacter species, Vibrio species, Helicobacter species, and Yersinia species, most preferably dysbiosis associated with E. coli infections.
[0088] For example, the therapeutic composition can comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten isolated bacteria that inhibit the growth of E. coli. In one embodiment, the bacteria in the therapeutic composition can consist of bacteria that inhibit the growth of E. coli.
[0089] The bacterium that inhibits the growth of Escherichia coli may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity with the sequence shown in any one of SEQ ID NOs 4, 10, 11, 13, 25, 27, 32, 34, 41, and 45.
[0090] Alternatively, the bacterium that inhibits the growth of Escherichia coli may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 4, 10, 11, 13, 25, 27, 32, 34, 41, and 45.
[0091] More preferably, the bacterium that inhibits the growth of Escherichia coli may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 92% sequence identity to the sequence shown in SEQ ID NO: 11, at least 93% sequence identity to the sequence shown in SEQ ID NO 13, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 41 or 45, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 10 or 32, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 25 or 34, at least 98% sequence identity to the sequence shown in SEQ ID NO: 4, or at least 99% sequence identity to the sequence shown in SEQ ID NO: 27.
[0092] Even more preferably, the bacterium that inhibits the growth of Escherichia coli may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 92% sequence identity to the sequence shown in SEQ ID NO: 11, at least 95% sequence identity to the sequence shown in any one of SEQ ID NOs 13, 41 or 45, at least 96% sequence identity to the sequence shown in SEQ ID NO 32, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 10 or 34, at least 98% sequence identity to the sequence shown in SEQ ID NO 4, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 25 or 27.
[0093] Most preferably, the bacteria that inhibit the growth of E. coli may be the bacteria deposited with DSMZ under the following accession numbers: DSM 32175, DSM 32166, DSM 32151, DSM 32193, DSM 32178, DSM 32179, DSM 32262, DSM 32219, DSM 32215, DSM 32218. Alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium that inhibits the growth of E. coli, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity with the sequence of the gene encoding 16S rRNA in the above-mentioned deposited bacteria.
[0094] In addition to the isolated bacteria that inhibit the growth of C. difficile and / or E. coli, the therapeutic composition may further comprise at least one isolated bacterium that co-occurs with the bacteria that inhibit the growth of C. difficile and / or E. coli as disclosed herein. Candidate bacteria for bacterial therapy that have been shown to co-occur with bacteria that inhibit the growth of C. difficile and / or E. coli as disclosed herein are HMI_2, HMI_5, HMI_6, HMI_7, HMI_8, HMI_9, HMI_10, HMI_11, HMI_12, HMI_14, HMI_15, HMI_16, HMI_17, HMI_18, HMI_19, HMI_20, HMI_26, HMI_27, HMI_31, HMI_33, HMI_34, HMI_35, HMI_37, HMI_38, HMI_39, HMI_41, HMI_42, HMI_43, HMI_44, HMI_46, HMI_47, HMI_48, HMI_50, HMI_51, and HMI_52 (see Table 1 for details).
[0095] Thus, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty, at least thirty-one, at least thirty-two, at least thirty-three, at least thirty-four, or thirty-five isolated bacteria that co-occur with a bacterium that inhibits the growth of Clostridium difficile and / or E. coli as disclosed herein.
[0096] The bacteria that co-occur with the bacteria that inhibit the growth of Clostridium difficile and / or Escherichia coli as disclosed herein can be bacteria that contain a gene encoding 16S ribosomal RNA (rRNA), wherein the gene contains a sequence having at least 90% sequence identity to the sequence shown in any one of SEQ ID NOs 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 30, 32, 33, 34, 36, 37, 38, 40, 41, 42, 43, 45, 46, 47, 49, 50 or 51.
[0097] Alternatively, the bacteria that co-occur with the bacteria that inhibit the growth of Clostridium difficile and / or Escherichia coli as disclosed herein can be bacteria that contain a gene encoding 16S ribosomal RNA (rRNA), wherein the gene contains a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 15, 16, 17, 18, 19, 25, 26, 30, 32, 33, 34, 36, 37, 38, 40, 41, 42, 43, 45, 46, 47, 49, 50, or 51.
[0098] Preferably, the bacterium co-occurring with the bacterium that inhibits the growth of Clostridium difficile and / or Escherichia coli as disclosed herein may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises
[0099] A sequence having at least 92% sequence identity to the sequence set forth in any one of SEQ ID NOs 6, 11, or 19, at least 93% sequence identity to the sequence set forth in any one of SEQ ID NOs 13 or 26, at least 94% sequence identity to the sequence set forth in any one of SEQ ID NOs 5, 14, 15, 17, 18, or 50, at least 95% sequence identity to the sequence set forth in any one of SEQ ID NOs 33, 41, 43, 45, 46, 47, or 49, at least 96% sequence identity to the sequence set forth in any one of SEQ ID NOs 2, 7, 8, 10, 12, 30, 32, or 42, at least 97% sequence identity to the sequence set forth in any one of SEQ ID NOs 16, 25, 34, 36, 37, or 40, at least 98% sequence identity to the sequence set forth in SEQ ID NO 9, or at least 99% sequence identity to the sequence set forth in any one of SEQ ID NOs 38 or 51.
[0100] More preferably, the bacterium co-occurring with the bacterium that inhibits the growth of Clostridium difficile and / or Escherichia coli as disclosed herein may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises
[0101] a sequence having at least 92% sequence identity to the sequence set forth in any one of SEQ ID NOs 6 or 11, at least 94% sequence identity to the sequence set forth in any one of SEQ ID NOs 5, 19 or 50, at least 95% sequence identity to the sequence set forth in any one of SEQ ID NOs 13, 15, 33, 41, 43, 45, or 46, at least 96% sequence identity to the sequence set forth in any one of SEQ ID NOs 7, 12, 32, or 42, at least 97% sequence identity to the sequence set forth in any one of SEQ ID NOs 8, 10, 16, 34, 36, 37, 40, or 49, at least 98% sequence identity to the sequence set forth in any one of SEQ ID NOs 9 or 17, at least 99% sequence identity to the sequence set forth in any one of SEQ ID NOs 2, 38, or 51, and at least 100% sequence identity to the sequence set forth in any one of SEQ ID NOs 14, 18, 25, 26, 30, or 47.
[0102] Most preferably, the bacteria that co-occur with the bacteria that inhibit the growth of Clostridium difficile and / or E. coli as disclosed herein are bacteria deposited with the DSMZ under the following accession numbers: DSM32147, DSM32153, DSM32152, DSM32158, DSM32192, DSM32148, DSM32166, DSM32151, DSM32150, DSM32193, DSM32162, DSM32194, DSM32163, DSM32205, DSM32206, DSM32207, DSM32208, DSM32209, DSM322147, DSM32153, DSM32152, DSM32158, DSM32192, DSM32148, DSM32166, DSM32151, DSM32150, DSM32193, DSM32162, DSM32194, DSM32163, DSM32209, DSM32208, DSM32209 2195, DSM32164, DSM32178, DSM32182, DSM32181, DSM32262, DSM32211, DSM32219, DSM32261, DSM32212, DSM3222 0, DSM32226, DSM32215, DSM32216, DSM32217, DSM32218, DSM32224, DSM32214, DSM32223, DSM32225, or DSM32265. Alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium that co-occurs with a bacterium that inhibits the growth of Clostridium difficile and / or Escherichia coli as disclosed herein, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-described deposited bacterium.
[0103] It has been shown that bacteria associated with the genus Clostridium are beneficial for reducing inflammation by interacting with the host immune system (Atarashi, Tanoue et al. 2013). Therefore, the isolated bacteria present in the therapeutic composition can be bacteria with immunomodulatory activity. For example, bacteria can reduce inflammation in an individual, for example, inflammation in the gastrointestinal tract of an individual. Candidate bacteria of the same genus as bacteria that have been shown to be beneficial for reducing inflammation by interacting with the host immune system are HMI_4, HMI_9, HMI_10, HMI_15, HMI_27, HMI_28 and HMI_38. Therefore, it is expected that the bacteria have immunomodulatory activity, for example, reducing inflammation in an individual, for example, inflammation in the gastrointestinal tract of an individual.
[0104] Thus, the therapeutic composition may comprise at least one, at least two, at least three, at least four, at least five, at least six, or at least seven isolated bacteria having immunomodulatory activity. In one embodiment, the bacteria in the therapeutic composition may consist of bacteria that reduce inflammation in a subject.
[0105] The bacterium having immunomodulatory activity may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity with the sequence shown in any one of SEQ ID NOs. 4, 9, 10, 14, 26, 27, or 37.
[0106] Alternatively, the bacterium having immunomodulatory activity may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 4, 9, 10, 14, 26, 27, or 37.
[0107] Preferably, the bacterium having immunomodulatory activity may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 93% sequence identity to the sequence shown in SEQ ID NO: 26, at least 94% sequence identity to the sequence shown in SEQ ID NO: 14, at least 96% sequence identity to the sequence shown in SEQ ID NO: 10, at least 97% sequence identity to the sequence shown in SEQ ID NO 37, at least 98% sequence identity to the sequence shown in any one of SEQ ID NOs 4 or 9, or at least 99% sequence identity to the sequence shown in SEQ ID NO 27. More preferably, the bacterium having immunomodulatory activity may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 97% sequence identity to the sequence shown in SEQ ID NO: 10 or 37, at least 98% sequence identity to the sequence shown in any one of SEQ ID NOs 4 or 9, or at least 100% sequence identity to the sequence shown in any one of SEQ ID NOs 14, 26 or 27.
[0108] Most preferably, the bacteria having immunomodulatory activity may be bacteria deposited with DSMZ under the following accession numbers: DSM 32175, DSM 32148, DSM 32166, DSM 32162, DSM 32182, DSM 32179, or DSM 32212. Alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium having immunomodulatory activity, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity with the sequence of the gene encoding 16S rRNA in the above-mentioned deposited bacteria.
[0109] The therapeutic composition of the present invention may comprise at least one isolated bacterium that is on the Human Microbiome Project (HMP) "most wanted" list. Bacteriotherapy candidates HMI_1, HMI_2, HMI_4, HMI_5, HMI_7, HMI_11, HMI_12, HMI_15, HMI_16, HMI_17, HMI_18, HMI_19, HMI_35, HMI_37, HMI_38, HMI_39, HMI_45, HMI_50, and HMI_51 are on the HMP "most wanted" list.
[0110] Thus, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, or nineteen bacteria on the HMP's "most wanted" list. In one embodiment, the bacteria in the therapeutic composition may consist of bacteria on the HMP's "most wanted" list.
[0111] Bacteria on the "most wanted" list of HMP can be bacteria that contain a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs 1, 2, 4, 5, 7, 11, 12, 14, 15, 16, 17, 18, 34, 36, 37, 38, 44, 49, or 50.
[0112] Alternatively, the bacterium on the "most wanted" list of HMP may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 1, 2, 4, 5, 7, 11, 12, 14, 15, 16, 17, 18, 34, 36, 37, 38, 44, 49, or 50.
[0113] Preferably, the bacteria on the "most wanted" list of HMP may be bacteria comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1, at least 92% sequence identity to the sequence shown in SEQ ID NO: 11, at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs: 5, 14, 15, 17, 18, or 50, at least 95% sequence identity to the sequence shown in SEQ ID NO: 49, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs: 2, 7, 12, or 44, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs: 16, 34, 36, or 37, at least 98% sequence identity to the sequence shown in SEQ ID NO: 4, or at least 99% sequence identity to the sequence shown in SEQ ID NO or 38.
[0114] More preferably, the bacterium on the "most needed" list of HMP may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 1, at least 92% sequence identity to the sequence shown in SEQ ID NO 11, at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs 5 or 50, at least 95% sequence identity to the sequence shown in SEQ ID NO 15, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 7, 12, or 44, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 16, 34, 36, 37 or 49, at least 98% sequence identity to the sequence shown in any one of SEQ ID NOs 4 or 17, at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 2 or 38, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 14 or 18.
[0115] Most preferably, the bacteria on the "most wanted" list of HMP are the bacteria deposited at DSMZ under the following accession numbers: DSM 32191, DSM 32147, DSM 32175, DSM 32153, DSM 32158, DSM 32151, DSM 32150, DSM 32162, DSM 32194, DSM 32163, DSM 32205, DSM 32195, DSM 32219, DSM 32261, DSM 32212, DSM 32220, DSM 32221, DSM 32223, or DSM 32225. Alternatively, the therapeutic composition of the present invention may comprise at least one bacterium on the "most needed" list of HMP, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-mentioned deposited bacterium.
[0116] The therapeutic compositions of the present invention may include at least one isolated bacterium that is a keystone species. Biotherapy candidates HMI_17, HMI_23, HMI_24, HMI_25, HMI_26, HMI_27, HMI_28, HMI_29, HMI_30, HMI_31, HMI_32, HMI_45, HMI_49, HMI_51, and HMI_52 will be keystone species.
[0117] Thus, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, or fifteen bacteria that are keystone species. In one embodiment, the bacteria in the therapeutic composition may consist of bacteria that are keystone species.
[0118] The bacterium as a key species can be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90% sequence identity with the sequence shown in any one of SEQ ID NOs 16, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 44, 48, 50 or 51.
[0119] Alternatively, the bacterium as a key species may be a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 16, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 44, 48, 50 or 51.
[0120] Preferably, the bacterium as the key species is a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 91% sequence identity to the sequence shown in SEQ ID NO: 29, at least 92% sequence identity to the sequence shown in SEQ ID NO 24, at least 93% sequence identity to the sequence shown in any one of SEQ ID NOs 22 or 26, at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs 23 or 50, at least 96% sequence identity to the sequence shown in any one of SEQ ID NOs 30, 44 or 48, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 16, 25 or 31, or at least 99% sequence identity to the sequence shown in any one of SEQ ID NOs 27, 28, or 51.
[0121] More preferably, the bacterium as the key species is a bacterium comprising a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 94% sequence identity to the sequence shown in any one of SEQ ID NOs 22, 23 or 50, at least 95% sequence identity to the sequence shown in SEQ ID NO 29, at least 96% sequence identity to the sequence shown in SEQ ID NO 44, at least 97% sequence identity to the sequence shown in any one of SEQ ID NOs 16 or 48, at least 98% sequence identity to the sequence shown in SEQ ID NO: 31, at least 99% sequence identity to the sequence shown in SEQ ID NO: 51, or a sequence having 100% sequence identity to the sequence shown in any one of SEQ ID NOs 24, 25, 26, 27, 28, or 30.
[0122] Most preferably, the bacterium as key species is the bacterium deposited at DSMZ under the following accession numbers: DSM32163, DSM32165, DSM32169, DSM32168, DSM32178, DSM32182, DSM32179, DSM32180, DSM32184, DSM32181, DSM32183, DSM32221, DSM32263, DSM32225, or DSM32265. Alternatively, the therapeutic composition of the present invention may comprise at least one bacterium as a key species, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-mentioned deposited bacteria.
[0123] Additionally or alternatively, the therapeutic compositions of the present invention may comprise at least one isolated bacterium that has been shown to be present after FMT. Suitable bacterial therapy candidates are listed in Table 1. Thus, the therapeutic compositions of the present invention may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, or twenty-two bacteria that have been shown to be present after FMT. For example, it has been shown that bacteria present after FMT can contain a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence shown in any one of SEQ ID NOs 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 38, 40, 43, 44, 45, 46, 48 or 51. Most preferably, the bacteria that have been shown to be present after FMT are the bacteria deposited at the DSMZ under the following accession numbers: DSM32165, DSM32169, DSM32168, DSM32178, DSM32182, DSM32179, DSM32180, DSM32184, DSM32181, DSM32183, DSM32262, DSM32211, DSM32219, DSM32261, DSM32220, DSM32226, DSM32217, DSM32221, DSM32218, DSM32224, DSM32263, or DSM32265. Alternatively, the therapeutic composition of the present invention may comprise at least one bacterium that has been shown to be present after FMT, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding the 16S rRNA in the above-deposited bacterium.
[0124] Additionally or alternatively, the therapeutic composition of the present invention may comprise at least one isolated bacterium that is expected to produce one or more beneficial metabolites, such as short-chain fatty acids (SCFAs). Suitable candidate bacteria for bacteriotherapy are listed in Table 1. Thus, the therapeutic composition may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen bacteria that produce one or more beneficial metabolites. For example, the bacteria that produce one or more beneficial metabolites may comprise a gene encoding 16S ribosomal RNA (rRNA), wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99%, or 100% sequence identity to the sequence set forth in any one of SEQ ID NOs 9, 12, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31. Preferably, the bacteria expected to produce one or more beneficial metabolites are bacteria deposited at DSMZ under the following accession numbers: DSM 32148, DSM 32150, DSM 32164, DSM 32177, DSM 32165, DSM 32169, DSM 32168, DSM 32178, DSM 32182, DSM 32179, DSM 32180, DSM 32184, DSM 32181, or DSM 32183. Alternatively, the therapeutic composition of the present invention may comprise at least one bacterium that produces one or more beneficial metabolites, wherein the bacterium comprises a gene encoding 16S rRNA, wherein the gene comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.7%, at least 99% or 100% sequence identity to the sequence of the gene encoding 16S rRNA in the above-mentioned deposited bacteria.
[0125] The isolated bacteria present in the therapeutic composition may constitute at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 7%, 75%, 80%, 85% or 90% by volume or weight of the therapeutic composition.
[0126] The therapeutic composition may contain no other active ingredients other than the isolated bacteria and may optionally contain a prebiotic. Thus, the active ingredient of the therapeutic composition may consist of one or more isolated bacteria disclosed herein and an optional prebiotic. This may also be referred to as a defined active ingredient.
[0127] The therapeutic composition of the present invention is not a fecal microbiota transplant (FMT). FMT is generally composed of a fecal sample from a healthy human donor, which is directly administered to the recipient, for example in the form of an enema, without isolating the bacteria present in the fecal sample before the FMT is administered to the recipient. An advantage of the therapeutic composition of the present invention is that it may not contain the undefined components present in FMT, thereby standardizing the therapeutic composition and increasing safety.
[0128] The therapeutic compositions of the present invention can be prepared by a method comprising culturing one or more isolated bacteria present in the therapeutic composition in a suitable culture medium. Suitable culture media and conditions for culturing bacteria to be included in the therapeutic compositions of the present invention are described in detail elsewhere herein. For example, a method of preparing a therapeutic composition according to the present invention may comprise the following steps:
[0129] (i) culturing the first isolated bacteria;
[0130] (ii) optionally culturing the second isolated bacterium; and
[0131] (iii) mixing the bacteria obtained in (i) and optionally (ii) to prepare a therapeutic composition. The isolated bacteria to be included in the therapeutic composition are preferably cultured in separate steps. In other words, separate cultures of each bacteria to be included in the therapeutic composition are preferably prepared. This allows the growth of each bacteria to be assessed and the amount of each bacteria included in the pharmaceutical composition to be controlled as needed. The bacteria cultured in steps (i) and (ii) preferably have different 16S rRNA sequences.
[0132] The above method may include the step of culturing each isolated bacterium to be included in the therapeutic composition. Thus, the method may, for example, further include the step of culturing a third, fourth, fifth, sixth, seventh, eighth, ninth, and / or tenth different isolated bacteria, as desired. In this manner, the method may include the step of culturing up to 51 different isolated bacteria. The bacteria cultured by the method may be any of the bacteria disclosed herein.
[0133] The method may optionally include one or more further steps in which the bacteria are mixed with one or more additional ingredients (e.g., pharmaceutically acceptable excipients, prebiotics, carriers, insoluble fibers, buffers, osmotic agents, defoaming agents, and / or preservatives). Additionally or alternatively, the method may include suspending the bacteria obtained in (i) and optionally (ii) in a chemostat medium or saline, such as 0.9% normal saline. The bacteria obtained in (i) and optionally (ii) may be provided under a reducing atmosphere (e.g., N2, CO2, H2, or a mixture thereof, e.g., N2:CO2:H2). The gases may be present in appropriate proportions to protect the bacteria present in the therapeutic composition. For example, the reducing atmosphere may include 80% N2, 10% CO2, and 10% H2. Additionally or alternatively, the method may include the step of lyophilizing the bacteria obtained in (i) and optionally (ii) in the presence of a stabilizer and / or cryoprotectant. The method may also include the step of preparing a capsule, tablet, or enema containing the bacteria obtained in (i) and optionally (ii). Capsules or tablets may be enteric-coated, pH-dependent, sustained-release and / or gastro-resistant.
[0134] The present invention also includes therapeutic compositions obtainable or obtainable by the methods disclosed herein. Such therapeutic compositions can further be used for therapeutic purposes in therapeutic methods, or for the preparation of medicaments as described herein, for example, to treat dysbiosis, particularly dysbiosis of the gastrointestinal tract.
[0135] It is expected that the bacteria disclosed herein are useful for treating dysbiosis, particularly dysbiosis of the gastrointestinal tract. Without wishing to be bound by theory, it is expected that administering one or more bacteria disclosed herein to an individual will resolve gastrointestinal dysbiosis present in the individual and / or prevent the onset of gastrointestinal dysbiosis. As used herein, "subject" refers to a human individual or human patient.
[0136] Treatment of dysbiosis can refer to curing, preventing, or ameliorating the dysbiosis, or ameliorating at least one symptom associated with the dysbiosis. When the dysbiosis is associated with a disease such as inflammatory bowel disease, treatment of the dysbiosis can refer to curing, preventing, or ameliorating the disease, or ameliorating at least one symptom associated with the disease.
[0137] Thus, the therapeutic compositions of the present invention can be used to treat dysbiosis, particularly dysbiosis of the gastrointestinal tract. Thus, the present invention provides methods of treating dysbiosis comprising administering a therapeutically effective amount of a therapeutic composition of the present invention to a subject in need thereof, therapeutic compositions of the present invention for use in methods of treating dysbiosis in a subject, and uses of therapeutic compositions of the present invention in the preparation of a medicament for treating dysbiosis in a subject.
[0138] In the context of the present invention, "dysbiosis" refers to a state in which the normal diversity and / or function of a microbiome or microorganism, particularly a human gastrointestinal microbiome, is disrupted. Any disruption of the normal state of the microbiome in a healthy individual can be considered dysbiosis, even if the dysbiosis does not result in a detectable decrease in the health of the individual. In a preferred embodiment, dysbiosis may be associated with one or more pathological symptoms. For example, "dysbiosis" may refer to a decrease in the microbial diversity of a microbiome. Additionally, or alternatively, "dysbiosis" may refer to an increase in the abundance of one or more bacteria (e.g., one or more pathogenic bacteria) in the microbiome of the individual relative to the abundance of one or more of the bacteria in the microbiome of a healthy individual (i.e., an individual without dysbiosis). The pathogenic bacteria present during dysbiosis are typically Proteobacteria and are resistant to one or more antibiotics. Examples of Proteobacteria include Escherichia, Salmonella, Campylobacter, Vibrio, Helicobacter, and Yersinia.
[0139] The dysbiosis may be that associated with an enteric bacterial infection, such as infection of the gastrointestinal tract with pathogenic bacteria.Many bacteria are known that are capable of causing gastrointestinal infections in humans, including gram-positive and gram-negative bacteria. The pathogenic bacterium is preferably a pathogenic species of the genus Clostridium, Escherichia, Enterococcus, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Staphylococcus, Vibrio, Aeromonas, Campylobacter, Plesiomonas, Bacillus, Helicobacter, Listeria, or Yersinia. Preferred examples of such pathogenic bacteria include Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Escherichia coli, Salmonella typhi, Staphylococcus aureus, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Campylobacter fetus, Campylobacter jejuni, Aeromonas hydrophila, Plesiomonas shigelloides, Bacillus cereus, Helicobacter pylori, Listeria monocytogenes, and the like. monocytogenes), and Yersinia enterocolitica. More preferably, the pathogenic bacteria is a pathogenic species of Clostridium or Escherichia. Most preferably, the pathogenic bacteria is Clostridium difficile or Escherichia coli.
[0140] Pathogenic bacteria may be resistant to one or more antibiotics. For example, pathogenic bacteria such as Clostridium difficile may be resistant to fluoroquinolones. Additionally, or alternatively, pathogenic bacteria may be resistant to one or more carbapenems. Carbapenem antibiotics are antibiotics used to treat multidrug-resistant (MDR) bacterial infections, examples of which include imipenem, meropenem, ertapenem, doripenem, panipenem, and biapenem.
[0141] Treatment of dysbiosis associated with a pathogenic bacterial infection can include reducing the abundance of the pathogenic bacteria, for example, in the gastrointestinal tract of an individual relative to the abundance of the pathogenic bacteria before treatment.
[0142] Dysbiosis can be recurrent or chronic. For example, Clostridium difficile is known to cause recurrent infections in some individuals, with the infection returning once antibiotic treatment is stopped. This is referred to as recurrent or chronic dysbiosis.
[0143] Dysbiosis of the gastrointestinal tract is known to be associated with, and is thought to play a causal role in, many different diseases, including inflammatory bowel disease, irritable bowel syndrome, metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic diseases, or cancer. Thus, dysbiosis can be dysbiosis associated with inflammatory bowel disease, irritable bowel syndrome, metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic diseases, cancer, or hepatic encephalopathy. Examples of inflammatory bowel diseases include ulcerative colitis and Crohn's disease.
[0144] Metabolic diseases in which gastrointestinal dysbiosis has been shown to play a role include metabolic syndrome, obesity, type 2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease.
[0145] Neuropsychiatric disorders in which gastrointestinal dysbiosis has been shown to play a role include Parkinson's disease, Alzheimer's disease, multiple sclerosis, myoclonic dystonia, autism, and chronic fatigue syndrome.
[0146] Autoimmune diseases in which gastrointestinal dysbiosis has been shown to play a role include idiopathic thrombocytopenic purpura, arthritis, Sjögren's syndrome ( syndrome, systemic lupus erythematosus, and Hashimoto's thyroiditis.
[0147] Allergic diseases in which gastrointestinal dysbiosis has been shown to play a role include atopy and asthma.
[0148] Cancers in which gastrointestinal dysbiosis has been shown to play a role include colorectal cancer, extraintestinal tumors, breast tumors, hepatocellular carcinoma, lymphoma, melanoma, and lung cancer.
[0149] The therapeutic compositions of the present invention may contain pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. These materials should be non-toxic and should not interfere with the efficacy of the isolated bacteria present in the therapeutic composition. The exact nature of the pharmaceutically acceptable excipients or other materials will depend on the route of administration, which may be oral or rectal. Many methods for preparing therapeutic compositions are known to those skilled in the art. See, for example, Robinson ed., Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, Inc., New York, 1978.
[0150] The therapeutic compositions of the present invention may comprise a prebiotic, a carrier, an insoluble fiber, a buffer, an osmotic agent, an anti-foaming agent, and / or a preservative.
[0151] Prebiotics can provide nutrition for the isolated bacteria present in the therapeutic composition to help them grow and colonize in the early stage after being administered to an individual. Any prebiotic known in the art can be used. Non-limiting examples of prebiotics include oligosaccharides, such as fructooligosaccharides, such as oligofructose and inulin, mannan oligosaccharides and oligogalactose, soluble, oligofructose-rich inulin and soluble fiber. Insoluble fiber can be included in the therapeutic composition as a carrier, for example, to provide protection during transportation or storage. A buffer can be included in the therapeutic composition to promote the viability of the isolated bacteria present. Antifungal agents can be included in the therapeutic composition as preservatives.
[0152] The therapeutic composition can be prepared or provided in a chemostat medium. Alternatively, the therapeutic composition can be prepared or provided in saline, such as 0.9% saline. It should be understood that any carrier or solution that does not impair the viability of the bacteria present in the therapeutic composition and is compatible with individual administration can be used.
[0153] The therapeutic composition can be prepared or provided under a reducing atmosphere, ie, in the absence of oxygen. The synthetic fecal preparation can be prepared or provided under N2, CO2, H2, or a mixture thereof (optionally with a controlled level of N2:CO2:H2 partial pressure levels).
[0154] The therapeutic composition can be administered to an individual orally or rectally. When the therapeutic composition is administered orally, the therapeutic composition can be in the form of a capsule or tablet. When the therapeutic composition is administered rectally, the therapeutic composition can be in the form of an enema. The preparation of suitable capsules, tablets, and enemas is well known in the art. The capsule or tablet can include a coating to protect the capsule or tablet from the effects of stomach acid. For example, the capsule or tablet can be enteric-coated, pH-dependent, sustained-release, and / or gastro-resistant. For example, such capsules and tablets are used to minimize dissolution of the capsule or tablet in the stomach while allowing dissolution in the small intestine.
[0155] The therapeutic composition can be lyophilized. The lyophilized therapeutic composition can contain one or more stabilizers and / or cryoprotectants. Prior to administration to an individual, the lyophilized therapeutic composition can be reconstituted using a suitable diluent.
[0156] The therapeutic compositions according to the present invention can be administered alone or in combination with other therapies, either simultaneously or sequentially, or as a combination formulation with another therapeutic agent, for the treatment of dysbiosis or a disease associated with dysbiosis as described herein. For example, the conjugates of the present invention can be used in combination with existing therapeutic agents for inflammatory bowel disease, irritable bowel syndrome, metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic diseases, cancer, or hepatic encephalopathy.
[0157] For example, when the therapeutic composition is used to treat dysbiosis associated with cancer, the therapeutic composition may optionally be administered to an individual in combination with a cancer immunotherapy (e.g., an immune checkpoint inhibitor). Examples of checkpoint inhibitors that can be used in this case include programmed cell death protein 1 (PD-1) inhibitors, programmed death ligand 1 (PD-L1) inhibitors, and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors. Manipulation of the intestinal microbiota in combination with immune checkpoint inhibitor therapy has been shown to improve the efficacy of immune checkpoint inhibitors in treating cancer (Snyder et al. 2015). In preferred embodiments, the cancer herein is lung cancer or melanoma. Immune checkpoint inhibitors have been approved for the treatment of these cancers, and bacterial therapy has been shown to improve the efficacy of checkpoint inhibitors in the treatment of melanoma (Snyder et al. 2015).
[0158] The therapeutic compositions of the present invention can be administered to individuals, preferably human individuals. Administration can be in a "therapeutically effective amount," sufficient to show a benefit to the individual. This benefit can include at least an amelioration of at least one symptom. Thus, "treatment" of a particular disease refers to an amelioration of at least one symptom. The actual amount administered, the rate of administration, and the time course of administration will depend on the nature and severity of the treatment being treated, the specific patient being treated, the individual patient's clinical condition, the cause of the dysbiosis, the delivery site of the composition, the type of therapeutic composition, the method of administration, the administration regimen, and other factors known to medical practitioners. Prescribing treatment, such as decisions regarding dosage, is the responsibility of general practitioners and other physicians and may depend on the severity of symptoms and / or the progression of the disease being treated. A therapeutically effective amount or appropriate dosage of the therapeutic compositions of the present invention can be determined by comparing their in vitro and in vivo activity in animal models. Methods for extrapolating effective doses in mice and other experimental animals to humans are known. The precise dosage depends on many factors, including whether the therapeutic composition is used for prophylaxis or treatment.
[0159] Other aspects and embodiments of the present invention will be apparent to those skilled in the art in view of this disclosure, including the following experimental exemplifications.
[0160] All documents mentioned in this specification are incorporated herein by reference in their entirety.
[0161] Unless the context otherwise requires, the singular includes the plural.
[0162] As used herein, the term "and / or" is considered a specific disclosure of each of two specified features or components with or without the other. For example, "A and / or B" should be considered a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were individually listed herein.
[0163] Unless the context dictates otherwise, the descriptions and definitions of the features above are not limited to any particular aspect or embodiment of the invention, and apply equally to all aspects and embodiments described.
[0164] Certain aspects and embodiments of the present invention will now be described by way of example and with reference to the above-identified drawings. Example
[0165] Example 1 - Identification and Isolation of Bacteriotherapy Candidates
[0166] Materials and methods
[0167] Two different methods are used to isolate bacterial species for inclusion in therapeutic compositions for treating dysbiosis. The first method relies on extensive culture methods from healthy adult donors to establish a culture collection that represents the bacterial components of the intestinal microbiota of healthy individuals as much as possible. The method also combines targeted culture methods to preferentially select bacteria that display specific phenotypes or functions (such as spore formation). The second method is more targeted in nature and aims to isolate bacterial species specifically associated with resolving gastrointestinal dysbiosis by comparing individual microbiota before and after fecal microbial transplantation (FMT) administered to resolve dysbiosis associated with Clostridium difficile. These two methods are referred to as Candidate Isolation Method 1 (CIP1) and Candidate Isolation Method 2 (CIP2) below.
[0168] Sample collection and culture
[0169] For CIP1, fresh fecal samples were obtained from six healthy adult donors (one fecal sample per donor - minimum 0.5g). Within 1 hour of transmission, the sample was placed under anaerobic conditions to maintain the vitality of anaerobic bacteria. All sample processing and cultivation were carried out under anaerobic conditions at 37°C on a Whitley DG250 workstation (Don Whitley, West Yorkshire, UK). Culture medium, phosphate buffered saline (PBS) and all other materials used for cultivation were placed in an anaerobic cabinet 24 hours before use. The fecal sample was divided into two parts. One part was homogenized in reduced PBS (0.1g feces / mlPBS), serially diluted and directly plated on YCFA (Duncan, Hold et al. 2002) agar (supplemented with glucose, maltose and cellobiose 0.002g / ml each) in a large (13.5cm diameter) culture dish. Metagenomic sequencing was also performed on this sample to depict the entire community. The other portion was treated with an equal volume of 70% (v / v) ethanol for 4 hours at room temperature under ambient aerobic conditions to kill vegetative cells. The solid material was then washed three times with PBS and finally resuspended in PBS. Plating was performed in the same manner as described for the non-ethanol-treated samples.
[0170] For ethanol-treated CIP1 samples, the culture medium was supplemented with 0.1% sodium taurocholate to stimulate spore germination. Colonies were picked from both ethanol-treated and non-ethanol-treated plates with non-confluent growth (i.e., plates with colonies on different, non-contiguous plates) 72 hours after plating. The picked colonies were restreaked to confirm purity.
[0171] For CIP2, 12 individuals who had experienced more than three recurrences of Clostridium difficile infection (CDI) and had failed treatment with metronidazole and vancomycin were selected for fecal microbial transplantation (FMT). As previously described (Landy, Al-Hassi et al. 2011), donors were screened for pathogens and other viral infections. Patients stopped taking oral vancomycin 1-2 days before FMT. FMT was administered to recipients by enema (n=3), pills (n=6), a combination of the two (n=2, R8 and R10), or by nasogastric infusion (n=1, R7). Fecal samples were collected from patients 1-2 days after stopping vancomycin treatment (before FMT) and at different times after FMT. Fecal samples for FMT were also collected from donors. Samples from healthy individuals and individuals infected with Clostridium difficile treated with antibiotics were also included as controls. Fecal samples were collected in sterile containers and frozen at -80°C. DNA was extracted from all samples for 454 sequencing and subsequent analysis as described below.
[0172] To culture samples from fecal microbiota transplant (FMT) recipients (CIP2), 50 mg of each fecal sample was thoroughly mixed in 0.5 ml of sterile reduced phosphate buffered saline (PBS). The homogenate was serially diluted to 10 -6 Aliquots of this dilution were plated under anaerobes on a set of media. The following media were used: fastidious anaerobic agar (FAA, Lab M Ltd, Lancashire, UK) containing 2% defibrinated horse blood, brain heart infusion (BHI, Oxoid UK), de Man Rogosa Sharpe, and CCEY (Bioconnections, UK) agar, with or without the addition of 10 μg / ml vancomycin (AppliChem, Germany). All plated media were incubated anaerobically at 37°C for 48-72 hours, except for BHI agar, which was incubated aerobically at 37°C for 24-48 hours.
[0173] Microbial characterization and sequencing
[0174] The full-length 16S rRNA gene was amplified by PCR (using Forward primer and Reverse primer) followed by capillary sequencing for identification of each culture isolate. For CIP1 and CIP2, 16S rRNA gene sequence reads were aligned in the Ribosomal Database Project (RDP) and manually curated in ARB (Ludwig, Strunk et al. 2004). For CIP1, the R package seqinr version 3.1 was used to determine sequence similarity between 16S rRNA gene sequences, and when generating full-length 16S rRNA gene sequence reads, 98.7% was used as a species-level cutoff to classify the reads into operational taxonomic units (OTUs) (Bosshard, Abels et al. 2003, Clarridge 2004). Because only partial-length 16S rRNA gene sequence reads were generated for candidate bacteria from CIP2, 97% was used as a species-level cutoff (Bosshard, Abels et al. 2003, Clarridge 2004), and OTUs at this cutoff were identified using mothur (Schloss, Westcott et al. 2009). For both CIP1 and CIP2, the 16S rRNA gene sequence of each species-level OTU was then compared to the Ribosomal Database Project (RDP) reference database to assign taxonomic designations to the genus level (Wang, Garrity et al. 2007). BLASTn searches were then performed using the 16S rRNA gene sequences to determine whether the OTU represented a previously characterized species or a novel species (Altschul, Gish et al. 1990).
[0175] Comparison of OTUs with the Human Microbiome Project (HMP) "most needed" list and the reference genome database was performed using 97% sequence identity of 16S rRNA gene sequences to define bacterial species, because only partial 16S rRNA gene sequences were available for bacteria on the HMP "most needed" list and the reference genome database. HMP data on the most needed taxa and completed sequencing projects were downloaded from the NIH Human Microbiome Project's "most needed" human microbiome whole-genome sequencing taxa (Web 8 March 2016).<http: / / hmpdacc.org / most_wanted / #data> ) and the NIH Human Microbiome Project reference genome data (Web 8March 2016<http: / / hmpdacc.org / HMRGD / > Genomic DNA was extracted from at least one representative of each unique OTU using a phenol-chloroform-based DNA isolation procedure. DNA was sequenced on an Illumina HiSeq platform, generating 100-bp reads, which were assembled and annotated for further analysis.
[0176] DNA was also extracted directly from each fecal sample using the MP Biomedical FastDNA SPIN Kit for Soil for whole-community metagenomic and 16S rRNA gene amplicon sequencing. To enable comparison with the intact community samples, nonconfluent cultures were scraped from agar plates 72 hours after inoculation of the initial fecal sample, and DNA was extracted from this community using the same DNA isolation procedure. 16S rRNA gene amplicon libraries were prepared by PCR amplification of variable regions 1 and 2 of the 16S rRNA gene using the Q5 High-Fidelity Polymerase Kit provided by New England Biolabs. Primers 27FAATGATACGGCGACCACCGAGATCTACAC TATGGTAATT CC AGMGTTYGATYMTGGCTCAG (Part 1 = Illumina adapter, Part 2 = forward primer pad, Part 3 = forward primer linker, and Part 4 = forward primer) and 338R CAAGCAGAAGACGGCATACGAGAT ACGAGACTGATT AGTCAGTCAG AA GCTGCCTCCCGTAGGAGT (Part 1 = reverse complement of 3' Illumina adapter, Part 2 = golay barcode, Part 3 = reverse primer pad, Part 4 = reverse primer linker, and Part 5 = reverse primer) were used. Four PCR amplification reactions were performed for each sample; the products were pooled and combined in equimolar amounts for sequencing using the Illumina MiSeq platform, generating 150 bp reads.
[0177] For 454 amplicon sequencing of CIP2-derived fecal samples, DNA was extracted directly from fecal samples (70 mg) using the FastDNA Spin Kit for Soil on a Fastprep instrument (MP Biomedicals, USA) according to the manufacturer's instructions. The V3-V5 region of the 16S rRNA gene was amplified using the barcoded primers 338F (5′-ACTCCTACGGGAGGCAGCAG-3′) and 926R (5′-CCG TCA ATT CMT TTR AGT-3′) adapted with adapters. Thermal cycling involved an initial 2-min denaturation step at 94°C, followed by 20 cycles of denaturation (94°C for 30 s), annealing (53°C for 30 s) and elongation (68°C for 2 min). PCR products were purified using Wizard SV Gel and PCR Clean-Up System (Promega, UK) according to the manufacturer's protocol and used. dsDNA HS assay kit (Life Technologies, UK) was used for quantification. An equimolar volume of each clean product from each PCR reaction was sequenced on a Roche 454 FLX-Titanium platform.
[0178] Microbiome analysis
[0179] The maximum likelihood phylogeny of culture-derived bacteria from CIP1 was generated from the aligned RDP sequences using FastTree version 2.1.3 (Price, Dehal et al. 2010): a generalized time-reversible (GTR) model of nucleotide substitution and a CAT approximation of inter-site rate variation with 20 rate categories. The ethanol resistance phylogeny was derived directly from the entire culture phylogeny. All phylogenetic trees were compiled in ITOL (Letunic and Bork 2011).
[0180] Analysis of partial 16S rRNA gene sequences generated from 16S rRNA gene amplicon libraries from CIP1-derived fecal samples was performed using the Mothur MiSeq SOP (Kozich, Westcott et al. 2013) on August 29, 2014, identifying 7549 OTUs across all samples. A sequence identity threshold of ≥97% was again used to define OTUs.
[0181] For 454 sequence analysis of fecal samples derived from CIP2, mothur software 454SOP (Schloss, Westcott et al. 2009, Schloss, Gevers et al. 2011) accessed in November 2012 was used to trim, filter and pre-process sequence reads. To ensure high-quality sequence data for analysis, sequences were trimmed using a 50 bp window size (average quality score of 35 bp), homopolymers of >8 bp were removed, and ambiguous bases or mismatches in primer sequences were not allowed. Redundant sequence reads were removed to generate unique sequences, which were aligned with the SILVA alignment database (Pruesse, Quast et al. 2007). These aligned sequences were screened to ensure that sequences overlapped in the same alignment space using the screen.seqs command in mothur. Unique sequences were generated again and sequences were pre-clustered to remove sequences that may be caused by pyrosequencing errors (Huse, Dethlefsen et al. 2008). Perseus (Quince, Lanzen et al. 2011) was used to remove chimeric sequences and other contaminants such as chloroplasts and mitochondria. Sequences with ≥97% sequence identity and their assigned classification from phylum to genus were considered to belong to the same operational taxonomic unit (OTU) according to the Ribosomal Database Project (RDP) (Cole, Wang et al. 2014) and SILVA (Pruesse, Quast et al. 2007) databases. The species diversity in each sample was measured by calculating the Shannon diversity index (SDI), which takes into account species richness and relative proportional abundance (Schloss, Westcott et al. 2009). OTUs were then used for cluster dendrograms using the Bray Curtis calculator in the mothur package. Other analyses, such as the Invsimpson index, principal component analysis (PCA) and the UniFrac method for comparing microbial communities were performed as previously described using mothur software (Lozupone and Knight 2005, Lawley, Clare et al. 2012).
[0182] Metagenomic analysis
[0183] Microbial abundance was calculated for 1883 healthy individuals (3218 samples) and 458 sick individuals (628 samples) using the human pan-microbial community database (Forster, Browne et al. 2015). The calculated occurrence was greater than 1000 independent standardized readings, wherein abundance was calculated relative to the total high-quality readings in the sample. Antimicrobial resistance and virulence factor identification were performed using automatic sequence homology searches for protein sequences annotated in the complete genome sequence. Antimicrobial resistance reference lists were defined based on the comprehensive antimicrobial CARD database (McArthur, Waglechner et al. 2013), and toxins were identified (Chakraborty, Ghosh et al. 2012) by the occurrence in the human bacterial exotoxin database (Database of Bacterial Exotoxins for Humans, DBETH).
[0184] Experimental setup and results
[0185] The inventors have established methods for isolating and identifying bacteria for incorporation into therapeutic compositions tailored for treating dysbiosis of the gastrointestinal tract, and, for example, intestinal infections, such as, but not limited to, infections caused by Clostridium difficile. As described above, two different approaches were used to obtain bacterial candidates for inclusion in therapeutic agents. The first approach (CIP1) relied on extensive culture methods from healthy adult donors to establish a culture collection that was as representative as possible of the bacterial components of the healthy human intestinal microbiome. The method also combined targeted culture methods to preferentially select bacteria that display specific phenotypes or functions (e.g., spore formation). The second approach (CIP2) is more targeted in nature, aiming to obtain bacterial species specifically associated with addressing gastrointestinal dysbiosis by comparing individuals who have undergone FMT before and after addressing C. difficile-related dysbiosis. Both approaches are described in more detail below.
[0186] CIP1 - Extensive culture method to identify therapeutic candidates:
[0187] The inventors first sought to establish a genome-based workflow that could serve as a platform for targeted cultivation of specific bacterial phenotypes ( Figure 1). Fresh stool samples were collected from 6 healthy individuals and the resident bacterial communities were determined using a combined metagenomic sequencing and bacterial culture approach. Applying shotgun metagenomic sequencing, the inventors described and compared the bacterial species present in the original stool samples with those that grew as distinct colonies on agar plates containing the complex broad-spectrum bacterial culture medium YCFA (Duncan, Hold et al. 2002) supplemented with glucose, maltose and cellobiose. Importantly, a strong correlation between the two samples was observed at the species level (Spearman Rho = 0.75, p < 0.01) ( Figure 2 When sequenced, the original stool samples and the cultured bacterial communities shared an average of 93% of the raw reads across the six donors.
[0188] These results unexpectedly demonstrate that, contrary to established belief in the art, a significant proportion of bacteria in the fecal microbiota can be cultured using a single growth medium. Thus, a broad culture method has been established that, when combined with high-throughput archiving or specific phenotypic selection, can be used to isolate and identify new bacteria from the human gastrointestinal tract.
[0189] The human gut microbiota is dominated by strict anaerobic bacteria that are extremely sensitive to ambient oxygen. Certain members of the phylum Firmicutes, including Clostridium difficile, produce metabolically dormant and highly resistant spores during colonization, promoting host persistence and environmental dissemination (Lawley, Clare et al. 2009, Francis, Allen et al. 2013, Janoir, Deneve et al. 2013). Relatively few intestinal spore-forming bacteria have been cultured to date, while metagenomic studies have revealed other unexpected members of the gut microbiota with potential spore-forming genes, but these remain poorly characterized (Galperin, Mekhedov et al. 2012, Abecasis, Serrano et al. 2013, Meehan and Beiko 2014, Rajilić-Stojanovic and de Vos 2014).
[0190] The inventors hypothesize that spore formation may be an underappreciated fundamental phenotype of the human gut microbiota that may have profound implications for microbiota persistence and transmission between humans. Spore formation is also considered desirable for bacteriotherapy formulations, as the resistant nature of the spore structure will promote drug survival during production and subsequent storage. Spores from C. difficile are resistant to ethanol, a phenotype that can be used to select spores from mixed spore populations and ethanol-sensitive vegetative cells (Riley, Brazier et al. 1987). Using our combined culture and metagenomics workflow ( Figure 1) were used to treat fecal samples with or without ethanol treatment. Principal component analysis showed that ethanol treatment profoundly altered the composition of culturable bacteria and effectively enriched ethanol-resistant bacteria compared to the original profile, facilitating their isolation ( Figure 3 ). Approximately 2,000 individual bacterial colonies were selected from both ethanol- and non-ethanol-treated conditions, restreaked to purity, and subjected to full-length 16S rRNA gene sequencing for taxonomic characterization. Unique taxa were then archived as frozen stocks for future phenotypic analysis.
[0191] In total, based on the average relative abundance of 6 donors ( Figure 4 A and 4B), bacteria representing 96% of bacterial abundance at the genus level and 90% of bacterial abundance at the species level were profiled. Even genera present at low mean relative abundance (<0.2%) were isolated and purified ( Figure 4 C). Ethanol-resistant species were isolated from five known families (Clostridiaceae, Peptostreptococcaceae, Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae) and two newly identified candidate families (bacterial isolates HMI_1 and HMI_22) (see Table 1 for details). The identification of these novel and unexpected spore formers highlights the broad taxonomic distribution of this phenotype among enteric species of the Firmicutes phylum. Overall, 137 different bacterial species were archived, including 45 candidate novel species and isolates representing 20 candidate novel genera and 2 candidate novel families ( Figure 5 ). Our collection contains the 90 "most wanted" species of the Human Microbiome Project (HMP) from previously uncultured and unsequenced microorganisms (Fodor, DeSantis et al. 2012). Nineteen of the deposited bacterial isolates listed in Table 1 are included in the HMP's "most wanted" list, namely: HMI_1, HMI_2, HMI_4, HMI_5, HMI_7, HMI_11, HMI_12, HMI_15, HMI_16, HMI_17, HMI_18, HMI_19, HMI_35, HMI_37, HMI_38, HMI_39, HMI_45, HMI_50, and HMI_51 (see Table 1 for details). Thus, our extensive YCFA-based culture approach led to the discovery of a large number of novel bacteria (including novel families, genera, species, and isolates) and challenges the prevailing view in the field that most of the gut microbiota is "unculturable."
[0192] CIP2: Targeted identification of candidate bacteria to address gastrointestinal dysbiosis
[0193] As mentioned above, FMT has been shown to be effective in resolving CDI. Therefore, the inventors attempted to culture stool samples from FMT donors and recipients to isolate candidate bacteria that could be used for treatment. A panel of different microbiological culture media was tested to recover the widest range of bacterial species from stool samples (see Methods). This method allows for the cultivation and archiving of candidate bacteria. More than 2,600 bacterial isolates were cultured and sequenced using the 16S rRNA gene, which were taxonomically classified ( Figure 7 These bacterial isolates were members of the four major phyla of the gut microbiota (Actinobacteria, Bacteroidetes, Proteobacteria, and Firmicutes). Based on partial-length 16S rRNA gene alignments, these bacterial isolates represented more than 350 different OTUs.
[0194] In silico analysis of candidate bacteria:
[0195] Having established culture collections by the two methods described above (CIP1 and CIP2), the inventors next sought to screen these bacteria to identify candidate bacteria for bacteriotherapy.
[0196] The inventors first attempted to analyze isolates cultured from FMT donors and recipients. One to three months after FMT, the fecal microbiota profiles of recipients were similar to those of donors and healthy controls. In particular, the relative abundance of the four major bacterial phyla present in the gut microbiota was also similar in these groups. Principal component analysis (PCA) was used to visualize the microbial community structure in donors and recipients (before and after FMT) to assess ( Figure 6 ). The PCA plot shows that there are two different compositional profiles, representing the "healthy-associated" microbiome and the "vancomycin" microbiome. The healthy-associated profile contains samples from FMT donors, healthy controls, and FMT recipients 2-3 months after treatment. The "vancomycin" microbiome profile is separated from the healthy-associated microbiome along principal component 1 and contains only individuals treated with vancomycin. These vancomycin control individuals were infected with C. difficile and were taking antibiotics for other diseases. In addition, the "metronidazole-associated" profile is separated from the "healthy-associated" profile along principal component 2 and contains samples from patients treated with metronidazole who were infected with C. difficile.
[0197] The donor-recipient profiles of each pair were compared before and after FMT to identify taxa present in the donor sample and whose relative abundance increased in the recipient after FMT. A total of 786 OTUs were detected from all recipient samples after FMT, but individual OTUs present at different time points were removed. This resulted in 375 OTUs for further analysis. Given that recurrence of CDI typically occurs 3-4 weeks after cessation of antibiotic treatment (Cornely, Miller et al. 2012, Abujamel, Cadnum et al. 2013), OTUs whose relative proportional abundance increased 2-3 months after FMT were further analyzed.
[0198] Next, the inventors performed computer simulation analysis to further screen bacterial therapy candidates from our two culture methods (CIP1 and CIP2). As mentioned above, a healthy intestinal microbiome is based on a diverse and rich microbial community. Using the whole genome sequences generated by the inventors from bacterial isolates of CIP1 and CIP2, the inventors used the HPMC database tool (Forster, Browne et al. 2015) to computationally assess their prevalence in healthy and diseased individuals in public metagenomic datasets. Candidate bacteria were first filtered to include only those isolates with an average abundance greater than 0.001% in the bacterial communities of all healthy individuals in which they were detected ( Figure 8 ). Thus, all bacteria deposited in the DSMZ had an average abundance greater than 0.001% in the bacterial communities of all healthy individuals in whom they were detected (see Table 1). In addition to health-associated bacteria, preferred candidates for bacterial therapy are expected to improve gastrointestinal dysbiosis. To identify these candidates, we examined the distribution of each isolate in publicly available metagenomic datasets. Bacterial species with a significantly reduced overall average abundance (greater than 4-fold reduction) in individuals with gastrointestinal dysbiosis relative to healthy individuals were selected and subjected to further analysis as described below ( Figure 9 Thus, all bacteria deposited in the DSMZ showed a decrease in overall mean abundance (greater than 4-fold decrease) in individuals with gastrointestinal dysbiosis compared to healthy individuals (see Table 1).
[0199] The list of candidate bacteria for bacteriotherapy was further analyzed based on computationally predicted antimicrobial resistance (AMR) and virulence factors. Bacteriotherapy candidate bacteria with an overall predicted resistance score lower than 20% of the overall predicted resistance score of known pathogens Clostridium difficile, Enterococcus faecalis, and Escherichia coli were included. Candidate bacteria were also screened for the absence of computer-predicted resistance to β-lactams, fusidic acid, alphamycin, aminoglycosides, fosfomycin, and tunicamycin, as well as the absence of known toxins listed in the Database of Bacterial Exotoxins for Humans (DBETH) (Chakrabory A. et al., 2012). Based on this analysis, the inventors identified 51 candidate bacteria for bacteriotherapy from CIP1 and CIP2 (see Table 1). Ten of these bacterial therapy candidates were identified using CIP2: HMI_23, HMI_24, HMI_25, HMI_26, HMI_27, HMI_28, HMI_29, HMI_30, HMI_31, and HMI_32 (see Table 1 for details). All 10 isolates were from healthy donors. The remaining bacterial therapy candidates were identified using CIP1.
[0200] Bacteriotherapy candidates (except HMI_17) identified using CIP1 and CIP2 as described in Example 2 below were then analyzed in vitro to determine their therapeutic efficacy in treating C. difficile and E. coli infections.
[0201] Example 2 - In vitro analysis of bacterial therapy candidates
[0202] Detecting the antipathogen activity of bacteriotherapy candidates using overlapping assays
[0203] The target bacterial isolate identified in Example 1 is streaked into an "X" shape on the surface of a standard culture dish containing warm and reduced YCFA agar. These inoculated plates are then cultured anaerobically at 37°C for 3 to 6 days until bacterial growth is clearly visible. Overlay agar is prepared by adding 0.8% agar to a suitable liquid culture medium. BHI liquid culture medium + 0.8% agar is used for Clostridium difficile. LB + 0.8% agar is prepared for Escherichia coli. The overlay agar is kept molten at 50°C before use. The overlay agar is inoculated (1% inoculum) with an aliquot of a turbid culture of the target pathogen (in this case Clostridium difficile M7404 or Escherichia coli (AIEC)). A 10ml aliquot of the inoculated overlay agar is added to the surface of the agar plate with each target symbiotic strain. The overlay agar is solidified and the plate is cultured anaerobically at 37°C for one to two days. After incubation, a clearance zone can be observed if the symbiotic strain of interest is able to inhibit the growth of the pathogen in the overlay. The width of each cleared area is measured with a ruler, e.g. Figure 10 The results are shown in Figure 11 middle.
[0204] Antipathogen activity was detected by CFS relative growth inhibition assay.
[0205] The bacterial therapy candidate bacteria were grown in 1 ml aliquots of reduced YCFA liquid medium at 37 ° C under anaerobic conditions for two days. Cell-free supernatant (CFS) was prepared by centrifuging each culture to remove bacteria and sterilizing the resulting supernatant through a 0.22 μm filter. Uninoculated YCFA liquid medium was also filter sterilized. CFS and filtered YCFA liquid medium aliquots were frozen at -20 ° C until they were needed. These filtrates were thawed at 37 ° C under anaerobic conditions, and 100 μl aliquots of each CFS were added to a well of a flat-bottomed 96-well plate. Several wells were filled with filter-sterilized YCFA liquid medium to serve as a positive control for pathogen growth. Each well was inoculated (2-5% inoculum) with a turbid early-mid exponential phase Clostridium difficile M7404 culture. Alternatively, the stationary phase Escherichia coli culture used (adjusted to OD 600 ≈1) of 5% inoculum. Seal the 96-well plate with optically transparent film and transfer it to a FLUOstar Omega microplate reader (BMG Labtech). Incubate the plate at 37°C in a plate reader and read the OD every 10 minutes. 600 Readings were taken for 18.17 hours. The plate was shaken for 10 seconds before each OD reading. All isolates except HMI17 were tested.
[0206] The relative growth of the target pathogen in each tested CFS was then calculated as follows: For each tested CFS, each raw data value was relative to the OD taken at the 10-min time point. 600 The relative growth of C. difficile or E. coli in the various CFSs was expressed as a function of the optical density of the CFSs. This data normalization allowed a direct comparison of the growth of C. difficile or E. coli in the various CFSs by eliminating the initial inherent variations in the optical density of the CFSs (due to pre-fermentation of the culture medium) from consideration. The relative growth of C. difficile or E. coli achieved in each CFS at the 18.17 h time point was compared to the relative growth of the target pathogen achieved in YCFA liquid medium. If the relative growth of the target pathogen in the CFS from the same commensal isolate plus two standard deviations was lower than the mean minus two standard deviations of the relative growth of the pathogen in YCFA liquid medium, the commensal strain was considered a potential inhibitor of C. difficile or E. coli. When only one relative growth value was available, the CFS was considered to have a potential inhibitory effect if the relative pathogen growth was more than two standard deviations lower than the mean relative growth in YCFA liquid medium. The results of the bacterial therapy candidates with inhibitory activity were found to be shown in Figure 12 middle.
[0207] result
[0208] A summary of the results obtained in the growth overlay and growth inhibition assays is shown in Figure 13 and Table 1. Bacteriotherapy candidates showing activity in each in vitro assay are shown in this figure.
[0209] Of the 50 bacteriotherapy candidates tested, 22 exhibited growth inhibition against at least one of C. difficile M7404 or E. coli (AIEC) in one of the assays performed. Eleven bacteriotherapy candidates inhibited the growth of at least one of C. difficile or E. coli in the overlay assay, indicating that the inhibitory effect conferred by these bacteriotherapy candidates was direct. Based on the overlay assay data, five of the bacteriotherapy candidates inhibited the growth of only C. difficile or E. coli, indicating that the inhibitory activity of these bacteriotherapy candidates was not universal, i.e., the inhibitory activity was specific to one or more pathogenic bacteria.
[0210] Of the 50 bacterial therapeutic candidates tested, six inhibited the growth of both C. difficile and E. coli in coverage assays, indicating that they have broad-spectrum inhibitory activity and may also have inhibitory activity against other pathogenic bacteria.
[0211] The results from the CFS relative growth inhibition assay showed that CFS from 16 of the 50 bacterial therapy candidate bacteria tested only supported the relative growth of Clostridium difficile to a level that was more than two standard deviations lower than the average relative growth of YCFA liquid medium at 18.17 hours. Therefore, these bacterial therapy candidate bacteria are considered to inhibit the growth of Clostridium difficile. Five of these bacterial therapy candidate bacteria were also shown in the coverage assay to directly inhibit the growth of Clostridium difficile and / or Escherichia coli. This suggests that these five bacterial therapy candidate bacteria secrete one or more substances that inhibit the growth of these pathogenic bacteria. The remaining 11 bacterial therapy candidate bacteria that showed inhibitory activity in the CFS relative growth inhibition assay may compete with Clostridium difficile for nutrients. CFS from two bacterial therapy candidate bacteria did not support the growth of E. coli to within two standard deviations of the average growth observed in YCFA liquid medium. Therefore, these isolates are considered to inhibit the growth of E. coli.
[0212] Example 3 - Computer Simulation of Co-abundance Network Analysis
[0213] In order to identify bacteria that do not directly inhibit pathogen growth as tested in Example 2 but can support the growth or survival of those bacteria that showed direct inhibition of pathogen growth in Example 2, a co-abundance network analysis was performed. This analysis was performed using the complete list of the health dataset in the HPMC database tool (Forster, Browne et al. 2015) as previously described. For each candidate bacterium that showed inhibition of pathogen growth in Example 2, a complete list of first-level neighbor species (which showed co-occurrence with the candidate bacterium in at least 95% of fecal samples, with an average abundance greater than 0.001%, and a minimum of 100 reads) was generated. Bacteria that showed extensive co-occurrence with candidate bacteria that showed direct inhibitory activity on pathogen growth are expected to provide metabolic, environmental, and / or immunomodulatory support functions required for the candidate bacteria to colonize the gastrointestinal tract. The deposited bacteria that showed such co-occurrence are shown in Table 1.
[0214] discuss
[0215] As shown in Example 2, bacterial isolates that inhibit the growth of one or more pathogenic bacteria are expected to be useful in treating gastrointestinal dysbiosis in humans.
[0216] However, bacterial isolates that did not show signs of pathogen inhibition in Example 2 are still expected to be useful in treating gastrointestinal dysbiosis.
[0217] First, based on the coexistence data obtained in Example 3, it is expected that the large number of deposited bacteria supports the colonization of the gastrointestinal tract through direct or indirect interactions with the inhibitory bacteria identified in Example 2. Metabolic networks (in which bacterial consortia thrive through cross-feeding, structural networks (such as biofilms) or interactions of "keystone species") enable the establishment and stability of the microbiota (Ze and Mougen et al. 2013). Coexistence analysis identified 35 candidate bacteria that formed first-level coexistence neighbors with directly inhibiting bacteria at a rate higher than 95% (HMI_2, HMI_5, HMI_6, HMI_7, HMI_8, HMI_9, HMI_10, HMI_11, HMI_12, HMI_14, HMI_15, HMI_16, HMI_17, HMI_18, HMI_19, HMI_20, HMI_26, HMI_27, HMI_31, HMI_33, HMI_34, HMI_35, HMI_37, HMI_38, HMI_39, HMI_41, HMI_42, HMI_43, HMI_44, HMI_46, HMI_47, HMI_48, HMI_50, HMI_51, and HMI_52; see Table 1 for details). Furthermore, several of the bacterial isolates listed in Table 1 belong to the same genus as known keystone species (HMI_17, HMI_23 to HMI_32, HMI_45, HMI_49, HMI_51, and HMI_52; see Table 1 for details) and are therefore expected to represent keystone species themselves.
[0218] Second, the bacterial isolates listed in Table 1 are shown in Example 1 to contribute to the overall diversity of the gastrointestinal microbiota, which is low during dysbiosis. Specifically, many of these bacteria (HMI_23 to HMI_32, inclusive) were recovered from the gut microbiota of FMT donors as part of CIP2. When the microbiota of healthy donors were transferred to individuals with dysbiosis due to antibiotic treatment for recurrent C. difficile infection, all recovered ( Figure 6 ), which was determined as the absence of C. difficile 2-3 months after FMT. The criteria for identifying bacterial therapy candidates by the CIP2 process require the presence of certain candidate bacterial species in the microbiota of half of the recipients, with an average relative abundance exceeding >0.6% 2-3 months after FMT. In addition, genera representing several of the 51 bacterial species listed in Table 1 were also identified in healthy donors and cured recipients after FMT ( Figure 14 In addition, the computer simulation analysis proposed in this paper ( Figure 8 and 9 ) showed that 51 candidate bacteriotherapy isolates were prevalent in healthy individuals, where they were present at an average relative abundance >0.001%, and that these bacteria tended to be depleted under conditions of dysbiosis ( Figure 9 Taken together, these data strongly suggest that the 51 bacterial isolates listed in Table 1 are suitable for the treatment of gastrointestinal dysbiosis.
[0219] Third, the bacterial isolates listed in Table 1 are expected to compete with enteric pathogens in the GI tract and therefore be useful in treating GI dysbiosis. Specifically, the widespread presence of these bacteria in healthy individuals means that they effectively colonize the GI tract. When the microbiota is populated with these health-associated bacteria, the likelihood of any pathogenic bacteria infecting the intestine is lower, as such infections do not typically occur in individuals with healthy GI microbiota. Indeed, genera representing many of the 51 bacterial species listed in Table 1 were identified in individuals treated for GI dysbiosis following antibiotic treatment for Clostridium difficile ( Figure 14 )) and restored a healthy microbiome profile ( Figure 6 and Figure 14 ) and no recurrence of C. difficile infection within 3 months. This suggests that these bacteria promote health according to the principle of colonization resistance, in which pathogens are excluded or suppressed by competing with resident, health-associated bacteria for nutrients and attachment sites (Britton & Young 2014; Lawley & Walker 2013).
[0220] Fourth, several of the bacterial isolates listed in Table 1 (e.g., HMI_9, HMI_12, HMI_20, HMI_21, and HMI_23–HMI_32; see Table 1 for details) were expected to produce metabolites such as short-chain fatty acids (SCFAs), which are known to be beneficial for gastrointestinal health, based on inferences from studies of other species in the same genus or clade (Louis & Flint, 2009).
[0221] Finally, some Clostridium-related species have been shown to have immunomodulatory effects and may be beneficial in reducing inflammation (Atarashi, Tanoue et al. 2013). Based on comparisons of 16S rRNA gene sequences, using 95% sequence identity as a cutoff for defining genera (Bosshard, Abels et al. 2003), examples of the same genus as these bacteria are HMI_4, HMI_9, HMI_10, HMI_15, HMI_27, HMI_28, and HMI_38.
[0222] Table 1 - Characteristics of deposited bacteriotherapy candidates
[0223]
[0224]
[0225]
[0226] Gray fill = positive / yes; no fill = negative / no; slash = no data available / not tested
[0227] Sequence Listing
[0228] The 16S rRNA gene sequences of the 51 deposited bacterial isolates listed in Table 1 are listed below. For each bacteriotherapy candidate, a putative genus and species name is given. As explained in Example 1, genus and species names were assigned based on the Ribosomal Database Project (RDP) reference database and BLASTn analysis. Therefore, the genus and species name assigned to each bacteriotherapy candidate is the name of the most closely related known bacterium and can vary.
[0229] HMI_1 Clostridium thermocellum 16S rDNA sequence (SEQ ID NO: 1)
[0230] CAGGACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAACGAGAATCTTTGAACAGA
[0231] TCTTTTCGGAGTGACGTTCAAAGAGGAAAGTGGCGGACGGGCGAGTAACGCGTGAGTAAC
[0232] CTGCCCATAAGAGGGGGATAATCCATGGAAACGTGGACTAATACCGCATATTGTAGTCAA
[0233] GTCGCATGACTAGATTATGAAAGATTTATCGCTTATGGATGGACTCGCGTCAGATTAGAT
[0234] AGTTGGTGAGGTAACGGCTCACCAAGTCAACGATCTGTAGCCGAACTGAGAGGTTGATCG
[0235] GCCGCATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTG
[0236] CGCAATGGGGGCAACCCTGACGCAGCAACGCCGCGTGCAGGAAGAAGGTCTTCGGATTGT
[0237] AAACTGTTGTCGCAAGGGAAGAAGACAGTGACGGTACCTTGTGAGAAAGTCACGGCTAAC
[0238] TACGTGCCAGCAGCCGCGGTAATACGTAGGTGACAAGCGTTGTCCGGGATTACTGGGTGT
[0239] AAAGGGCGCGTAGGCGGACTGTCAAGTCAGTCGTGAAATACCGGGGCTTAACCCCGGGGC
[0240] TGCGATTGAAACTGACAGCCTTGAGTATCGGAGAGGAAAGCGGAATTCCTAGTGTAGCGG
[0241] TGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTTCTGGACGACAACT
[0242] GACGCTGAGGCGCGAAAGTGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACACC
[0243] GTAAACGATGGATACTAGGTGTAGGAGGTATCGACCCCCTTCTGTGCCGCAGTTAACACAA
[0244] TAAGTATCCCACCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGC
[0245] CCGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCTGGGC
[0246] TTGACATCCCTGGAATCGAGTAGAGATACTTGAGTGCCTTCGGGAATCAGGTGACAGGTG
[0247] GTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCA
[0248] ACCCCTATTGTCAGTGCCATCATTAAGTTGGGCACTCTGGCGAGACTGCCGGTGACAAA
[0249] TCGGAGGAAGGTGGGGACGACGTCCAAATCATCATGCCCCTTATGCCCAGGGCTACACACG
[0250] TACTACAATGGCCGATAACAAAGTGCAGCGAAACCGTGAGGTGGAGCGAATCACAAAACT
[0251] CGGTCTCAGTTCAGATTGCAGGCTGCAACTCGCCTGCATGAAGTTGGAATTGCTAGTAAT
[0252] CGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACAC
[0253] CATGAGAGTCGATAACACCCGAAGCCTGTGAGCTAACCTATTAGGAGGCAGCAGTCGAAG
[0254] GTGGGGTTGATGATTGGGGTGAAGTCG
[0255] HMI_2Flavonifractor plautii16SrDNA sequence (SEQ IDNO:2)
[0256] GAGTGCTCATGACAGAGGATTCGTCCAATGGAGTGAGTTACTTAGTGGCGGACGGGTGAGTAACGCGTGAGTAAC
[0257] CTGCCTTGGAGTGGGGAATAACAGGTGGAACATCTGCTAATACCGCATGATGCAGTTGGGTCGCATGGCTCTGA
[0258] CTGCCAAAGATTTATCGCTCTGAGATGGACTCGCGTCTGATTAGCTGGTTGGCGGGGTAACGGCCCACCAAGGCG
[0259] ACGATCAGTAGCCGGACTGAGAGGTTGGCCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA
[0260] GCAGTGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAGCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTG
[0261] TAAACTTCTTTTCTCAGGGACGAAGCAAGTGACGGTACCTGAGGAATAAGCCACGGCTAACTACGTGCCAGCAGC
[0262] CGCGGTAATACGTAGGTGGCGAGCGTTATCCGGATTTACTGGGTGTAAAGGGCGTGTAGGCGGGACTGCAAGTCA
[0263] GATGTGAAAACCATGGGCTCAACCTGTGGCCTGCATTTGAAACTGTAGTTCTTGAGTACTGGAGAGGCAGACGGA
[0264] ATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGTCTGCTGGACAGCAAC
[0265] TGACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCTGTAAACGATGGATA
[0266] CTAGGTGTGGGGGGTCTGACCCCCTCCGTGCCGCAGTTAACACAATAAGTATCCCACCTGGGGAGTACGATCGCA
[0267] AGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAA
[0268] GAACCTTACCAGGGCTTGACATCCCGGTGACCGGTGTAGAGATACACCTTCTTCTTCGGAAGCGCCGGTGACAGG
[0269] TGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTGTTA
[0270] GTTGCTACGCAAGAGCACTCTAGCGAGACTGCCGTTGACAAAACGGAGGAAGGTGGGGACGACGTCAAATCATCA
[0271] TGCCCCTTATGTCCTGGGCCACACACGTACTACAATGGTGGTCAACAGAGGGAAGCAAGACCGCGAGGTGGAGCA
[0272] AACCCCTAAAAGCCATCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGTATGAAGTTGGAATCGCTAGTAATCGC
[0273] GGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTCGGGAACAC
[0274] CCGAAGTCCGTAGCCTAACCGCAAGGGGGGCGCGGCCGAAGGTGGGTTCGATAATTGGGGTGAAGTCGT
[0275] HMI_3 Flavonifractor plautii 16S rDNA sequence (SEQ ID NO:3)
[0276] TGGCTGTTTAGTGGCGGACGGGTGAGTAACGCGTGAGTAACCTGCCTTGGAGTGGGGAATAACACAGTGAAAACT
[0277] GTGCTAATACCGCATGACATATTGGTGTCGCATGGCACTGATATCAAAGATTTATCGCTCTGAGATGGACTCGCG
[0278] TCTGATTAGATAGTTGGCGGGGTAACGGCCCACCAAGTCGACGATCAGTAGCCGGACTGAGAGGTTGGCCGGCCA
[0279] CATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGGGCAATGGGCGCAAGCCTG
[0280] ACCCAGCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAAACTTCTTTTAACAGGGACGAAGTAAGTGACGG
[0281] TACCTGTTGAATAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGAT
[0282] TTACTGGGTGTAAAGGGCGTGTAGGCGGGACTGCAAGTCAGATGTGAAAACTATGGGCTCAACCCATAGCCTGCA
[0283] TTTGAAACTGTAGTTCTTGAGTGTCGGAGAGGCAATCGGAATTCCGTGTGTAGCGGTGAAATGCGTAGATATACG
[0284] GAGGAACACCAGTGGCGAAGGCGGATTGCTGGACGATAACTGACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAG
[0285] GATTAGATACCCTGGTAGTCCACGCCGTAAACGATGGATACTAGGTGTGGGGGGTCTGACCCCCTCCGTGCCGCA
[0286] GCTAACGCAATAAGTATCCCACCTGGGGAGTACGATCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCA
[0287] CAAGCGGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGGCTTGACATCCTACTAACGAAC
[0288] CAGAGATGGATTAGGTGCCCTTCGGGGAAAGTAGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGA
[0289] TGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTGTTAGTTGCTACGCAAGAGCACTCTAGCGAGACTGCCG
[0290] TTGACAAAACGGAGGAAGGTGGGGACGACGTCAAATCATCATGCCCCTTATGTCCTGGGCCACACACGTACTACA
[0291] ATGGCGGTTAACAGAGGGAGGCAAAGCCGCGAGGCAGAGCAAACCCCTAAAAGCCGTCCCAGTTCGGATTGCAGG
[0292] CTGAAACCCGCCTGTATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGC
[0293] CTTGTACACACCGCCCGTCACACCATGAGAGTCGGGAACACCCGAAGTCCGTAGCCTAACTGCAAAGGGGGCGCG
[0294] GCCGAAGGTGGGTTCGATAATTGGGGTGAAGTCGTAACAGGGTAACCG
[0295] HMI_4 Clostridium orbiscindens 16S rDNA sequence (SEQ ID NO: 4)
[0296] TGGCGGACGGGTGAGTAACGCGTGAGGAACCTGCCTCGGAGTGGGGAATAACAGACCGAAAGGCCTGCTAATACC
[0297] GCATGATGCAGTTGGACCGCATGGTCCTGACTGCCAAAGATTTATCGCTCTGAGATGGCCTCGCGTCTGATTAGC
[0298] TTGTTGGCGGGGTAATGGCCCACCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGGCCGGCCACATTGGGACT
[0299] GAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAGCAAC
[0300] GCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAAACTTCTTTTCTCAGGGACGAACAAATGACGGTACCTGAGGAA
[0301] TAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTACTGGGTGT
[0302] AAAGGGCGTGTAGGCGGGAAGGCAAGTCAGATGTGAAAACTATGGGCTCAACCCATAGCCTGCATTTGAAACTGT
[0303] TTTTCTTGAGTGCTGGAGAGGCAATCGGAATTCCGTGTGTAGCGGTGAAATGCGTAGATATACGGAGGAACACCA
[0304] GTGGCGAAGGCGGATTGCTGGACAGTAACTGACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGATACC
[0305] CTGGTAGTCCACGCTGTAAACGATGGATACTAGGTGTGGGGGGTCTGACCCCCTCCGTGCCGCAGTTAACACAAT
[0306] AAGTATCCCACCTGGGGAGTACGATCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGA
[0307] GTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGGCTTGACATCCTACTAACGAAGCAGAGATGCAT
[0308] TAGGTGCCCTTCGGGGAAAGTAGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAA
[0309] GTCCCGCAACGAGCGCAACCCTTATTGTTAGTTGCTACGCAAGAGCACTCTAGCGAGACTGCCGTTGACAAAACG
[0310] GAGGAAGGCGGGGACGACGTCAAATCATCATGCCCCTTATGTCCTGGGCTACACACGTACTACAATGGTGGTAAA
[0311] CAGAGGGAAGCAAGACCGCGAGGTGGAGCAAATCCCTAAAAGCCATCCCAGTTCGGATTGCAGGCTGAAACCCGC
[0312] CTGTATGAAGTTGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACAC
[0313] CGCCCGTCACACCATGAGAGTCGGGAACACCCGAAGTCCGTAGTCTAACCGCAAGGGGGACGCGGCCGAAGGTGG
[0314] GTTCGATAATTGGGGTGAAGTCGTAACAGGGTAACC
[0315] HMI_5 Ruminococcus flavefaciens 16S rDNA sequence (SEQ ID NO:5)
[0316] CGGATCAGTGGCGGACGGGTGAGTAACACGTGAGCAACCTGCCTTTAAGAGGGGGATAACGTTTGGAAACGAACG
[0317] CTAATACCGCATAACATAGAAGATTCACATGTTTCTTCTATCAAAGATTTATCGCTTAAAGATGGGCTCGCGTCT
[0318] GATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCGACGATCAGTAGCCGTACTGAGAGGTAGAACGGCCACAT
[0319] TGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGAGGAAACTCTGATG
[0320] CAGCGATGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAAACCTCTGTCTTCAGGGACGATAATGACGGTACCTG
[0321] AGGAGGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTGTCCGGAATTACTG
[0322] GGTGTAAAGGGAGCGTAGGCGGGATCTTAAGTCAGGTGTGAAACTATGGGCTCCAACCCATAGACTGCACTTGAA
[0323] ACTGAGGTTCTTGAGTGAAGTAGAGGCAGGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAA
[0324] CATCAGTGGCGAAGGCGGCCTGCTGGGCTTTTACTGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAG
[0325] ATACCCTGGTAGTCCACGCTGTAAACGATGATTACTAGGTGTGGGGGGACTGACCCCTTCCGTGCCGCAGTTAAC
[0326] ACAATAAGTAATCCACCTGGGGAGTACGGCCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCA
[0327] GTGGAGTATGTGGTTTAATTCGAAGCACGCGAAGAACCTTACCGGGTCTTGACATCTCAGAATCCTTTAGAGAT
[0328] AAGGGAGTGCCCTTCGGGAACTGTAAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGT
[0329] TAAGTCCCGCAACGAGCGCAACCCCTATCATTAGTTGCTACGCAAGAGCACTCTAATGAGACTGCCGTTGACAAA
[0330] ACGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCCGGGCTACACACGTACTACAATGGCGTA
[0331] ACAGAGGGAAGCAACATCGCGAGGTGAAGCAAATCTCTAAAAAACGTCCCAGTTCAGATTGCAGGCTGCAACTCG
[0332] CCTGCATGAAGACGGAATTGCTAGTAATCGCAGATCAGCATGCTGCGGTGAATACGTTCCCGGGCCTTGTACACA
[0333] CCGCCCGTCACACCATGGGAGTCGGTAACACCCGAAGTCGCTTGTCTAA
[0334] HMI_6 Anaerotruncus colihominis 16S rDNA sequence (SEQ ID NO: 6)
[0335] AGTCGACGGACACATCCGACGGAATAGCTTGCTAGGAAGATGGATGTTGTTAGTGGCGGACGGGTGAGTAACACG
[0336] TGAGCAACCTACCTCAGAGTGGGGGACAACAGTTGGAAACGACTGCTAATACCGCATAAGATGGCAGGGTCGCAT
[0337] GGCCTGGTCATAAAAGGAGCAATTCGCTCTGAGATGGGCTCGCGTCTGATTAGCTAGTTGGTGAGGTAACGGCTC
[0338] ACCAAGGCAACGATCAGTAGCCGGACTGAGAGGTTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTA
[0339] CGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGGGAAGACGGTT
[0340] TTCGGATTGTAAACCTCTGTCTTGTGGGACGATAGTGACGGTACCACAGGAGGAAGCCATGGCTAACTACGTGCC
[0341] AGCAGCCGCGGTAATACGTAGATGGCGAGCGTTGTCCGGAATTACTGGGTGTAAAGGGAGTGTAGGCGGGCTGGT
[0342] AAGTTGAATGTGAAACCTTCGGGCTCAACCCGGAGCGTGCGTTCAAAACTGCTGGTCTTGAGTGAAGTAGAGGCA
[0343] GGCGGAATTCCCGGTGTAGCGGTGGAATGCGTAGATATCGGGAGGAACACCAGTGGCGAAGGCGGCCTGCTGGGC
[0344] TTTTACTGACGCTGAGGCTCGAAAGCATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGA
[0345] TGATTACTAGGTGTGGGGGGATTGACCCCCTCCGTGCCGGAGTTAACACAATAAGTAATCCACCTGGGGAGTACG
[0346] ACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAA
[0347] CGCGAAAAACCTTACCAGGTCTTGACATCCATCGCCAGGCTAAGAGATTAGCTGTTCCCTCCGGGGACGATGAGA
[0348] CAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTACT
[0349] ATTAGTTGCTACGCAAGAGCACTCTAATGGGACTGCCGTTGACAAAACGGAGGAAGGTGGGGATGACGTCAAATC
[0350] ATCATGCCCCTTATGACCTGGGCTACACACGTACTACAATGGCCGTTAACAGAGAGCAGCGATACCGCGAGGTGG
[0351] AGCGAATCTAGAAAAACGGTCTCAGTTCGGATTGCAGGCTGAAACTCGCCTGCATGAAGTCGGAATTGCTAGTAA
[0352] TCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGCCGGTA
[0353] ACACCCGAAGTCAGTAGCCTAACCGCAAGGAGGGCGCTGCCGAAGGTGGGGCTGGTAATTGGGGTGAAGTCGTAA
[0354] C
[0355] HMI_7 Clostridium xylanophilum 16S rDNA sequence (SEQ ID NO: 7)
[0356] GTAACGCGTGGGTAACCTGCCTCATACAGGGGGATAACAGTTAGAAATGACTGCTAATACCGCATAAGCGCACAG
[0357] GGTCGCATGACCTAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGAGGTAA
[0358] CGGCTCACCAAGGCGACGATCAGTAGCCGACCTGAGAGGGTGATCGGCCACATTGGGACTGAGACACGGCCCAAA
[0359] CTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAG
[0360] AAGTATTTCGGTATGTAAACTTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTA
[0361] CGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGGCGG
[0362] TCTGACAAGTCAGAAGTGAAAGCCCGGGGCTCAACTCCGGGACTGCTTTTGAAACTGCCGGACTAGATTGCAGGA
[0363] GAGGTAAGTGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTA
[0364] CTGGACTGTAAATGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGT
[0365] AAACGATGAATACTAGGTGTTGGGGAGCACAGCTCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGG
[0366] AGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCG
[0367] AAGCAACGCGAAGAACCTTACCAAGTCTTGACATCCCGATGACCGTCCCGTAACGGGGGCTTCTCTTCGGAGCAT
[0368] CGGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACC
[0369] CTTATCTTTAGTAGCCAGCGGTACGGCCGGGCACTCTAGAGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGA
[0370] TGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAAA
[0371] CTGTGAAGTCTAGCAAATCTCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGG
[0372] AATCGCTAGTAATCGCGAATCAGCATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCA
[0373] TGGGAGTTGGAAACGCCCGAAGTCAGTGACCCAACCGTAAGGAGGGAGCTGCCGAAGGCGGGTCTGATAACTGGG
[0374] GTGAAGTCGTAACAAGGTAACCG
[0375] HMI_8 Clostridium orotidis 16S rDNA sequence (SEQ ID NO: 8)
[0376] TTTTGATTGATTTCTTCGGAAAGAGAGAGACTGTGACTGAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGC
[0377] CTCATACAGGGGGATAACAGTTAGAAATGACTGCTAATACCGCATAAGCACACAGCTTCGCATGAAGCAGTGTGA
[0378] AAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGGTAGTTGGTGGGGTAACGGCCCACCAAGCCGACGAT
[0379] CAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGT
[0380] GGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGATGAAGTATTTCGGTATGTAAAC
[0381] TTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAA
[0382] TACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTAATGCAAGTCTGGAGTGAA
[0383] AACCCGGGGCTCAACCCCGGGACTGCTTTGGAAACTGTGTAACTAGAGTGTCGGAGAGGCAAGTGGAATTCCTAG
[0384] TGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTGCTGGACGATGACTGACGTTG
[0385] AGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGACTACTAGGTGT
[0386] CGGTAAGCAAAGCTTATCGGTGCCGCAGCAAACGCAATAAGTAGTCCACCTGGGGAGTACGTTCGCAAGAATGAA
[0387] ACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTA
[0388] CCTGGTCTTGACATCCCTCTGACAGCTGAGTAATGTCGGTTTTCTTTCGGGACAGAGGAGACAGGTGGTGCATGG
[0389] TTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCTTCAGTAGCCAGCA
[0390] TATGAGATGGGCACTCTGGAGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGATGACGTCAAATCATCATGCC
[0391] CCTTATGATCAGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCTGCGAGGGGGAGCAAATCC
[0392] CAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTAATCGCGAAT
[0393] CAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGA
[0394] AGTCAGTGACCCAACCTTTCAGGAGGGAGCTGCCGAAGGCGGGACCGATAACTGGGGTGAAGTCGT
[0395] HMI_9 Eubacterium contortus 16S rDNA sequence (SEQ ID NO: 9)
[0396] CTTAAGTTTGATTCTTCGGATGAAGACTTTTGTGACTGAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCC
[0397] TCATACAGGTGGATAACAGTTAGAAATGACTGCTAATACCGCATAAGACCACAGCACCGCATGGTGCAGGGGTAA
[0398] AAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGGGGTAACGGCCTACCAAGGCGACGATC
[0399] AGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTG
[0400] GGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGATGAAGTATTTCGGTATGTAAACT
[0401] TCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAAT
[0402] ACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTATGGCAAGTCTGATGTGAAA
[0403] GGCCAGGGCTCAACCCTGGGACTGCATTGGAAACTGTCGAACTAGAGTGTCGGAGAGGCAAGTGGAATTCCTAGT
[0404] GTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTGCTGGACGATGACTGACGTTGA
[0405] GGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGACTACTAGGTGTC
[0406] GGGTAGCAGAGCTATTCGGTGCCGCAGCCAACGCAATAAGTAGTCCACCTGGGGAGTACGTTCGCAAGAATGAAA
[0407] CTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTAC
[0408] CTGCTCTTGACATCTCCCTGACCGGCAAGTAATGTTGCCTTTCCTTCGGGACAGGGATGACAGGTGGTGCATGGT
[0409] TGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCTTTAGTAGCCAGCGG
[0410] TTTGGCCGGGCACTCTAGAGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCC
[0411] CTTATGAGCAGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCTGCGAGGGTAAGCAAATCTC
[0412] AAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTAATCGCGAATC
[0413] AGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTTGGTAACGCCCGAA
[0414] GTCAGTGACCCAACCGCAAGGAGGGAGCTGCCGAAGGTGGGACCGATAACTGGGGTGAAGTCGTAACAAGGTAAC
[0415] CG
[0416] HMI_10 Clostridium orotidis 16S rDNA sequence (SEQ ID NO: 10)
[0417] ACATGCAAGTCGAGCGAGCGCTTTAGTGGAATTCTACGGAAGGAAAGTGAAGTGACTGAGCGGCGGACGGGTGAG
[0418] TAACGCGTGGGTAACCTGCCTCATACAGGGGGATAACAGTTAGAAATGACTGCTAATACCGCATAAGACCCCAGT
[0419] ACCGCATGGTACAGAGGTAAAAACTGAGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGAGGTAGA
[0420] GGCTCACCAAGGCGACGATCAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAAAC
[0421] TCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGCGAAGA
[0422] AGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCACCGGCTAAATAC
[0423] GTGCCAGCAGCCGCGGTAATACGTATGGTGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGA
[0424] GCAGCAAGTCTGATGTGAAAACCCGGGGCTCAACCCCGGGAGTGCATTGGAAACTGTTGATCTAGAGTGCTGGAG
[0425] AGGTAAGTGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTAC
[0426] TGGACAGTGACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTA
[0427] AACGATGACTACTAGGTGTCGGGTAGCAAAGCTATTCGGTGCCGCAGCCAACGCAATAAGTAGTCCACCTGGGGA
[0428] GTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGA
[0429] AGCAACGCGAAGAACCTTACCTGCCCTTGACATCCGGGTGACCGGCGAGTAATGTCGCCTTCTCTTCGGAGCAGC
[0430] CGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCC
[0431] TTATCTTTAGTAGCCAGCGGATAAGCCGGGGACTCTAGAGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGAT
[0432] GACGTCAAATCATCATGCCCCTTATGGGCAGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAAGC
[0433] TGTGAAGCGGAGCGAATCTCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGA
[0434] ATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCAT
[0435] GGGAGTCAGTAACGCCCGAAGTCAGTGACCCAACCGTAAGGAGGGAGCTGCCGAAGGCGGGACGGATAACTGGGG
[0436] TGAAGTCGTAACAAGGTAACCG
[0437] HMI_11Lachnospirapectinoschiza 16S rDNA sequence (SEQ ID NO: 11)
[0438] AGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCCTGTACAGGGGGACAACAGCTGGAAACGGCTGCTAATA
[0439] CCGCATAAGCCCTTAGCACTGCATGGTGCATAGGGAAAAGGAGCAATCCGGTACAGGATGGACCCGCGTCTGATT
[0440] AGCCAGTTGGCAGGGTAACGGCCTACCAAAGCGACGATCAGTAGCCGATCTGAGAGGATGTACGGCCACATTGGG
[0441] ACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGAGGAAACTCTGATGCAGC
[0442] GACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTA
[0443] AGAAGCACCGGCTAAATACGTGCCAGCAGCCGCGGTAATACGTATGGTGCAAGCGTTATCCGGATTTACTGGGTG
[0444] TAAAGGGAGCGTAGGTGGCAAGGCAAGCCAGAAGTGAAACCCGGGGCTCAACCGCGGGATTGCTTTTGGAACTG
[0445] TCATGCTAGAGTGCAGGAGGGGTGAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACC
[0446] GGAGGCGAAGGCGGCTCACTGGACTGTAACTGACACTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATAC
[0447] CCTGGTAGTCCACGCGGTAAACGATGAATACTAGATGTCGGGTAGCAAAGCTACTCGGTGTCGTCGCAAACGCAA
[0448] TAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGG
[0449] AGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCTGCTCTTGACATCCCATTCGATAGAGGGTAATGCT
[0450] TCTAGCCCTTCGGGGGAATGGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGT
[0451] CCCGCAACGAGCGCAACCCTTATTGTCAGTAGCCAGCAGGTGAAGCTGGGCACTCTGATGAGACTGCCGGGGATA
[0452] ACCCGGAGGAAGGTGGGGATCGTCAAATCATCATGCCCCTTATGAGCAGGGCTACACACGTGCTACAATGGCG
[0453] TAAACAGAGGGAAGCGAAGGAGTGATCTGGAGCAAATCTCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAA
[0454] CTCGACTACATGAAGCTGGAATCGCTAGTAATCGCAGATCAAAATGCTGCGGTGAATACGTTCCCGGGTCTTGTA
[0455] CACACCGCCCGTCACACCATGGGAGTCGGTAATGCCCGAAGTCAGTGACTCAACCGAAAGGAAAAAGCTGCCGAA
[0456] GGCAGGACTGGTAACTGGGGTGAAGTCGT
[0457] HMI_12 Roseburia faecis 16S rDNA sequence (SEQ ID NO:12)
[0458] AGTCGAACGAAGCACTTTATTACGATTTCTTCGGAATGACGATTTAGTGACTGAGTGGCGGACGGGTGAGTAACG
[0459] CGTGGGTAACCTGCCTTATACAGGGGGATAACAGTTAGAAATGACTGCTAATACCGCATAAGCGCACAGGATTGC
[0460] ATGATCTGGTGTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTCTGATTAGCTGGTTGGTGAGGTAACGGCCC
[0461] ACCAAGGCGACGATCAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTA
[0462] CGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGCGAAGAAGTAT
[0463] TTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAAAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGT
[0464] GCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGCAGGCGGTGC
[0465] GGCAAGTCTGATGTGAAAGCCCGGGGCTCAACCCCGGGACTGCATTGGAAACTGTCGTACTTGAGTATCGGAGAG
[0466] GTAAGTGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTG
[0467] GACGATAACTGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAA
[0468] CGATGAATACTAGGTGTCGGGGGACATAGTCCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGGAGT
[0469] ACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAG
[0470] CAACGCGAAGAACCTTACCAAGTCTTGACATCCCGGTGACAAAGTATGTAATGTACTCTTTCTTCGGAACACCGG
[0471] TGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCT
[0472] GTTCTTAGTAGCCAGCGGTTCGGCCGGGCACTCTAGGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGA
[0473] CGTCAAATCATCATGCCCCTTATGACTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAAAAGG
[0474] TGACTTCTAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGTAGTCTGCAACTCGACTACACGAAGCTGGAAT
[0475] CGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGG
[0476] GAGTCGGGAATGCCCGAAGCCGGTGACTCAACCGAAAGGAGAGAGCCGTCGAAGGCAGGTCTGATAACTGGGGTG
[0477] AAGTCGTAACAAGGTAACC
[0478] HMI_14 Clostridium hathewayi 16S rDNA sequence (SEQ ID NO:13)
[0479] AGTCGACGGAGATGCGATGTGAGCGAGAGGTGCTTGCACTGATCAATCTTTTCGTATCTTAGTGGCGGACGGGTG
[0480] AGTAACGCGTGGGTAACCTGCCTTATACCGGGGGATAACACTTAGAAATAGGTGCTAATACCGCATAAGCGCACG
[0481] GTGTCGCATGACACAGTGTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTCTGATTAGCCAGTTGGCAGGGTA
[0482] ACGGCCTACCAAAGCGACGATCAGTAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAA
[0483] ACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGTGAA
[0484] GAAGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAGAAATGACGGTACCTGACTAAGAAGCCCCGGCTAA
[0485] CTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGA
[0486] CGGTGAAGCAAGTCTGAAGTGAAAGGTTGGGGCTCAACCCCGAAACTGCTTTGGAAACTGTTTAACTGGAGTACA
[0487] GGAGAGGTAAGTGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGC
[0488] TTACTGGACTGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGC
[0489] CGTAAACGATGATTACTAGGTGTTGGTGGATATGGATCCATCGGTGCCGCAGCAAACGCAATAAGTAATCCACCT
[0490] GGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAA
[0491] TTCGAAGCAACGCGAAGAACCTTACCTGATCTTGACATCCCTATGAATACAGGGTAATGCCTGTAGTACTTCGGT
[0492] ACATAGGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGC
[0493] AACCCCTATCTTTAGTAGCCAGCAGTAAGATGGGCACTCTAGAGAGACTGCCGGGGATAACCCGGAGGAAGGTGG
[0494] GGATGACGTCAAATCATCATGCCCCTTATGACCAGGGCTACACACGTGCTACAATGGCGTAAACAGAGGGAAGCG
[0495] AAGTGGTGACATGGAGCAAATCCCAAAAATAACGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGC
[0496] TGGAATCGCTAGTAATCGCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACA
[0497] CCATGGGAGTAGGTAATGCCCGAAGTCGGTGACCTAACCGCAAGGAAGGAGCCGCCGAAGGCAGGACTTATAACT
[0498] GGGGTGAAGTCGTAACAAGGTAACCGT
[0499] HMI_15 Fusicatenibacter_saccharivorans 16S rDNA sequence (SEQ ID NO:14)
[0500] CGGATGGAATCGGTATAACTTAGTGGCGGACGGGTGAGTAACGCGTGGGAAACCTGCCCTGTACCGGGGGATAAC
[0501] ACTTAGAAATAGGTGCTAATACCGCATAAGCGCACGGAACTGCATGGTTCTGTGTGAAAAACTCCGGTGGTACAG
[0502] GATGGTCCCGCGTCTGATTAGCCAGTTGGCAGGGTAACGGCCTACCAAAGCGACGATCAGTAGCCGGCCTGAGAG
[0503] GGTGAACGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATG
[0504] GGGGAAACCCTGATGCAGCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGA
[0505] AAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGT
[0506] TATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCATGGCAAGCCAGATGTGAAAACCCAGGGCTCAACCTT
[0507] GGGATTGCATTTGGAACTGCCAGGCTGGAGTGCAGGAGAGGTAAGCGGAATTCCTAGGTAGCGGTGAAATGCGT
[0508] AGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACTGTAACTGACGTTGAGGCTCGAAAGCGTGGGG
[0509] AGCAAACAGGATTAGATACCCTGGTAGTCCACGCGGTAAACGATGATTGCTAGGTGTAGGTGGGTATGGACCCAT
[0510] CGGTGCCGCAGCTAACGCAATAAGCAATCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTTGACG
[0511] GGGACCCGCAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCCC
[0512] AATGACGCACCTGTAAAGAGGTGTTCCCTTCGGGGCATTGGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGT
[0513] CGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTCTTAGGCCAGCAGGTGAAGCTGGGCACTC
[0514] TAAGGAGACTGCCGGGGATAACCCGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTTATTTGGGCT
[0515] ACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGACAGTGATGTGGAGCAAATCCCAGAAATAACGTCTCA
[0516] GTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTAATCGCGAATCAGCATGTCGCGGTGA
[0517] ATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTTGGAAATGCCCGAAGTCTGTGACCTAACC
[0518] GAAAGGGAGGAGCAGCCGAAGGCAGGTCTGATAACTGGGGTGAAGTCGTA
[0519] HMI_16 Clostridium_clostridioforme 16S rDNA sequence (SEQ ID NO: 15)
[0520] CTGCTTTGATGAAGTTTTCGGATGGATTTAAAACAGCTTAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGC
[0521] CTCACACTGGGGGATAACAGTTAGAAATAGCTGCTAATACCGCATAAGCGCACGGTTCCGCATGGAACAGTGTGA
[0522] AAAACTCCGGTGGTGTGAGATGGACCCGCGTCTGATTAGCCAGTTGGCGGGGTAACGGCCCACCAAAGCGACGAT
[0523] CAGTAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGT
[0524] GGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAAAG
[0525] CTCTATCAGCAGGGAAGAAAGTGACGGTACCTGAATAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAA
[0526] TACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCAAGGCAAGTCTGAAGTGAA
[0527] AGCCCGGTGCTTAACGCCGGGACTGCTTTGGAAACTGTTTAGCTGGAGTGCCGGAGAGGTAAGCGGAATTCCTAG
[0528] TGTAGCGGTGAAATGCGTAGATATTAGGAAGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTG
[0529] AGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGATTGCTAGGTGT
[0530] AGGTGGGTATGGACCCATCGGTGCCGCAGCTAACGCAATAAGCAATCCACCTGGGGAGTACGTTCGCAAGAATGA
[0531] AACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTT
[0532] ACCAGGTCTTGACATCCCGATGAAAAACCCGTAACGGGGTTCCCTCTTCGGAGCATCGGAGACAGGTGGTGCATG
[0533] GTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTCTTAGTAGCCAGC
[0534] AGGTAAGGCTGGGCACTCTAAGGAGACTGCCGGGGATAACCCGGAGGAAGGTGGGGATGACGTCAAATCATCATG
[0535] CCCCTTATGATCTGGGCTACACACGTGCTACAATGGCGTAACAAAGGGAAGCGAGCCTGCGAGGGTGAGCAAATC
[0536] CCAAAAATAACGTCCCAGTTCGGACTGTAGTCTGCAACCCGACTACACGAAGCTGGAATCGCTAGTAATCGCGAA
[0537] TCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCGGAAATGCCCG
[0538] AAGTCTGTGACTCAACCGCAAGGAGAGAGCAGCCGAAGGCAGGTCTGATAACTGGGGTGAAGTCGT
[0539] HMI_17 Ruminococcus contortus 16S rDNA sequence (SEQ ID NO: 16)
[0540] CGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGGGGTAACGGCCTACCAAGGCG
[0541] ACGATCAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAAA
[0542] CTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGAC
[0543] GCCGCGTGAGCGAAGAAGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAAATGAC
[0544] GGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGG
[0545] GCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCGAGGCAAGTCTGAT
[0546] GTGAAAACCCGGGGCTCAACCCCGTGACTGCATTGGAAACTGTTTTGCTTGAGTGCCGGA
[0547] GAGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGT
[0548] GGCGAAGGCGGCTTACTGGACGGCAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAAC
[0549] AGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCGGGGAGCAA
[0550] AGCTCTTCGGTGCCGCCGCAAACGCAATAAGTATTCCACCTGGGGAGTACGTTCGCAAGA
[0551] ATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCG
[0552] AAGCAACGCGAAGAACCTTACCAAGCCTTGACATCCCATTGACAGAGCATGTAATGTGCT
[0553] TTCCCTTCGGGGCAGTGGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGAT
[0554] GTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCTTCAGTAGCCAGCGGTTTGGCCGG
[0555] GCACTCTGGAGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGATGACGTCAAATCATC
[0556] ATGCCCCTTATGGCTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGC
[0557] CTGCGAGGGGGAGCAAATCCCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCG
[0558] ACTACATGAAGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCC
[0559] CGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCGGCAACGCCCGAAGCCAGTGAC
[0560] CCAACCGAAAG
[0561] HMI_18 Clostridium_celerecrescens 16S rDNA sequence (SEQ ID NO:17)
[0562] AGTCGACGAGGTAATGAGATGAAGTTTTCGGATGGATTCTTATTTCCGAGTGGCGGACGGGTGAGTAACGCGTGG
[0563] GTAACCTGCCTCATACAGGGGGATAACGATTGGAAACGATTGCTAATACCGCATAAGCGCACAGTACCACATGGT
[0564] ACAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGAGGTAACGGCCCACCAA
[0565] GGCAACGATCAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGA
[0566] GGCAGCAGTGGGGGATATTGCACAATGGAGGAAACTCTGATGCAGCGACGCCGCGTGAGTGAAGAAGTATTTCGG
[0567] TATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAG
[0568] CCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCGATGCAAGTC
[0569] TGAAGTGAAATACCCGGGCTCAACCTGGGAACTGCTTTGGAAACTGTATGGCTAGAGTGCTGGAGAGGTAAGCGG
[0570] AATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAAGAACACCAGTGGCGAAGGCGGCTTACTGGACAGTAA
[0571] CTGACGTTCAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAAT
[0572] ACTAGGTGTCGGGGGACAAAGTCTTTCGGTGCCGCCGCAAACGCAAATAAGTATTCCACCTGGGGAGTACGTTCGC
[0573] AAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGA
[0574] AGAACCTTACCAAATCTTTGACATCCCTCTGAAAAGCCTTTAATCGAGCTCCTCCTTCGGGACAGAGGTGACAGGT
[0575] GGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATTGTCAG
[0576] TAGCCAGCAGGTAAAGCTGGGCACTCTGATGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGATGACGTCAAA
[0577] TCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGAGAGGCGAAGCTGTGAGGCA
[0578] GAGCAAATCTCAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGT
[0579] AATCGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCGG
[0580] AAATGCCCGAAGCCAGTGACCCAAGCGAAAGCAGGGAGCTGTCGAAGGCAGGTCTGATAACTGGGGTGAAGTCGT
[0581] HMI_19Clostridium_celerescens 16S rDNA sequence (SEQ ID NO:18)
[0582] TCGACGAGGTATTTTGATTGAAGTTTTCGGATGGATTTCAGATACCGAGTGGCGGACGGGTGAGTAACGCGTGGG
[0583] TAACCTGCCTCATACAGGGGGATAACGGTTAGAAATGACTGCTAATACCGCATAAGCGCACAGTACCGCATGGTA
[0584] CGGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGTGGGGTAACGGCCCACCAAG
[0585] GCGACGATCAGTAGCCGACCTGAGAGGGTGACCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAG
[0586] GCAGCAGTGGGGGATATTGCACAATGGAGGAAACTCTGATGCAGCGACGCCGCGTGAGTGAAGAAGTATTTCGGT
[0587] ATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGC
[0588] CGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCGACGCAAGTCT
[0589] GAAGTGAAATACCCGGGCTCAACCTGGGAACTGCTTTGGAAACTGTGTTGCTAGAGTGCTGGAGAGGTAAGCGGA
[0590] ATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAAGAACACCAGTGGCGAAGGCGGCTTACTGGACAGTAAC
[0591] TGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATA
[0592] CTAGGTGTTGGTGAGCAAAGCTCATCGGTGCCGCCGCAAACGCAATAAGTATTCCACCTGGGGAGTACGTTCGCA
[0593] AGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAA
[0594] GAACCTTACCAAATCTTGACATCCCTCTGAAACGCCCTTAATCGGGCTCCTCCTTCGGGACAGAGGTGACAGGTG
[0595] GTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATTGTCAGT
[0596] AGCCAGCAGGTAAAGCTGGGCACTCTGATGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGGATGACGTCAAAT
[0597] CATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGAGAAGCGAGCCTGCGAGGGGG
[0598] AGCAAATCTCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTA
[0599] ATCGCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCGGA
[0600] AATGCCCGAAGCCAGTGACCCAAGCGAAAGCAGGGAGCTGTCGAAGGCAGGTCTGATAACTGGGGTGAAGTCGTA
[0601] ACAGGGTAACCG
[0602] HMI_20 Eubacterium_infirmum 16S rDNA sequence (SEQ ID NO:19)
[0603] GAGCTCATCACAGATGCTTCGGTTGAAGTGATGAGTGGAAAGCGGCGGACGGGTGAGTAA
[0604] CGCGTAGGCAACCTGCCCTTTGCAGAGGGATAGCCTCGGGAAACCGGGATTAAAACCTCA
[0605] TGACACCTCTTAAAGACATCTTTGAGAGGTCAAAGATTTATCGGCAGAGGATGGGCCTGC
[0606] GTCTGATTAGCTAGTTGGTGGGGTAACGGCCTACCAAGGCGACGATCAGTAGCCGACCTG
[0607] AGAGGGTGATCGGCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAGCAG
[0608] TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCAACGCCGCGTGAAGGAAGAAGG
[0609] CCTTTGGGTCGTAAACTTCTGTTCTAAGGGAAGATAATGACGGTACCTTAGGAGCAAGTC
[0610] CCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGAATT
[0611] ATTGGGCGTAAAGAGTACGTAGGTGGTTACCTAAGCACGAGGTATAAGGCAATGGCTTAA
[0612] CCATTGTTCGCCTTGTGAACTGGGCTACTTGAGTGCAGGAGAGGAAAGCGGAATTCCTAG
[0613] TGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTTCTGGA
[0614] CTGTAACTGACACTGAGGTACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAG
[0615] TCCACGCCGTAAACGATGAGCACTAGGTGTCGGGGTCGCAAGACTTCGGTGCCGCAGTTA
[0616] ACGCAATAAGTGCTCCGCCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGAC
[0617] GGGGACCCGCACAAGCAGCGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTAC
[0618] CAGGACTTGACATCCCTCTGACAGCCTTTTAATCGAGGTTTTCTACGGACAGAGGAGACA
[0619] GGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG
[0620] CGCAACCCTTGTCATTAGTTGCCAGCAGTAAGATGGGCACTCTAGTGAGACTGCCGGGGA
[0621] TAACTCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGTTCTGGGCTACA
[0622] CACGTGCTACAATGGCCGGTACAGAGAGAAAGCGAGACTGCGAAGTGGAGCGAAACTCAA
[0623] AAGCCGGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGTCGGAGTTGCTAG
[0624] TAATCGCAGATCAGAATGCTGCGGTGAATGCGTTCCCGGGTCTTGTACACACCGCCCGTC
[0625] ACACCATGGAAGTTGGGGGCGCCCGAAGTTGGCAGATAAATATGTTACCTAAGGCGAAAT
[0626] CAATGACTGGGGTGAAGTCGT
[0627] HMI_21 Eubacterium_infirmum 16S rDNA sequence (SEQ ID NO:20)
[0628] TCGGTAAAGGGATATGGCGGAAAGCGGCGGACGGGTGAGTAACGCGTAGGCAACCTGCCC
[0629] CTTACAGAGGGATAGCCATTGGAAACGATGATTAAGACCTCATAACGCCTCCCTCCCACA
[0630] TGAGGGGGAGGCCAAAGATTCATCGGTAAGGGATGGGCCTGCGTCTGATTAGCTTGTTGG
[0631] CGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGACCTGAGAGGGTGATCGGCCACA
[0632] TTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAAT
[0633] GGGCGGAAGCCTGATGCAGCAACGCCGCGTGAGGGATGAAGGCCTTCGGGTCGTAAACCT
[0634] CTGTCCTTGGGGAAGAAACAAATGACGGTACCCATGGAGGAAGCCCCGGCTAACTACGTG
[0635] CCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGAATTATTGGGCGTAAAGAG
[0636] TGCGTAGGTGGTTACCTAAGCGCAGGGTCTAAGGCAATGGCTCAACCATTGTTCGCCCTG
[0637] CGAACTGGGCTACTTGAGTGCAGGAGAGGAAAGCGGAATTCCTAGTGTAGCGGTGAAATG
[0638] CGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTTCTGGACTGTTACTGACACTG
[0639] AGGCACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACG
[0640] ATGAGCACTAGGTGTCGGGGCCGCAAGGCTTCGGTGCCGCAGTTAACGCATTAAGTGCTC
[0641] CGCCTGGGGAGTACGCACGCAAGTGTGAAACTCAAAGGAATTGACGGGGACCCGCACAAG
[0642] CAGCGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGACTTGACATCC
[0643] CCCTGACAGATCCTTAACCGGATCCTTCTTCGGACAGGGGAGACAGGTGGTGCATGGTTG
[0644] TCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGCCAT
[0645] TAGTTGCCATCATTCAGTTGGGCACTCTAATGGGACTGCCGGGGACAACTCGGAGGAAGG
[0646] TGGGGATGACGTCAAATCATCATGCCCCTTATGTTCTGGGCTACACACGTGCTACAATGG
[0647] CCGGTACAGCAGGAAGCGATCCCGCGAGGGGGAGCAAATCCCAAAAACCGGTCCCAGTTC
[0648] GGACTGCAGGCTGCAACCCGCCTGCACGAAGCCGGAGTTGCTAGTAATCGTGGATCAGAA
[0649] TGCCACGGTGAATGCGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGAAGTTGG
[0650] GGGTGCCCGAAGCCGGCAGGGAGATATGCTGTCTAAGGCAAAACCAAT
[0651] HMI_22 Clostridium thermocellum 16S rDNA sequence (SEQ ID NO: 21)
[0652] GGATGAGGAAATGCTTCGGCATGGAGACATCCGATCTAGTGGCGGACGGGTGAGTAACGC
[0653] GTGAGCAACCTGTCCTGCACAGGGGGATAACACTGAGAAATCAGTGCTAATACCGCATGA
[0654] GACCACAGTATCACATGGTACAGGGGTCAAAGGAGAAATCCGGTGCAGGGTGGGCTCGCG
[0655] TCCCATTAGCTAGTTGGTAGGGTAAAGGCCTACCAAGGCGACGATGGGTAGCCGGACTGA
[0656] GAGGTTGGCCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGT
[0657] GGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAGCAACGCCGCGTGAAGGAAGAAGGT
[0658] CTTTGGATTGTAAACTTTTGTCCTATGGGAAGAAGGAAGTGACGGTACCATGGGAGGAAG
[0659] CCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTGTCCGGAA
[0660] TTACTGGGCGTAAAGGGCGCGCAGGCGGCCGATCAAGTTAGATGTGAAATACCCGGGCTT
[0661] AACCTGGGAACTGCATTTAAAACTGGTTGGCTAGGAGTGCAGGAGAGGGAAGCGGAATTC
[0662] CTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTTC
[0663] TGGACTGTAACTGACGCTGAGGCGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTG
[0664] GTAGTCCACGCTGTAAACGATGAATACTAGGTGTAGGGGGTATCGACCCCCCCTGTGCCG
[0665] GAGCAAACGCAATAAGTATTCCGCCTGGGGAGTACGGCCGCAAGGTTGAAACTCAAAGGA
[0666] ATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAA
[0667] CCTTACCAGGTCTTGACATCCCTCGAAGTGCATAGAGATATGTACGTCCTTCGGGACGAG
[0668] GAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGC
[0669] AACGAGCGCAACCCCTACAGTTAGTTACCAGCGGGTAAAGCCGGGGACTCTAACAGGACT
[0670] GCCGTGGATAACACGGAGGAAGGTGGGGACGACGTCAAATCATCATGCTCCTTATGACCT
[0671] GGGCTACACACGTGCTACAATGGCCGGTACAAAGAGAAGCGAGACCGTAAGGTGGAGCGG
[0672] ATCTCAAAAAACCGGTCCCAGTTCGGATTGTGGGCTGCAACCCGCCCACATGAAGTTGGA
[0673] GTTGCTAGTAATCGCGAATCAGCATGTCGCGGTGAATGCGTTCCCGGGCCTTGTACACAC
[0674] CGCCCGTCACACCATGGGAGTTGGGAGCGCCCGAAGTCGTTGAGGTAACCCGCAAGGGAG
[0675] CCAGGCGCCGAAGGTGAGACCGATAACTGGGGTGAAGTCGT
[0676] HMI_23Anaerovorax_odorimutans 16S rDNA sequence (SEQ ID NO:22)
[0677] AGAGTTTGATCCTGGCTCAGGATGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGC
[0678] GGGAAATCTTGGAACGATACTTCGGTAAAGGGAAGAGATGGATAGCGGCGGACGGGTGAG
[0679] TAACGCGTAGGTAACCTGCCTCATGCAGAGGGATAGCCTCGGGAAACTGGGATTAATACC
[0680] TCATAATGCGGAGGAGTCACATGGCTCCATCGCCAAAGATTTATCGGCATGAGATGGACC
[0681] TGCGTCTGATTAGTTAGTTGGTGAGGTAACGGCTCACCAAGGCAGCGATCAGTAGCCGAC
[0682] CTGAGAGGGTAATCGGCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG
[0683] CAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCAACGCCGCGTGAGCGATGA
[0684] AGGTCTTCGGATCGTAAAGCTCTGTCCTAGGGGAAGAATATATGACGGTACCCTTGGAGG
[0685] AAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCG
[0686] GAATTATTGGGCGTAAAGAGTTCGTAGGTGGTTTTGTAAGCGCGGGGTTTAAGGCAACGG
[0687] CTCAACCGTTGTTCGCCTTGCGAACTGCAAGACTTGAGTGCGGGAGAGGAAAGTGGAATT
[0688] CCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGACTTT
[0689] CTGGACCGTAACTGACACTGAGGAACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCT
[0690] GGTAGTCCACGCCGTAAACGATGAGCACTAGGTGTCGGGGCCGCAAGGTTTCGGTGCCGC
[0691] AGTTAACGCATTAAGTGCTCCGCCTGGGGAGTACGCACGCAAGTGTGAAACTCAAAGGAA
[0692] TTGACGGGGACCCGCACAAGCAGCGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAAC
[0693] CTTACCAGGGCTTGACATCCCGATGACCGGCGGGTAACGCCGCCTTCTCTTCGGAGCATC
[0694] GGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCG
[0695] CAACGAGCGCAACCCTTGTCATTAGTTGCCAGCAGTTCGGCTGGGCACTCTAGTGAGACT
[0696] GCCGGGGACAACTCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGTTCT
[0697] GGGCTACACACGTGCTACAATGGCCGGTACAGAGAGACGCAAGACTGTGAAGTGGAGCAA
[0698] AACTCTAAAACCGGTCCCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTTGGAG
[0699] TTGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATGCGTTCCCGGGTCTTGTACACACC
[0700] GCCCGTCACACCATGGAAGTTGGGGGCGCCCGAAGTTGGTCAACAAATCGATTACCTAAG
[0701] GCGAAACCAATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTATCGGAAGGTGCGGCTGG
[0702] ATCACCT
[0703] HMI_24 Clostridium_saccharogumia 16S rDNA sequence (SEQ ID NO:23)
[0704] AGCCACCGGCTTCGGGTGTTATCAACTCTCATGGTGTGACGGGCGGTGTGTACAAGGCCC
[0705] GAGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCGATTCCATCTTCATGCAG
[0706] GCGAGTTGCAGCCTGCAATCCGAACTGAGAACGGGTTTTTGAGTTTCGCTCCAAGTCGCC
[0707] TCTTCGCTTCCCTTTGATCCGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCA
[0708] TGATGATTTGACGTCATCCCCGCCTTCCTCCGGCTTGTCACCGGCTGTCTCGTTAGAGTC
[0709] CCCATCTTACTGCTGGTAACTAACGACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAAC
[0710] ATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTTGAGTATATCTATCCCTC
[0711] TATCTCTAGAGTCTTTACTCTGATGTCAAGACCTGGTAAGGTTCTTCGCGTTGCTTCGAA
[0712] TTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCATTCTT
[0713] GCGAACGTACTACTCAGGCGGAGTACTTATTGCGTTAACTGCAGCACTGAGGCTTGTCCC
[0714] CCCAACACTTAGTACTCATCGTTTACGGCGTGGACTACTAGGGTATCTAATCCTATTTGC
[0715] TCCCCACGCTTTCGGGACTGAGCGTCAGTTACAGACCAGATCGTCGCCTTCGCCACTGGT
[0716] GTTCCTCCATATATCTACGCATTTCACCGCTACACATGGAATTCCACGATCCTCTTCTGC
[0717] ACTCTAGCTATTTGGTTTCCATGGCTTACTGAAGTTAAGCTTCAGCCTTTTACCACAGAC
[0718] CTCCATTGCCGCCTGCTCCCTCTTTACGCCCAATAATTCCGGATAACGCTTGCCACCTAC
[0719] GTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTGGCTTCCTCACAAAGTACCGTCACTC
[0720] TAATACCATTCCCTGTATTAGTCGTTCTTCCTTTATAACAGAAGTTTACAACCCGAAGGC
[0721] CTTCTTCCTTCACGCGGCGTTGCTCGGTCAGGGTTCCCCCCATTGCCGAAAATTCCCTAC
[0722] TGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGTTCACCCTCTC
[0723] AGGCCGGCTATGCATCGTCGCCTTGGTAGGCCGTTACCCCTCCAACTAGCTAATGCACCA
[0724] TAAGCCCATCTGTTCCCTATCCCTTAGGATATTTAACTTAGAGAAAATGCTTCCTCTAAG
[0725] CCTATGCGGTGTTAGCGCATGTTTCCACGCGTTATCCCCCTGGTACAGCCAGGTTGCTTA
[0726] TGTCTTACTCACCCGTTCGCCACTCATCACCGAAGTGATGCGTTCGACTTGCATGTAT
[0727] HMI_25Clostridium_saccharogumia16S rDNA sequence (SEQ ID NO:24)
[0728] GGCATCTACAGGGGGATAACTGATGGAAACGTCAGCTAAGACCGCATAGGTGTAGAGATC
[0729] GCATGAACTCTATATGAAAAGTGCTACGGGACTGGTAGATGATGGACTTATGGCGCATTA
[0730] GCTTGTTGGTAGGGTAACGGCCTACCAAGGCGACGATGCGTAGCCGACCTGAGAGGGTGA
[0731] CCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATT
[0732] TTCGGCAATGGGGGAAACCCTGACCGAGCAACGCCGCGTGAAGGAAGAAGTAATTCGTTA
[0733] TGTAAACTTCTGTCATAGAGGAAGAACGGTGGATATAGGGAATGATATCCAAGTGACGGT
[0734] ACTCTATAAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCG
[0735] AGCGTTATCCGGAATTATTGGGCGTAAAGAGGGAGCAGGCGGCACTAAGGGTCTGTGGTG
[0736] AAAGATCGAAGCTTAACTTCGGTAAGCCATGGAAACCGTAGAGCTAGAGTGTGTGAGAGG
[0737] ATCGTGGAATTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAGGAACACCAGTGGCG
[0738] AAGGCGACGATCTGGCGCATAACTGACGCTCAGTCCCGAAAGCGTGGGGAGCAAATAGGA
[0739] TTAGATACCCTAGTAGTCCACGCCGTAAACGATGAGTACTAAGTGTTGGGTGTCAAAGCT
[0740] CAGTGCTGCAGTTAACGCAATAAGTACTCCGCCTGAGTAGTACGTTCGCAAGAATGAAAC
[0741] TCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAAC
[0742] GCGAAGAACCTTACCAGGTCTTGACATCGATCTAAAGGCTCCAGAGATGGAGAGATAGCT
[0743] ATAGAGAAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAG
[0744] TCCCGCAACGAGCGCAACCCCTGTTGCCAGTTGCCAGCATTAAGTTGGGGACTCTGGCGA
[0745] GACTGCCGGTGACAAGCCGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTTATG
[0746] ACCTGGGCTACACACGTGCTACAATGGACAGAGCAGAGGGAAGCGAAGCCGCGAGGTGGA
[0747] GCGAAACCCATAAAACTGTTCTCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGAAGA
[0748] TGGAATCGCTAGTAATCGCGAATCAGCATGTCGCGGTGAATACGTTCTCGGGCCTTGTAC
[0749] ACACCGCCCGTCACACCATGAGAGTCGGTAACACCCGAAGCCGGTGGCCTAACCGCAAGG
[0750] AAGGAGCTGTCTAAGGTGGGACTGATGATTGGGGTGAAGTCGTAACAAGGGTAACC
[0751] HMI_26 Blautia_luti 16S rDNA sequence (SEQ ID NO:25)
[0752] CGGGAATACTTTATTGAAACTTCGGTGGATTTAATTTATTTCTAGTGGCGGACGGGTGAGTAACGCGTGGGTAAC
[0753] CTGCCTTATACTGGGGGATAACAGCCAGAAATGACTGCTAATACCGCATAAGCGCACAGAACCGCATGGTTCCGT
[0754] GTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTTGGATTAGCTAGTTGGCAGGGCAGCGGCCTACCAAGGCGA
[0755] CGATCCATAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAG
[0756] CAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGT
[0757] AAACTTCTATCAGCAGGGAAGATAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCG
[0758] GTAATACGTAGGGGGCAAGCGTTATCCGGGATTACTGGGTGTAAAGGGAGCGTAGACGGCGCAGCAAGTCTGATG
[0759] TGAAAGGCAGGGGCTTAACCCCTGGACTGCATTGGAAACTGCTGTGCTTGAGTGCCGGAGGGGTAAGCGGAATTC
[0760] CTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGAC
[0761] GTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAG
[0762] GTGTCAGGGAGCACAGCTCTTTGGTGCCGCCGCAAACGCATTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAA
[0763] TGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAAC
[0764] CTTACCAAATCTTGACATCCCTCTGACCGGGACTTAACCGTCCCTTTCCTTCGGGACAGGGGAGACAGGTGGTGC
[0765] ATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCCTTAGTAGCC
[0766] AGCACGTAATGGTGGGCACTCTGAGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATC
[0767] ATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAACCCGCGAGGGTGGGCA
[0768] AATCTCAAAAATAACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGAAGCTGGAATCGCTAGTAATCG
[0769] CGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACG
[0770] CCCGAAGTCAG
[0771] HMI_27 Clostridium_clostridioforme 16S rDNA sequence (SEQ ID NO: 26)
[0772] TTGCGGTAGGTCACAGGCTTCGGGCATTTCCAACTCCCATGGTGTGACGGGCGGTGTGTA
[0773] CAAGACCCGGGAACGTATTCACCGCGACATGCTGATTCGCGATTACTAGCGATTCCAGCT
[0774] TCATGTAGTCGAGTTGCAGACTACAATCCGAACTGAGACGTTATTTCTGGGATTTGCTCA
[0775] ACATCACTGTCTCGCTTCCCTTTGTTTACGCCATTGTAGCACGTGTGTAGCCCAAATCAT
[0776] AAGGGGCATGATGATTTGACGTCATCCCCGCCTTCCTCCGGGTTATCCCCGGCAGTCTCC
[0777] CTAGAGTGCCCAGCTCTACCTGCTGGCTACTAAGGATAAGGGTTGCGCTCGTTGCGGGAC
[0778] TTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTCCAATGCT
[0779] CCGAAGAGAATGCCCCGTTACGGACACGTCATTGGGATGTCAAGACTTGGTAAGGTTCTT
[0780] CGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTCCCCGTCAATTCCTT
[0781] TGAGTTTCATTCTTGCGAACGTACTCCCCAGGTGGATTGCTTATTGCGTTAGCTGCGGCA
[0782] CCGATGGGTCCATACCCACCTACACCTAGCAATCATCGTTTACCGCGTGGACTACCAGGG
[0783] TATCTAATCCTGTTTGCTCCCCACGCTTTCGAGCCTCAACGTCAGTTACAGTCCAGTAAG
[0784] CCGCCTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCACCGCTACACTAGGAATT
[0785] CCGCTTACCTCTCCTGCACTCCAGCCTGGCAGTTCCAAATGCAGTCCCAGGGTTGAGCCC
[0786] TGGGTTTTCACATCTGGCTTGTCATGCCGTCTACGCTCCCTTTACACCCAGTAAATCCGG
[0787] ATAACGCTTGCCCCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGGGCTTCTT
[0788] AGTCAGGTACCGTCATTTTCTTCCCTGCTGATAGAGCTTTACATACCGAAATACTTCTTC
[0789] ACTCACGCGGCGTCGCTGCATCAGGGTTTCCCCCATTGTGCAATATTCCCCACTGCTGCC
[0790] TCCCGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCACCCTCTCAGGCCGG
[0791] CTACTGATCGTCGCTTTGGTAGGCCGTTACCCTGCCAACTGGCTAATCAGACGCGGGACC
[0792] ATCCTGTACCACCGGAGTTTTTCACACTGCCTCATGTGAAGCTGTGCGCTTATGCGGTAT
[0793] TAGCACCTATTTCTAAGTGTTATCCCCCGGTACAGGGCAGGTTTCCCACGCGTTACTCAC
[0794] CCGTCCGCCACTAAGTTACGCCGATTCCATCCGAAAACTTCCTCTGCATAACTCCGTCGA
[0795] CTG
[0796] HMI_28 Blautia_producta 16S rDNA sequence (SEQ ID NO:27)
[0797]
[0798]
[0799] HMI_29 Blautia glucerasea 16S rDNA sequence (SEQ ID NO: 28)
[0800] GCCTTCGGCAGCTCCGTCCTTTCGGTTCGGTCACTGACTTCGGGCGTTACTGACTCCCAT
[0801] GGTGTGACGGGCGGTGTGTACAAGACCCGGGAACGTATTCACCGCGGCATTCTGATCCGC
[0802] GATTACTAGCGATTCCAGCTTCGTGCAGTCGAGTTGCAGACTGCAGTCCGAACTGGGACG
[0803] TTATTTTTGGGATTTGCTTAAGCTCACACTCTCGCTTCCCTTTGTTTACGCCATTGTAGC
[0804] ACGTGTGTAGCCCAAATCATAAGGGGCATGATGATTTGACGTCATCCCCGCCTTCCTCCA
[0805] GGTTATCCCTGGCAGTCTCCTCAGAGTGCCCGGCCAAACCGCTGGCTACTAAGGATAGGG
[0806] GTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGC
[0807] ACCACCTGTCTCCGATGCTCCGAAGAAAAGGCGACGTTACTCGCCGGTCATAGGGATGTC
[0808] AAGACTTGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGC
[0809] GGGTCCCCGTCAATTCCTTTGAGTTTCATTCTTGCGAACGTACTCCCCAGGTGGAATACT
[0810] TACTGCGTTTGCTGCGGCACCGAATGGCTCTGCCACCCGACACCTAGTATTCATCGTTTA
[0811] CGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGAGCCTCAACGT
[0812] CAGTTACCGTCCAGTAAGCCGCCTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTC
[0813] ACCGCTACACTAGGAATTCCGCTTACCTCTCCGGTACTCAAGATCAACAGTTTCCAATGC
[0814] AGTCCGGGGGTTGAGCCCCCGCCTTTCACATCAGACTTGCTGCTCCGTCTACGCTCCCTT
[0815] TACACCCAGTAAATCCGGATAACGCTTGCCCCCTACGTATTACCGCGGCTGCTGGCACGT
[0816] AGTTAGCCGGGGCTTCTTAGTCAGGTACCGTCATTTTCTTCCCTGCTGATAGAAGTTTAC
[0817] ATACCGAGATACTTCTTCCTTCACGCGGCGTCGCTGCATCAGGGTTTCCCCCATTGTGCA
[0818] ATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAATGTGGCCG
[0819] TCCACCCTCTCAGGCCGGCTATGGATCGTCGCTTTGGTAGGCCGTTACCCTGCCAACTGG
[0820] CTAATCCAACGCGGGTCCATCTCACACCACCGGAGTTTTTCACACTGGATCATGCAATCC
[0821] CGTGCGCTTATGCGGTATTAGCAGTCATTTCTGACTGTTATCCCCCAGTGTGAGGCAGGT
[0822] TACCCACGCGTTACTCACCCGTCCGCCACTAGGATTATAACGACTTCAACCGAAGTCTCT
[0823] GTCAAAATAATCCCCGTTCGACTTGCATGTGT
[0824] HMI_30 Clostridium_straminisolvens 16S rDNA sequence (SEQ ID NO:29)
[0825] AGCGGCGGACGGGTGAGTAACGCGTGAGTAACCTGCCTTTAGGAGGGGGACAACATTCCGAAAGGGATGCTAATA
[0826] CCGCATAAAATTATTGTATCGCATGGTATAATAATCAAAGATTTATCGCCTAAAGATGGACTCGCGTCCGATTAG
[0827] CTAGTTGGTGGGGTAAAAGCCTACCAAGGCGACGATCGGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGAC
[0828] TGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGGATATTGCGCAATGGGGGAAACCCTGACGCAGCAA
[0829] CGCCGCGTGAAGGAAGAAGGCCTTCGGGTTGTAAACTTCTTTAAGTGTGGAAGATAATGACGGTACACACAGAAT
[0830] AAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTACTGGGTGTA
[0831] AAGGGCGTGTAGGCGGGTAGACAAGTCAGATGTGAAATACCGGGGCTCAACTCCGGGGCTGCATTTGAAACTGTA
[0832] TATCTTGAGTGTCGGAGAGGAAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAG
[0833] TGGCGAAGGCGGCTTTCTGGACGATAACTGACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCC
[0834] TGGTAGTCCACGCCGTAAACGATGGATACTAGGTGTAGGAGGTATCGACCCCTTCTGTGCCGCAGTTAACACAAT
[0835] AAGTATCCCACCTGGGGAGTACGGTCGCAAGATTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGTGGA
[0836] GTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGACTTGACATCCCACGCATAGCCTAGAGATAGGT
[0837] GAAGTCCTACGGGACGTGGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCC
[0838] CGCAACGAGCGCAACCCTTACTGTCAGTTACCATCATTAAGTTGGGGACTCTGGCAGGACTGCCGGTGACAAATC
[0839] GGAGGAAGGTGGGGACGACGTCAAATCATCATGCCCCTTATGTCCTGGGCTACACACGTACTACAATGGCTGTTA
[0840] ACAAAGTGAAGCAAAGCAGTGATGTGGAGCAAAACACAAAAAGCAGTCTCAGTTCAGATTGTAGGCTGAAACTCG
[0841] CCTATATGAAGTCGGAATTGCTAGTAATCGCAGATCAGCATGCTGCGGTGAATACGTTCCCGGGCCTTGTACACA
[0842] CCGCCCGTCACACCATGAGAGTCGATAACACCCGAAGCCTGT
[0843] HMI_31 Butyricoccus_pullicaecorum 16S rDNA sequence (SEQ ID NO:30)
[0844] AGTGGCGGACGGGTGAGTAACGCGTGAGCAATCTGCCTTTAAGAGGGGGATAACAGTCGGAAACGGCTGCTAATA
[0845] CCGCATAAAGCATCGAAACCGCATGATTTTGATGCCAAAGGAGCAATCCGCTTTTAGATGAGCTCGCGTCTGATT
[0846] AGCTGGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGAACGGCCACATTGGG
[0847] ACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCGCAATGGGGGAAACCCTGACGCAGC
[0848] AACGCCGCGTGATTGAAGAAGGCCTTCGGGTTGTAAAGATCTTTAATCAGGGACGAAACAAATGACGGTACCTGA
[0849] AGAATAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCAAGCGTTATCCGGATTTACTGG
[0850] GTGTAAAGGGCGCGCAGGCGGGCCGGTAAGTTGGAAGTGAAATCTATGGGCTTAACCCATAAACTGCTTTTCAAA
[0851] CTGCTGGTCTTGAGTGATGGAGAGGCAGGCGGAATTCCGTGTGTAGCGGTGAAATGCGTAGATATACGGAGGAAC
[0852] ACCAGTGGCGAAGGCGGCCTGCTGGACATTAACTGACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGA
[0853] TACCCTGGTAGTCCACGCCGTAAACGATGGATACTAGGTGTGGGAGGTATTGACCCCTTCCGTGCCGCAGTTAAC
[0854] ACAATAAGTATCCCACCTGGGGAGTACGGCCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCA
[0855] GTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCCGATGACCGCCTCAGAG
[0856] ATGAGCCTTTTCTTCGGAACATCGGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTT
[0857] AAGTCCCGCAACGAGCGCAACCCTTACGGTTAGTTGATACGCAAGATCACTCTAGCCGGACTGCCGTTGACAAAA
[0858] CGGAGGAAGGTGGGGACGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTACTACAATGGCAGTC
[0859] ATACAGAGGGAAGCAAAACCGCGAGGTGGAGCAAATCCCTAAAAGCTGTCCCAGTTCAGATTGCAGGCTGCAACC
[0860] CGCCTGCATGAAGTCGGAATTGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACA
[0861] CACCGCCCGTCACACCATGAGAGCCGTCAATACCCGAAGTCCGT HMI_32Clostridium_ maritium 16S rDNA sequence (SEQ ID NO: 31)
[0862]
[0863] HMI_33_Eubacterium fissicatens 16S rDNA sequence (SEQ ID NO: 32)
[0864]
[0865]
[0866] HMI_34_ Clostridium saccharolyticum 16S rDNA sequence (SEQ ID NO: 33)
[0867]
[0868]
[0869] HMI_35 Blautia_luti 16S rDNA sequence (SEQ ID NO:34)
[0870]
[0871] HMI_36Clostridium_methylpentosum16SrDNA sequence (SEQ IDNO:35)
[0872] GGTTACCTTGTTACGACTTCACCCCAATCATCAACCCCACCTTCGACGACGTCCCCCTTG
[0873] CGGTTAGACTATCGGCTTCGGGTGTTGCCAACTCTCATGGTGTGACGGGCGGTGTGTACA
[0874] AGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCAATTCCGGCTTC
[0875] ATGCAGGCGGGTTGCAGCCTGCAATCCGAACTGAGACTATTTTTAGGGGTTTGCTCCATG
[0876] TCACCATCTTGCTTCCCTCTGTTAATAGCCATTGTAGTACGTGTGTAGCCCAGGTCATAA
[0877] GGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGTTTTGTCAACGGCAGTCCGTCT
[0878] AGAGTGCTCTTGCGTAGCAACTAAACGTAAGGGTTGCGCTCGTTGCGGGACTTAACCCAA
[0879] CATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTCGGTGCCCCGAAGGGCT
[0880] TCACCTATCTCTAGGCTATGCACCGGATGTCAAGACCTGGTAAGGTTCTTCGCGTTGCTT
[0881] CGAATTAAACCACATACTCCACTGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAA
[0882] CCTTGCGGTCGTACTCCCCAGGTGGATTACTTATTGTGTTAACTCCGGCACGGAAGGGGT
[0883] CAGTCCCCCCACACCTAGTAATCATCGTTTACAGCGTGGACTACCAGGGTATCTAATCCT
[0884] GTTTGCTACCCACGCTTTCGAGCCTCAGCGTCAGTTAAAGCCCAGCAGGCCGCCTTCGCC
[0885] ACTGGTGTTCCTCCTAATATTTACGCATTTCACCGCTACACTAGGAATTCCGCCTGCCTC
[0886] TACTTCACTCAAGAACTGCAGTTTTGAACGCGGCTATGGGTTGAGCCCATAGATTTAACA
[0887] TTCAACTTGCAATCCCGCCTACGCTCCCTTTACACCCAGTAATTCCGGACAACGCTCGCT
[0888] ACCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTAGCTTCCTCCTTGGTTACCG
[0889] TCATTATCTTCACCAAGGACAGAGGTTTACAATCCGAAAACCTTCTTCCCTCACTCGGCG
[0890] TCGCTGCATCAGGGTTTCCCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGT
[0891] CTGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCAACCTCTCAGTCCGGCTACCAATCGTC
[0892] GCCTTGGTGGGCCGTTACCTCACCAACTAGCTAATTGGACGCGAGTCCATCTTTCAGCGG
[0893] ATTGCTCCTTTGATATCAGCTCCATGCGAAACCAATATGTTATGCGGTATTAGCGTCCGT
[0894] TTCCAGACGTTATCCCCCTCTGAAAGGCAGGTTACTCACGCGTTACTCACCCGTCCGCCA
[0895] CTAAGTTGAATCAAATTCCTTCCGAAGAATTCATTCAAAGCAACTTCGTCGACTTGCATG
[0896] TGTAAGGCGCGCCGACAGCGTTCGT
[0897] HMI_37 Clostridium xylanicum 16S rDNA sequence (SEQ ID NO: 36)
[0898] AGAGTTTGATCCTGGCTCAGGATGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAAC
[0899] GGAATTTACATGAAGCCTAGCGATTGTAAATTTAGTGGCGGACGGGTGAGTAACGCGTGG
[0900] GTAACCTGCCTTGTACTGGGGGACAACAGTTGGAAACGACTGCTAATACCGCATAAGCGC
[0901] ACAGCTTCGCATGAAGCAGTGTGAAAAACTCCGGTGGTACAAGATGGACCCGCGTCTGAT
[0902] TAGCTGGTTGGTGAGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGCCTGAGAGGGT
[0903] GAACGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTGGGGAA
[0904] TATTGCACAATGGGGGAAACCCTGATGCAGCAACGCCGCGTGAGTGAAGAAGTATTTCGG
[0905] TATGTAAAGCTCTATCAGCAGGAAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTA
[0906] ACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGT
[0907] GTAAAGGGAGCGTAGACGGTTTTGCAAGTCTGAAGTGAAAGCCCGGGGCTTAACCCCGGG
[0908] ACTGCTTTGGAAACTGTAGGACTAGAGTGCAGGAGAGGTAAGTGGAATTCCTAGTGTAGC
[0909] GGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACTGTAA
[0910] CTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACG
[0911] CCGTAAACGATGATTACTAGGTGTTGGTGGGTACGACCCATCGGTGCCGCAGCAAACGCA
[0912] ATAAGTAATCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGA
[0913] CCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCTGGT
[0914] CTTGACATCCCTATGAATAACGGGCAATGCCGTTAGTACTTCGGTACATAGGAGACAGGT
[0915] GGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGC
[0916] AACCCTTATCTTTAGTAGCCAGCAGTAAGATGGGCACTCTAGAGAGACTGCCGGGGATAA
[0917] CCCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCAGGGCTACACAC
[0918] GTGCTACAATGGCGTAAACAAAGAGAAGCGAAGTCGTGAGGCAGAGCGAATCTCAAAAAT
[0919] AACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTAA
[0920] TCGCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACA
[0921] CCATGGGAGTCGGAAATGCCCGAAGTCGGTGACCTAACCGAA
[0922] HMI_38 Oscillibacter_valericigenes 16S rDNA sequence (SEQ ID NO:37)
[0923] CTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAGCACCCTTGACT
[0924] GAGGTTTCGGCCAAATGATAGGAATGCTTAGTGGCGGACTGGTGAGTAACGCGTGAGGAA
[0925] CCTACCTTCCAGAGGGGGACAACAGTTGGAAACGACTGCTAATACCGCATGACGCATGAC
[0926] CGGGGCATCCCGGGCATGTCAAAGATTTTATCGCTGGAAGATGGCCTCGCGTCTGATTAG
[0927] CTAGATGGTGGGGTAACGGCCCACCATGGCGACGATCAGTAGCCGGACTGAGAGGTTGAC
[0928] CGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATAT
[0929] TGGGCAATGGACGCAAGTCTGACCCAGCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTT
[0930] GTAAACTTCTTTTGTCAGGGAAGAGTAGAAGACGGTACCTGACGAATAAGCCACGGCTAA
[0931] CTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTACTGGGTG
[0932] TAAAGGGCGTGCAGCCGGGCCGGCAAGTCAGATGTGAAATCTGGAGGCTTAACCTCCAAA
[0933] CTGCATTTGAAACTGTAGGTCTTGAGTACCGGAGAGGTTATCGGAATTCCTTGTGTAGCG
[0934] GTGAAATGCGTAGATATAAGGAAGAACACCAGTGGCGAAGGCGGATAACTGGACGGCAAC
[0935] TGACGGTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGC
[0936] TGTAAACGATGGATACTAGGTGTGCGGGGACTGACCCCCTGCGTGCGCAGTTAACACAA
[0937] TAAGTATCCCACCTGGGGAGTACGATCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGC
[0938] CCGCACAAGCGGTGATTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGGC
[0939] TTGACATCCTACTAACGAAAGTAGAGATACATCAGGTGCCCTTCGGGGAAAGTAGAGACAG
[0940] GTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCCGCAACGAGC
[0941] GCAACCCTATTGTTAGTTGCTACGCAAGAGCACTCTAGCGAGACTGCCGTTGACAAAAC
[0942] GGAGGAAGGTGGGACGACGTCAAATCATCATGCCCCTTATGTCCTGGGCTACACACGTA
[0943] ATACAATGGCGGTCAACAGAGGGAGGCAAAGCCGCGAGGCAGAGCAAACCCCCAAAAGCC
[0944] GTCCCAGTTCGGATCGCAGGCTGCAACCCGCCTGCGTGAAGTCGGAATCGCTAGTAATCG
[0945] CGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCA
[0946] TGAGAGTCGGGAACACCCGAAGTCCGTAGCCTAACCGCAAGGAGGGCGCGGCCGAAGGTG
[0947] GGTTCGATAATTGGGGTGAAGTCGTAACAAGGTAACCG
[0948] HMI_39 Ruminococcus_obeum 16S rDNA sequence (SEQ ID NO:38)
[0949] AGTCGAACGGGAACCTTTTATTGAAGCTTCGGCAGATTTAGCTGGTTTCTAGTGGCGGAC
[0950] GGGTGAGTAACGCGTGGGTAACCTGCCCTATACAGGGGGATAACAACCAGAAATGGTTGC
[0951] TAATACCGCATAAGCGCACAGGACCGCATGGTCCGGTGTGAAAAACTCCGGTGGTATAGG
[0952] ATGGACCCGCGTTGGATTAGCCAGTTGGCAGGGTAACGGCCTACCAAAGCGACGATCCAT
[0953] AGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGG
[0954] GAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGA
[0955] AGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGATATGACGGTACCTGA
[0956] CTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTT
[0957] ATCCGGATTACTGGGTGTAAAGGGAGCGTAGACGGATTAGCAAGTCTGATGTGAAAGGC
[0958] AGGGGCTCAACCCCTGGACTGCATTGGAAACTGCCAGTCTTGAGTGCCGGAGAGGTAAGC
[0959] GGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGC
[0960] GGCTTACTGGACGGCAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTA
[0961] TACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTTGGGGAGCAAAGCTCTTCG
[0962] GTGCCGCCGCAAACGCATTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTC
[0963] AAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGC
[0964] GAAGAACCTTACCAAGTCTTGACATCCCTCTGACGGACTCTTAACCGAGTCTTTCCTTCG
[0965] GGACAGAGGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTA
[0966] AGTCCCGCAACGAGCGCAACCCCTATCCCCAGTAGCCAGCATTTCGGATGGGCACTCTGA
[0967] GGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTT
[0968] ATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCTGCGAGGG
[0969] TAAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGA
[0970] AGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTG
[0971] TACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCTAACCGCA
[0972] AGGGAGGAGCTGCCGAAGGCGGGACCGATGACTGGGGTGAAGTCGTAACAAGGTAACCGT
[0973] GACTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGAATACGTTCC
[0974] CGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACC
[0975] TAACCGCAAGGAAGGAGCTGCCGAAGGCGGGACCGATGACTGGGGTGAAGTCGTAACA
[0976] HMI_40 Megasphaera elsdenii 16S rDNA sequence (SEQ ID NO: 39)
[0977] ACGCGTAAGCAACCTGCCCTCCGGATGGGGACAACAGCTGGAAACGGCTGCTAATACCGA
[0978] ATACGTTTCCATTGCCGCATGGCAGTGGGAAGAAAGGTGGCCTCTGAATATGCTACCGCC
[0979] GGGGGAGGGGCTTGCGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGA
[0980] TCAGTAGCCGGTCTGAGAGGATGAACGGCCACATTGGAACTGAGACACGGTCCAGACTCC
[0981] TACGGGAGGCAGCAGTGGGGAATCTTCCGCAATGGGCGAAAGCCTGACGGAGCAACGCCG
[0982] CGTGAGCGAAGACGGCCTTCGGGTTGTAAAGCTCTGTTATACGGGACGAACGGCTAGTGT
[0983] GCCAATACCACATTAGAATGACGGTACCGTAAGAGAAAGCCACGGCTAACTACGTGCCAG
[0984] CAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCGCG
[0985] CAGGCGGTTTCATAAGTCTGTCTTAAAAGTGCGGGGCTTAACCCCGTGAGGGGACGGAAA
[0986] CTGTGAGACTGGAGTGTCGGAGAGGAAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTA
[0987] GATATTAGGAGGAACACCAGTGGCGAAAGCGGCTTTCTGGACGACAACTGACGCTGAGGC
[0988] GCGAAAGCCAGGGGAGCGAACGGGATTAGATACCCCGGTAGTCCTGGCCGTAAACGATGG
[0989] ATACTAGGTGTAGGGGGTATCGACCCCTCCTGTGCCGGAGTTAACGCAATAAGTATCCCG
[0990] CCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCG
[0991] GTGGAGTATGTGGTTTAATTCGACGCAACGCGAAGAACCTTACCAAGCCTTGACATTGAG
[0992] TGCTATCCTCAGAGATGAGGAGTTCTTCTTCGGAAGACGCGAAAACAGGTGGTGCACGGC
[0993] TGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATC
[0994] TTCTGTTGCCAGCGCGTCATGGCGGGGACTCAGGAGAGACTGCCGCAGACAATGCGGAGG
[0995] AAGGCGGGGATGACGTCAAGTCATCATGCCCCTTATGGCTTGGGCTACACACGTACTACA
[0996] ATGGCTCTTAATAGAGGGAAGCGAAGGAGCGATCCGGAGCAAACCCCAAAAACAGAGTCC
[0997] CAGTTCGGATTGCAGGCTGCAACCCGCCTGCATGAAGCAGGAATCGCTAGTAATCGCAGG
[0998] TCAGCATACTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCACGAA
[0999] AGTCATTCACACCCGAAGCCGGTGAGGTAACCGTAAGGAGCCAGCCGTCGAAGGTGGGGG
[1000] CGATGATTGGGGTGAAGTCGTAA
[1001] HMI_41 Blautia_luti 16S rDNA sequence (SEQ ID NO:40)
[1002] GGTGAGTAACGCGTGGTAACCTGCCTTATACAGGGGATAACAGTCAGAAATGGCTGCT
[1003] AATACCGCATAAGCGCACAGGGCCGCATGGCCCGGTGAAAACTGAGGTGGTATAAGA
[1004] TGGACCCGCGTTGGATTAGCCAGTTGGCAGGGTAACGGCCTACCAAAGCGACGATCCATA
[1005] GCCGGCCTGAGGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGG
[1006] AGGCAGCAGTGGGGAATATTGCACAATGGGGAAACCCTGATGCAGCGACGCCGCGTGAA
[1007] GGAAAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAAAAATGACGGTACCTGAC
[1008] TAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTA
[1009] TCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGCATAACAAGTCTGATGTGAAAGGCT
[1010] GGGGCTTAACCCCGGGACTGCATTGGAAACTGTTAAGCTTGAGTGCCGGAGGGGTAAGCG
[1011] GAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCG
[1012] GCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGAT
[1013] ACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCGGGGAGCACAGCTCTTCGG
[1014] TGCCGCCGCAAACGCATTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCA
[1015] AAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCG
[1016] AAGAACCTTACCAAGTCTTGACATCTGCCTGACCGGTGAGTAACGTCACCTTTCCTTCGG
[1017] GACAGGCAAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAA
[1018] GTCCCGCAACGAGCGCAACCCCTATCCCCAGTAGCCAGCATGTAAAGGTGGGCACTCTGA
[1019] GGAGACTGCCAGGGATAACCTGGAGGAAGGTGGGATGACGTCAAATCATCATGCCCCTT
[1020] ATGATTTGGGCTACACCGTGCTACAATGGCGTAAACAGAGGAAGCGAAAGGGTGACCT
[1021] GGAGCAAATCCCAAAAAATAACGTCCCAGTTCGGACTGTAGTCTGCAACCCGACTACACGA
[1022] AGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGATACGTTCCCGGGTCTTG
[1023] TACACACCGCCCGTCACACATGGGAGTCAGTAACGCCGAAGTCAGTGACCTAACCGAA
[1024] AGGGAGGAGCTGCCGAAGGCGGGACGGATGACTGGGGTGAAGTCGTAAC
[1025] HMI_42 Bacteroides coprocola 16S rDNA sequence (SEQ ID NO:41)
[1026] GTATCCAACCTTCCGTTTACTCAGGGATAGCCTTTCGAAAGAAAGATTAATACCTGATAG
[1027] TATGGTAAGATTGCATGATAATACCATTAAAGATTCATCGGTAAACGATGGGGATGCGTT
[1028] CCATTAGGTAGTAGGCGGGGTAACGGCCCACCTAGCCGACGATGGATAGGGGTTCTGAGA
[1029] GGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAGCAGTGA
[1030] GGAATATTGGTCAATGGGCGAGAGCCTGAACCAGCCAAGTAGCGTGAAGGATGAAGGTTC
[1031] TATGGATTGTAAACTTCTTTTATAAGGGAATAAAGTGCTTTACGTGTAGAGTTTTGTATG
[1032] TACCTTATGAATAAGCATCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGATGC
[1033] GAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGACGGGATGTTAAGTCAGCTGT
[1034] GAAAGTTTGGGGCTCAACCTTAAAATTGCAGTTGAAACTGGCGTTCTTGAGTGCGGTAGA
[1035] GGCAGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACCCCGATTG
[1036] CGAAGGCAGCTTGCTGGAGCGTAACTGACGTTGATGCTCGAAAGTGTGGGTATCAAACAG
[1037] GATTAGATACCCTGGTAGTCCACACGGTAAACGATGGATACTCGCTGTTGGCGATATACG
[1038] GTCAGCGGCCAAGCGAAAGCATTAAGTATCCCACCTGGGGAGTACGCCGGCAACGGTGAA
[1039] ACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTCGATGAT
[1040] ACGCGAGGAACCTTACCCGGGCTTAAATTATGCATGAATGATCTGGAGACAGATCAGCCG
[1041] CAAGGCATGTATGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTGTCGGCTT
[1042] AAGTGCCATAACGAGCGCAACCCTTTCTGCCAGTTACTAACAGGCAATGCTGAGGACTCT
[1043] GGCGGTACTGCCATCGTAAGATGTGAGGAAGGTGGGGATGACGTCAAATCAGCACGGCCC
[1044] TTACGTCCGGGGCTACACACGTGTTACAATGGGGGGTACAGAAGGCAGCTTACCGGCGAC
[1045] GGTTGGCCAATCCCTAAAGCCCCTCTCAGTTCGGACTGGAGTCTGCAACCCGACTCCACG
[1046] AAGCTGGATTCGCTAGTAATCGCGCATCAGCCACGGCGCGGTGAATACGTTCCCGGGCCT
[1047] TGTACACACCGCCCGTCAAGCCATGAAAGCCGGGAGTACCTGAAGTGCGTAACCGCGAGG
[1048] AGCGCCCTAGGGTAACACTGGTAATTGGGGCTAAGTCGT
[1049] HMI_43 Bacteroides plebius 16S rDNA sequence (SEQ ID NO:42)
[1050] GGGGCAGCATGAACTTAGCTTGCTAAGTTCGATGGCGACCGGCGCACCGTTGAGTAACGC
[1051] GTATCCAACCTTCCGTACACTCAGGAATAGCCTTTCGAAAGAAAGATTAATACCTGATGG
[1052] TATGATGGGATTGCATGAAATCATCATTAAAGATTCATCGGTGTACGATGGGGATGCGTT
[1053] CCATTAGATAGTAGGCGGGGTAACGGCCCACCTAGTCGACGATGGATAGGGGTTCTGAGA
[1054] GGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAGCAGTGA
[1055] GGAATATTGGTCAATGGGCGCGAGCCTGAACCAGCCAAGTAGCGTGAAGGATGAAGGTCC
[1056] TACGGATTGTAAACTTCTTTTATAAGGGAATAAAGTCACCCACGTGTGGGTGTTTGTATG
[1057] TACCTTATGAATAAGCATCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGATGC
[1058] GAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGACGGGTCGTTAAGTCAGCTGT
[1059] GAAAGTTCGGGGCTCAACCTTGAAATTGCAGTTGATACTGGCGTCCTTGAGTACGGTTGA
[1060] GGCAGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACCCCGATTG
[1061] CGAAGGCAGCCTGCTAAACCGCCACTGACGTTGAGGCTCGAAAGTGTGGGTATCAAACAG
[1062] GATTAGATACCCTGGTAGTCCACACGGTAAACGATGGATACTCGCTGTTGGCGATAGACT
[1063] GTCAGCGGCTTAGCGAAAGCGTTAAGTATCCCACCTGGGGAGTACGCCGGCAACGGTGAA
[1064] ACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTCGATGAT
[1065] ACGCGAGGAACCTTACCCGGGCTTGAATTGCAGACGAATTGCTTGGAAACAGGCAAGCCG
[1066] CAAGGCGTCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTGTCGGCTT
[1067] AAGTGCCATAACGAGCGCAACCCTCGTGTCCAGTTGCTAGCAGGTAGTGCTGAGGACTCT
[1068] GGACAGACTGCCATCGTAAGATGTGAGGAAGGTGGGGATGACGTCAAATCAGCACGGCCC
[1069] TTACGTCCGGGGCTACACACGTGTTACAATGGGGGGTACAGCAGGCAGCTACCGGGCGAC
[1070] CGGATGCCAATCCCGAAAGCCTCTCTCAGTTCGGACTGGAGTCTGCAACCCGACTCCACG
[1071] AAGCTGGATTCGCTAGTAATCGCGCATCAGCCACGGCGCGGTGAATACGTTCCCGGGCCT
[1072] TGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGTACCTGAAGTGCGTAACCGCAAGG
[1073] AGCGCCCTAGGGTAAAACTGGTAATT
[1074] HMI_44 Roseburia inulinivorans 16S rDNA sequence (SEQ ID NO:43)
[1075] GCACTTTTGCCGATTTTCTTCGGAACTGAAGTAATAGTGACTGAGTGGCGGACGGGTGAG
[1076] TAACGCGTGGATAACCTGCCTCACACAGGGGGATAACAGTTAGAAATGACTGCTAATACC
[1077] GCATAAGCGCACAGTACCGCATGGTACAGTGTGAAAAACTCCGGTGGTGTGAGATGGATC
[1078] CGCGTCTGATTAGCCAGTTGGCGGGGTAACGGCCCACCAAAGCGACGATCAGTAGCCGGC
[1079] CTGAGAGGGCGACCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAG
[1080] CAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGCGAAGA
[1081] AGTATTTCGGTATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAA
[1082] GCTCCGGCTAAATACGTGCCAGCAGCCGCGGTAATACGTATGGAGCAAGCGTTATCCGGA
[1083] TTTACTGGGTGTAAAGGGAGCGCAGGCGGTATGACAAGTCTGATGTGAAAGGCTGGGGCT
[1084] CAACCCCAGGACTGCATTGGAAACTGTCAGACTAGAGTGTCGGAGAGGTAAGTGGAATTC
[1085] CTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTAC
[1086] TGGACGACAACTGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTG
[1087] GTAGTCCACGCCGTAAACGATGAATACTAGGTGTCGGGAGGCAGAGCCTTTCGGTGCCGC
[1088] AGCAAACGCAGTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAA
[1089] TTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAAC
[1090] CTTACCAGGCCTTGACATCCCCCTGACGGGACAGTAATGTGTCCGTTCCTTCGGGACAGA
[1091] GGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCG
[1092] CAACGAGCGCAACCCTTATCCTCAGTAGCCAGCGGATAAAGCCGGGCACTCTGTGGAGAC
[1093] TGCCAGGGACAACCTGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGGCC
[1094] TGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAAGCTGTGAAGTGAAGCA
[1095] AATCCCAAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGG
[1096] AATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACA
[1097] CCGCCCGTCACACCATGGGAGTCGGGAATGCCCGAAGCCGGTGACCCAACCTTAAGGAGG
[1098] GAGCCGTCGAAGGCAGGCCTGATAACTGGGGTGAAGTCGT
[1099] HMI_45 Ruminococcus albus 16S rDNA sequence (SEQ ID NO: 44)
[1100] CTGATCTAGTGGCGGACGGGTGAGTAACACGTGAGCAATCTGCCTTTCAGAGGGGGATAC
[1101] CGATTGGAAACGATCGTTAATACCGCATAACATAATTGAACCGCATGATTTGATTATCAA
[1102] AGATTTATCGCTGAAAGATGAGCTCGCGTCTGATTAGCTAGTTGGTAAGGTAACGGCTTA
[1103] CCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGATCGGCCACATTGGGACTGAGACAC
[1104] GGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGAGGAAACTCTGAT
[1105] GCAGCGATGCCGCGTGAGGGAAGAAGGTTTTAGGATTGTAAACCTCTGTCTTCAGGGACG
[1106] AAAAAAGACGGTACCTGAGGAGGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAAT
[1107] ACGTAGGGAGCGAGCGTTGTCCGGAATTACTGGGTGTAAAGGGAGCGTAGGCGGGATCGC
[1108] AAGTCAGATGTGAAAACTATGGGCTTAACCCATAAACTGCATTTGAAACTGTGGTTCTTG
[1109] AGTGAAGTAGAGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGG
[1110] AACATCAGTGGCGAAGGCGGCTTACTGGGCTTTAACTGACGCTGAGGCTCGAAAGCGTGG
[1111] GGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGATTACTAGGTGTG
[1112] GGGGGACTGACCCCTTCCGTGCCGCAGCAAACGCAATAAGTAATCCACCTGGGGAGTACG
[1113] ACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGTGGAGTATGTGG
[1114] ATTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCGTATGCATAGCTCAGA
[1115] GATGAGTGAAATCTCTTCGGAGACATATAGACAGGTGGTGCATGGTTGTCGTCAGCTCGT
[1116] GTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTACTGTTAGTTGCTACGC
[1117] AAGAGCACTCTAGCAGGACTGCCGTTGACAAAACGGAGGAAGGTGGGGATGACGTCAAAT
[1118] CATCATGCCCCTTATGACCTGGGCCTCACACGTACTACAATGGCTGTTAACAGAGGGATG
[1119] CAAAGCCGCGAGGTAGAGCGAACCCCTAAAAGCAGTCTTAGTTCGGATTGTAGGCTGCAA
[1120] CCCGCCTACATGAAGTCGGAATTGCTAGTAATCGCAGATCAGCATGCTGCGGTGAATACG
[1121] TTCCCGGGCCTTGTACACACCGCCCGTCACGCCATGGGAGTCGGTAACACCCGAAGCCTG
[1122] TAGTCTAACCGCAAGGAGGACGCAGTCGAAGGTGGGATTGATGACTGGGGTGAAGTCGTA
[1123] ACAGGGTAACCG
[1124] HMI_46 Blautia producta 16S rDNA sequence (SEQ ID NO:45)
[1125] TGGACAGATTCTTCGGATGAAGTCCTTAGTGACTGAGTGGCGGACGGGTGAGTAACGCGT
[1126] GGGTAACCTGCCTCATACAGGGGGATAACAGTTAGAAATGGCTGCTAATACCGCATAAGC
[1127] GCACGGTACTGCATGGTACAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTTGG
[1128] ATTAGCTAGTTGGCAGGGTAACGGCCTACCAAGGCGACGATCCATAGCCGGCCTGAGAGG
[1129] GTGGACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGG
[1130] AATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAGCGAAGAAGTATTTC
[1131] GGTATGTAAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGC
[1132] TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGG
[1133] GTGTAAAGGGAGCGTAGACGGAATGGCAAGTCTGATGTGAAAGGCCGGGGCTCAACCCCG
[1134] GGACTGCATTGGAAACTGTCAATCTAGAGTACCGGAGGGGTAAGTGGAATTCCTAGTGTA
[1135] GCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGT
[1136] AACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA
[1137] CGCCGTAAACGATGAATACTAGGTGTTGGGGAGCAAAGCTCTTCGGTGCCGCAGCAAACG
[1138] CAATAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGG
[1139] GACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAA
[1140] ATCTTGACATCGATCTGACCGGACTGTAATGAGTCCTTTCCCTTCGGGGACAGAGAAGAC
[1141] AGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGA
[1142] GCGCAACCCTTATCCTCAGTAGCCAGCAAGTGAAGTTGGGCACTCTGTGGAGACTGCCAG
[1143] GGATAACCTGGAGGAAGGTGGGATGACGTCAAATCATCATGCCCCTTATGATTTGGGCT
[1144] ACACACGTGCTACAATGGCGTAACAAAGGGAAGCGATCACGCGAGTGTGAGCAAATCTC
[1145] AAAAATAACGTCTCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGCTGGAATCGC
[1146] TAGTAATCGCGAGGTCAGCATACTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCC
[1147] GTCACACCATGGGAGTCAGTAACACCCGAAGCCGGTGACCTAACCGAAAGGAAGGAGCCG
[1148] TCGAAGGTGGGACCGATAACTGGGGTGAAGTCGT
[1149] HMI_47 is the 16S rDNA sequence of Clostridium tumefaciens (SEQ ID NO: 46)
[1150] GTTTGTGACTTAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTTATACAGGGGG
[1151] ATAACAGTTAGAAATGACTGCTAATACCGCATAAGCGCACAGTCTCGCATGGGACAGTGT
[1152] GAAAAAACTAGGTGGTTAAGATGGACCCGCGTCTGATTAGCTAGTTGGTGGGGTAAGG
[1153] CCTACCAAGGCGACGATCAGTAGCCGACCTGAGAGGGTGATCGGCCACATTGGGACTGAG
[1154] ACACGGCCCAAACTCCTACGGGAGGCAGCAGTGGGGGAATATTGCACAATGGGGGAAACCC
[1155] TGATGCAGCAACGCCGCGTGAAGGAAGTATCTCGGTATGTAAACTTCTATCAGCAGG
[1156] GAAGAAAATGACGGTACCTGACTAAGAAGCTCCGGCTAAATACGTGCCAGCAGCCCGCGGT
[1157] AATACGTATGGAGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGGCGGTTA
[1158] TGCAAGTCAGATGTGAAAGCCCGGGGCTTAACCCGGGACTGCATTTGAAACTGTGTAAC
[1159] TAGAGTGTCGGGAGGTAAGTGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGG
[1160] AGGAACACCAGTGCGAAGGCGGCTACTGGACGATAACTGACGCTGAGGCTCGAAAGCG
[1161] TGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATCTAGGT
[1162] GTTGGGGAGCAAAGCTCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGGGAGT
[1163] ACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATG
[1164] TGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCTGGATGACCGGAC
[1165] CGTAATGGGTCCTTTCCTTCGGGACATCCAAGACAGGTGGTGCATGGTTGTCGTCAGCTC
[1166] GTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTAGTAGCCAG
[1167] CAGTAAGATGGGCACTCTAGGGAGACTGCCGGAGACAATCCGGAGGAAGGTGGGGATGAC
[1168] GTCAAATCATCATGCCCCTTATGACTTGGGCTACACCGTGCTACAATGGCGTAAAAAA
[1169] GGGAAGCGAGACCGCGAGGTTAAGCAAATCTCAAAATAACGTCTCAGTTCGGATTGTAG
[1170] TCTGCAACTCGACTACATGAAGCTGGAATCGCTAGTAATCGCGAATCAGCATGTCGCGGT
[1171] GAATACGTTCCCGGGTCTTGTACACACCGCCCGTCAACCATGGGAGTCGATAACGCCCG
[1172] AAGCCGGTGACTCAACCGAAAGGAGAGAGCCGTCGAAGGCGGGATGGATAACTGGGGTGA
[1173] AGTCGTAAC
[1174] HMI_48 Butyricicoccus pullicaecorum 16S rDNA sequence (SEQ ID NO:47)
[1175] ATCTCTTCGGAGATGGAATTCTTAACCTAGTGGCGGACGGGGTGAGTAACGCGTGAGCAAT
[1176] CTGCCTTTAGGAGGGGGATAACAGTCGGAAACGGCTGCTAATACCGCATAATACGTTTGG
[1177] GAGGCATCTCTTGAACGTCAAAGATTTTATCGCCTTTAGATGAGCTCGCGTCTGATTAGC
[1178] TGGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGAAC
[1179] GGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATT
[1180] GCGCAATGGGGGAAACCCTGACGCAGCAACGCCGCGTGATTGAAGAAGGCCTTCGGGTTG
[1181] TAAAGATCTTTAATCAGGGACGAAAAATGACGGTACCTGAAGAATAAGCTCCGGCTAACT
[1182] ACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCAAGCGTTATCCGGATTTACTGGGTGTA
[1183] AAGGGCGCGCAGGCGGGCCGGCAAGTTGGGAGTGAAATCCCGGGGCTTAACCCCGGAACT
[1184] GCTTTCAAAACTGCTGGTCTTGAGTGATGGAGAGGCAGGCGGAATTCCGTGTGTAGCGGT
[1185] GAAATGCGTAGATATACGGAGGAACACCAGTGGCGAAGGCGGCCTGCTGGACATTAACTG
[1186] ACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCG
[1187] TAAACGATGGATACTAGGTGTGGGAGGTATTGACCCCTTCCGTGCCGCAGTTAACACAAT
[1188] AAGTATCCCACCTGGGGAGTACGGCCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCC
[1189] CGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCT
[1190] TGACATCCCGATGACCGGCGTAGAGATACGCCCTCTCTTCGGAGCATCGGTGACAGGTGG
[1191] TGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA
[1192] CCCTTACGGTTAGTTGATACGCAAGATCACTCTAGCCGGACTGCCGTTGACAAAACGGAG
[1193] GAAGGTGGGGACGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTACTAC
[1194] AATGGCAGTCATACAGAGGGAAGCAATACCGCGAGGTGGAGCAAATCCCTAAAAGCTGTC
[1195] CCAGTTCAGATTGCAGGCTGCAACCCGCCTGCATGAAGTCGGAATTGCTAGTAATCGCGG
[1196] ATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGA
[1197] GAGCCGTCAATACCCGAAGTCCGTAGCCTAACCGCAAGGGGGGCGCGGCCGAAGGTAGGG
[1198] GTGGTAATTAGGGTGAAGTCGTAC
[1199] HMI_49 Ruminococcus flavefaciens 16S rDNA sequence (SEQ ID NO:48)
[1200] AGTCGACGGACGAGGAGGAGCTTGCTTCTCCGAGTTAGTGGCGGACGGGTGAGTAACACG
[1201] TGAGCAACCTACCCTTGAGAGGGGGATAGCTTCTGGAAACGGATGGTAATACCCCATAAC
[1202] ATATATTTTAGGCATCTAAGATATATCAAAGAAATTCGCTCAAGGATGGGCTCGCGTCTG
[1203] ATTAGATAGTTGGTGAGGTAACGGCCCACCAAGTCGACGATCAGTAGCCGGACTGAGAGG
[1204] TTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGG
[1205] AATATTGCACAATGGGGGGAACCCTGATGCAGCGATGCCGCGTGGAGGAAGAAGGTTTTC
[1206] GGATTGTAAACTCCTTTTAACAGGGACGATAATGACGGTACCTGAAGAAAAAGCTCCGGC
[1207] TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTGTCCGGAATTACTGG
[1208] GTGTAAAGGGAGCGTAGGCGGGACGGTAAGTCAGGTGTGAAATATACGTGCTCAACATGT
[1209] AGACTGCACTTGAAACTGCTGTTCTTGAGTGAAGTAGAGGTAAGCGGAATTCCTAGTGTA
[1210] GCGGTGAAATGCGTAGATATTAGGAGGAACATCGGTGGCGAAGGCGGCTTACTGGGCTTT
[1211] TACTGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA
[1212] CGCTGTAAACGATGATTACTAGGTGTGGGGGGACTGACCCCTTCCGTGCCGCAGTTAACA
[1213] CAATAAGTAATCCACCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGG
[1214] GGCCCGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAG
[1215] GTCTTGACATCGTATGCATAGTCTAGAGATAGATGAAATCCCTTCGGGGACATATAGACA
[1216] GGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG
[1217] CGCAACCCTTACCTTTAGTTGCTACGCAAGAGCACTCTAGAGGGACTGCCGTTGACAAAA
[1218] CGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGT
[1219] ACTACAATGGCAATTAACAGAGGGAAGCAAAACAGCGATGTGGAGCAAATCCCGAAAAAT
[1220] TGTCCCAGTTCAGATTGCAGGCTGCAACTCGCCTGCATGAAGTCGGAATTGCTAGTAATC
[1221] GCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACC
[1222] ATGGGAGTCGGTAACACCCGAAGCCTGTAGTCTAACCTTATAGGAGGACGCAGTCGAAGG
[1223] TGGGATTGATGACTGGGGTGAAGTCGT
[1224] HMI_50 Clostridium orbiscindens 16S rDNA sequence (SEQ ID NO:49)
[1225] AAAGGGAATGCTTAGTGGCGGACGGGTGAGTAACGCGTGAGTAACCTGCCTTGGAGTGGG
[1226] GAATAACAGCCGGAAACGGCTGCTAATACCGCATGATGTATCTGGATCGCATGGTTCTGG
[1227] ATACCAAAGATTTATCGCTCTGAGATGGACTCGCGTCTGATTAGCTAGTTGGTGAGGTAA
[1228] CGGCTCACCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGGCCGGCCACATTGGGACT
[1229] GAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGGGCAATGGGCGAAA
[1230] GCCTGACCCAGCAACGCCGCGTGAAGGAAGAAGGCCCTCGGGTTGTAAACTTCTTTTGTC
[1231] AGGGACGAAGCAAGTGACGGTACCTGACGAATAAGCCACGGCTAACTACGTGCCAGCAGC
[1232] CGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGCGTGTAGG
[1233] CGGGAGTGCAAGTCAGATGTGAAAACTATGGGCTCAACCCATAGCCTGCATTTGAAACTG
[1234] TACTTCTTGAGTGATGGAGAGGCAGGCGGAATTCCCTGTGTAGCGGTGAAATGCGTAGAT
[1235] ATAGGGAGGAACACCAGTGGCGAAGGCGGCCTGCTGGACATTAACTGACGCTGAGGCGCG
[1236] AAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGGATA
[1237] CTAGGTGTGGGGGGTCTGACCCCCTCCGTGCCGCAGTTAACACAATAAGTATCCCACCTG
[1238] GGGAGTACGATCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGG
[1239] AGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGACTTGACATCCTACTAA
[1240] CGAAGCAGAGATGCATAAGGTGCCCTTCGGGGAAAGTAGAGACAGGTGGTGCATGGTTGT
[1241] CGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTGTT
[1242] AGTTGCTACGCAAGAGCACTCTAGCGAGACTGCCGTTGACAAAACGGAGGAAGGTGGGGA
[1243] CGACGTCAAATCATCATGCCCCTTATGTCCTGGGCCACACACGTACTACAATGGCGGTCA
[1244] ACAGAGGGAAGCAAAGCCGCGAGGTGGAGCAAATCCCTAAAAGCCGTCCCAGTTCGGATT
[1245] GCAGGCTGAAACTCGCCTGTATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCG
[1246] CGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTCGGGAACA
[1247] CCCGAAGTCCGTAGCCTAACAGCAATGGG
[1248] HMI_51 Ruminococcus_bromii_16S rDNA sequence (SEQ ID NO:50)
[1249] ACGAAGCTTTGAGGAGCTTGCTTTTTAAGCTTAGTGGCGGACGGGTGAGTAACGCGTGAG
[1250] CAACCTGCCTCTCAGAGGGGAATAACGTTTTGAAAAGAACGCTAATACCGCATAACATAT
[1251] CGGAACCGCATGATTCTGATATCAAAGGAGCAATCCGCTGAGAGATGGGCTCGCGTCCGA
[1252] TTAGTTAGTTGGTGAGGTAACGGCTCACCAAGACTACGATCGGTAGCCGGACTGAGAGGT
[1253] TGATCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGG
[1254] ATATTGCGCAATGGGGGAAACCCTGACGCAGCAACGCCGCGTGAAGGAAGAAGGTCTTCG
[1255] GATTGTAAACTTCTTTTGTCAGGGACGAAGAAAGTGACGGTACCTGACGAATAAGCTCCG
[1256] GCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTGTCCGGATTTACT
[1257] GGGTGTAAAGGGTGCGTAGGCGGCCGAGCAAGTCAGTTGTGAAAACTATGGGCTTAACCC
[1258] ATAACGTGCAATTGAAACTGTCCGGCTTGAGTGAAGTAGAGGTAGGCGGAATTCCCGGTG
[1259] TAGCGGTGAAATGCGTAGAGATCGGGAGGAACACCAGTGGCGAAGGCGGCCTACTGGGCT
[1260] TTAACTGACGCTGAGGCACGAAAGCATGGGTAGCAAACAGGATTAGATACCCTGGTAGTC
[1261] CATGCCGTAAACGATGATTACTAGGTGTGGGGGGACTGACCCCTTCCGTGCCGCAGTTAA
[1262] CACAATAAGTAATCCACCTGGGGAGTACGGCCGCAAGGTTGAAACTCAAAGGAATTGACG
[1263] GGGGCCCGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACC
[1264] AGGTCTTGACATCCTGAGAATCCTTAAGAGATTAGGGAGTGCCTTCGGGAACTCAGAGAC
[1265] AGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGA
[1266] GCGCAACCCTTGCTATTAGTTGCTACGCAAGAGCACTCTAATAGGACTGCCGTTGACAAA
[1267] ACGGAGGAAGGTGGGGACGACGTCCAAATCATCATGCCCCTTATGACCTGGGCTACACACG
[1268] TACTACAATGGCATTAACAGAGGGAAGCAAAACCGCGAGGCAGAGCAAACCCCTAAAAA
[1269] TGGTCCCAGTTCGGATTGTAGGCTGCAACCCGCCTACATGAAGTTGGAATTGCTAGTAAT
[1270] CGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACAC
[1271] CATGGGAGCCGGTAATACCCGAAGTCAGTAGTCTAACAGCAATGAGGACGCTGCCGAAGG
[1272] TAGGATTGGCGACTGGGGTGAAGTCGTAACAAGGTAACCG
[1273] HMI_52 Ruminococcus albus 926R 16S rDNA sequence (SEQ ID NO: 51)
[1274] AGAGTTTGATCCTGGCTCAGGACGACGCTGGCGGCACGCTTAACACATGCAAGTCGAAC
[1275] GAGAGAAGAGAAGCTTGCTTTTCTGATCTAGTGGCGGACGGTGAGTAACACGTGAGCAA
[1276] TCTGCCTTTCAGAGGGGGATACCGATTGGAAACGATCGTTAATACCGCATAACATAATTG
[1277] AACCGCATGATTTGATTATCAAAGATTTATCGCTGAAAGATGAGCTCGCGTCTGATTAGC
[1278] TAGTTGGTAAGGTAACGGCTTACCAAGGCGACGATCAGTAGCCGGACTGAGAGGTTGATC
[1279] GGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATT
[1280] GCACAATGGAGGAAACTCTGATGCAGCGATGCCGCGTGAGGGAAGAAGGTTTTTAGGATTG
[1281] TAAACCTCTGTCTTCAGGGACGAAAAAAAAAGCGGTACCTGAGGAGGAAGCTCCGGCTAA
[1282] CTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTGTCCGGAATTACTGGGGTG
[1283] TAAAGGGAGCGTAGGCGGGATCGCAAGTCAGATGTGAAAAACTATGGGCTTAACCCATAAA
[1284] CTGCATTTGAAACTGTGGTTCTTGAGTGAAAGTAGGGTAAGCGGAATTCCTAGTGTAGCG
[1285] GTGAAATGCGTAGATATTAGGAGGAACATCAGTGGCGAAGGCGGCTTACTGGGCTTTAAC
[1286] TGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGC
[1287] CGTAAACGATGATTACTAGGTGTGGGGGGACTGACCCCTTCCGTGCCGCAGCAAACGCAA
[1288] TAAGTAATCCACCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGC
[1289] CCGCACAAGCAGTGGAGTATGTGGATTAATTCGAAGCAACGCGAAGAACCTTACCAGGTC
[1290] TTGACATCGTATGCATAGCTCAGAGATGAGTGAAATCTCTTCGGAGACATATAGACAGGT
[1291] GGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGC
[1292] AACCCTTACTGTTAGTTGCTACGCAAGAGCACTCTAGCAGGACTGCCGTTGACAAAACGG
[1293] AGGAAGGTGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCCTCACACGTACT
[1294] ACAATGGCTGTCAACAGAGGGATGCAAAGCCGCGAGGTGGAGCGAACCCCTAAAAGCAGT
[1295] CTTAGTTCGGATTGTAGGCTGCAACCCGCCTACATGAAGTCGGAATTGCTAGTAATCGCA
[1296] GATCAGCATGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGCCATG
[1297] GGAGTCGGTAACACCCGAAGCCTGTAGTCTAACCGCAAGGAGGAGCAGTCGAAGGTGGG
[1298] ATTGATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTATCGGAAGGTGCG
[1299] References
[1300] Check out the rest of the door in the doorway.
[1301] Abecasis, AB, M. Serrano, R. Alves, L. Quintais, JBPereira-Leal and A.O. Henriques(2013).
[1302] Abujamel,T et al.(2013)."Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment ofC.difficile Infection with Oral Vancomycin or Metronidazole."PLoS ONE 8(10):e76269.
[1303] Altschul,S.F.,W.Gish,W.Miller,E.W.Myers and D.J.Lipman(1990)."Basiclocal alignment search tool."Journal of Molecular Biology 215(3):403-410.
[1304] Altschul,S.F.,W.Gish,W.Miller,E.W.Myers and D.J.Lipman(1990)."Basiclocal alignment search tool."J Mol Biol 215(3):403-410.
[1305] Angriman,I.,M.Scarpa and I.Castagliuolo(2014).“Relationship betweenpouch microbiota and pouchitis following restorative proctocolectomy forulcerative colitis.”World J Gastroenterol 20(29):9665-9674.
[1306] Atarashi,K.,T.Tanoue,K.Oshima,W.Suda,Y.Nagano,H.Nishikawa,S.Fukuda,T.Saito,S.Narushima,K.Hase,S.Kim,J.V.Fritz,P.Wilmes,S.Ueha,K.Matsushima,H.Ohno,B.Olle,S.Sakaguchi,T.Taniguchi,H.Morita,M.Hattori and K.Honda(2013).“T reg induction by a rationally selected mixture of Clostridia strains fromthe human microbiota”.Nature500(7461):232-236.
[1307] Blanton,L.V.,M.R.Charbonneau,T.Salih,M.J.Barratt,S.Venkatesh,O.Ilkaveya,S.Subramanian,M.J.Manary,I.Trehan,J.M.Jorgensen,Y.M.Fan,B.Henrissat,S.A.Leyn,D.A.Rodionov,A.L.Osterman,K.M.Maleta,C.B.Newgard,P.Ashorn,K.G.Dewey and J.I.Gordon(2016)."Gut bacteria that prevent growthimpairments transmitted by microbiota from malnourished children."Science 351(6275).
[1308] Bajaj,J.S.(2014).“The role of microbiota in hepatic encephalopathy.”Gut Microbes 5(3):397-403.
[1310] Bajaj,J.S.,P.B.Hylemon and Z.Younossi(2012).“The intestinalmicrobiota and liver disease.”Am J Gastroenterol.Suppl.1:9-14
[1311] Bosshard,P.P.,S.Abels,R.Zbinden,E.C.Bottger and M.Altwegg(2003)."Ribosomal DNA sequencing for identification of aerobic gram-positive rods inthe clinical laboratory(an18-month evaluation)."J Clin Microbiol 41(9):4134-4140.
[1312] Britton, R.A. and V.B. Young (2014). "Role of the intestinal microbiota in resistance to colonization by Clostridium difficile." Gastroenterology 146(6):1547-1553.
[1313] Buffie, C.G., et al. (2015). "Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile." Nature 517(7533):205-208.
[1314] Chakraborty, A., S. Ghosh, G. Chowdhary, U. Maulik and S. Chakrabarti (2012). "DBETH: a Database of Bacterial Exotoxins for Human." Nucleic Acids Res 40(Database issue):D615-620.
[1315] Clarridge, J.E., 3rd (2004). "Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases." Clin Microbiol Rev 17(4):840-862, table of contents.
[1316] Cole, J.R., et al. (2014). "Ribosomal Database Project: data and tools for high throughput rRNA analysis." Nucleic Acids Research 42(D1):D633-D642.
[1317] Collins,S.M.(2014)."A role for the gut microbiota in IBS."Nat RevGastroenterol Hepatol11(8):497-505.
[1318] Cornely,O.A.,M.A.Miller,T.J.Louie,D.W.Crook and S.L.Gorbach(2012)."Treatment of First Recurrence of Clostridium difficile Infection:FidaxomicinVersus Vancomycin."Clinical Infectious Diseases:An Official Publication ofthe Infectious Diseases Society of America 55(Suppl 2):S154-S161.
[1319] Dominguez-Bello,M.G.,E.K.Costello,M.Contreras,M.Magris,G.Hidalgo,N.Fierer and R.Knight(2010)."Delivery mode shapes the acquisition andstructure of the initial microbiota across multiple body habitats innewborns."Proc Natl Acad Sci U S A 107(26):11971-11975.
[1321] Duncan,S.H.,G.L.Hold,H.J.Harmsen,C.S.Stewart and H.J.Flint(2002)."Growth requirements and fermentation products of Fusobacterium prausnitzii,and a proposal to reclassify it as Faecalibacterium prausnitzii gen.nov.,comb.nov."Int J Syst Evol Microbiol52(Pt 6):2141-2146.
[1324] Eckburg,P.B.,E.M.Bik,C.N.Bernstein,E.Purdom,L.Dethlefsen,M.Sargent,S.R.Gill,K.E.Nelson and D.A.Relman(2005)."Diversity of the human intestinalmicrobial flora."Science 308(5728):1635-1638.
[1325] Fodor,A.A.,T.Z.DeSantis,K.M.Wylie,J.H.Badger,Y.Ye,T.Hepburn,P.Hu,E.Sodergren,K.Liolios,H.Huot-Creasy,B.W.Birren and A.M.Earl(2012)."The"mostwanted"taxa from the human microbiome for whole genome sequencing."PLoS One 7(7):e41294.
[1326] Forster,S.C.,H.P.Browne,N.Kumar,M.Hunt,H.Denise,A.Mitchell,R.D.Finnand T.D.Lawley(2015)."HPMCD:the database of human microbial communities frommetagenomic datasets and microbial reference genomes."Nucleic Acids Res.
[1327] Francis,M.B.,C.A.Allen,R.Shrestha and J.A.Sorg(2013)."Bile acidrecognition by the Clostridium difficile germinant receptor,CspC,is importantfor establishing infection."PLoS Pathog 9(5):e1003356.
[1328] Galperin,M.Y.,S.L.Mekhedov,P.Puigbo,S.Smirnov,Y.I.Wolf and D.J.Rigden(2012)."Genomic determinants of sporulation in Bacilli and Clostridia:towardsthe minimal set of sporulation-specific genes."Environ Microbiol 14(11):2870-2890.
[1329] Goodman,A.L.,G.Kallstrom,J.J.Faith,A.Reyes,A.Moore,G.Dantas andJ.I.Gordon(2011)."Extensive personal human gut microbiota culture collectionscharacterized and manipulated in gnotobiotic mice."Proc Natl Acad Sci U S A108(15):6252-6257.
[1330] Hattori,M.and T.D.Taylor(2009)."The human intestinal microbiome:a newfrontier of human biology."DNA Res 16(1):1-12.
[1331] Hold,G.L.,M.Smith,C.Grange,E.R.Watt,E.M.El-Omar and I.Mukhopadhya(2014).
[1332] "Role of the gut microbiota in inflammatory bowel diseasepathogenesis:what have we learnt in the past 10years?"World J Gastroenterol20(5):1192-1210.
[1333] Hooper,L.V.,D.R.Littman and A.J.Macpherson(2012)."Interactionsbetween the microbiota and the immune system."Science 336(6086):1268-1273.
[1334] Hooper,L.V.,M.H.Wong,A.Thelin,L.Hansson,P.G.Falk and J.I.Gordon(2001).
[1335] "Molecular analysis of commensal host-microbial relationships in theintestine."Science291(5505):881-884.
[1336] Huse,S.M.,L.Dethlefsen,J.A.Huber,D.M.Welch,D.A.Relman and M.L.Sogin(2008)."Exploring Microbial Diversity and Taxonomy Using SSU rRNAHypervariable Tag Sequencing."PLoS Genet 4(11):e1000255.
[1337] Janoir,C.,C.Deneve,S.Bouttier,F.Barbut,S.Hoys,L.Caleechum,D.Chapeton-Montes,F.C.Pereira,A.O.Henriques,A.Collignon,M.Monot and B.Dupuy(2013)."Adaptive strategies and pathogenesis of Clostridium difficile fromin vivotranscriptomics."Infect Immun 81(10):3757-3769.
[1338] Johnson, M., I. Zaretskaya, Y. Raytselis, Y. Merezhuk, S. McGinnis and T. L. Madden (2008). "NCBI BLAST: a better web interface." Nucleic Acids Research 36 (Web Server issue): W5-W9.
[1339] Jostins, L., et al. (2012). "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease." Nature 491(7422): 119-124.
[1340] Koenig, J. E., et al. (2011). "Succession of microbial consortia in the developing infant gut microbiome." Proc Natl Acad Sci U S A 108 Suppl 1: 4578-4585.
[1341] Kozich, J. J., S. L. Westcott, N. T. Baxter, S. K. Highlander and P. D. Schloss (2013).
[1342] "Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform." Appl Environ Microbiol 79(17): 5112-5120.
[1343] Lagier,J.C.,P.Hugon,S.Khelaifia,P.E.Fournier,B.La Scola and D.Raoult(2015)."The Rebirth of Culture in Microbiology through the Example ofCulturomics To Study Human Gut Microbiota."Clin Microbiol Rev 28(1):237-264.
[1344] Landy,J.,H.O.Al-Hassi,S.D.McLaughlin,A.W.Walker,P.J.Ciclitira,R.J.Nicholls,S.K.Clark and A.L.Hart(2011)."Review article:faecaltransplantation therapy for gastrointestinal disease."AlimentaryPharmacology&Therapeutics 34(4):409-415.Lawley,T.D.,et al.(2009)."Antibiotictreatment of clostridium difficile carrier mice triggers a supershedderstate,spore-mediated transmission,and severe disease in immunocompromisedhosts."Infect Immun 77(9):3661-3669.
[1345] Lawley,T.D.,et al.(2012)."Targeted restoration of the intestinalmicrobiota with a simple,
[1346] defined bacteriotherapy resolves relapsing Clostridiumdifficiledisease in mice."PLoS Pathog 8(10):e1002995.
[1347] Lawley, T.D. and A.W. Walker (2013). "Intestinal colonization resistance." Immunology 138(1): 1-11.
[1348] Letunic, I. and P. Bork (2011). "Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy." Nucleic Acids Res 39(Web Server issue): W475-478. Louis, P and H.J. Flint (2009). “Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine.” FEMS Microbiol. Lett. 294(1): 1-8. Lozupone, C. and R. Knight (2005). "UniFrac: a New Phylogenetic Method for Comparing Microbial Communities." Applied and Environmental Microbiology 71(12): 8228-8235. Ludwig, W., et al. (2004). "ARB: a software environment for sequence data." Nucleic Acids Res 32(4): 1363-1371.
[1349] McArthur, A.G. et al. (2013). "The comprehensive antibiotic resistance database." Antimicrob Agents Chemother 57(7): 3348-3357.
[1350] Meehan,C.J.and R.G.Beiko(2014)."A phylogenomic view of ecologicalspecialization in the Lachnospiraceae,a family of digestive tract-associatedbacteria."Genome Biol Evol 6(3):703-713.
[1351] Nielsen,H.B.,et al.(2014)."Identification and assembly of genomes andgenetic elements in complex metagenomic samples without using referencegenomes."Nat Biotechnol 32(8):822-828.
[1352] Ottman,N.,H.Smidt,W.M.de Vos and C.Belzer(2012)."The function of ourmicrobiota:who is out there and what do they do?"Front Cell Infect Microbiol2:104.
[1353] Perez Martinez, G., C. Bauerl and M. C. Collado (2014). "Understanding gut microbiota in elderly's health will enable intervention through probiotics." Benef Microbes 5(3): 235 - 246. Petrof, E. O., G. B. Gloor, S. J. Vanner, S. J. Weese, D. Carter, M. C. Daigneault, E. M. Brown, K. Schroeter and E. Allen-Vercoe (2013). "Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut." Microbiome 1(1): 3. Price, M. N., P. S. Dehal and A. P. Arkin (2010). "FastTree 2--approximately maximum-likelihood trees for large alignments." PLoS One 5(3): e9490.
[1354] Pruesse, E., C. Quast, K. Knittel, B. M. Fuchs, W. Ludwig, J. Peplies and F. O. (2007). "SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequences data compatible with ARB." Nucleic acids research 35(21): 7188 - 7196.
[1355] Qin, J., et al. (2010). "A human gut microbial gene catalogue established by metagenomic sequencing." Nature 464(7285): 59 - 65.
[1356] Quince,C.,A.Lanzen,R.Davenport and P.Turnbaugh(2011)."Removing NoiseFrom Pyrosequenced Amplicons."BMC Bioinformatics 12(1):38.
[1357] Rajilic-Stojanovic,M.and W.M.de Vos(2014)."The first 1000culturedspecies of the human gastrointestinal microbiota."FEMS Microbiol Rev 38(5):996-1047.
[1358] Riley,T.V.,J.S.Brazier,H.Hassan,K.Williams and K.D.Phillips(1987)."Comparison of alcohol shock enrichment and selective enrichment for theisolation of Clostridium difficile."Epidemiol Infect 99(2):355-359.
[1359] Scheperjans,F.,et al.(2015)."Gut microbiota are related to Parkinson's disease and clinical phenotype."Mov Disord 30(3):350-358.
[1360] Schloss,P.D.,D.Gevers and S.L.Westcott(2011)."Reducing the Effects ofPCR Amplification and Sequencing Artifacts on 16S rRNA-Based Studies."PLoSONE 6(12):
[1361] e27310.
[1362] Schloss,P.D.,et al.(2009)."Introducing mothur:Open-Source,Platform-Independent,
[1363] Community-Supported Software for Describing and Comparing MicrobialCommunities."Applied and Environmental Microbiology 75(23):7537-7541.
[1364] Schloss,P.D.,et al.(2009)."Introducing mothur:open-source,platform-independent,community-supported software for describing and comparingmicrobial communities."Appl Environ Microbiol 75(23):7537-7541.
[1365] Sekirov,I.,S.L.Russell,L.C.Antunes and B.B.Finlay(2010)."Gutmicrobiota in health and disease."Physiol Rev 90(3):859-904.
[1366] Snyder,A(2014).“Genetic basis for clinical response to CTLA-4blockade in melanoma”.N Engl J Med.371(23):2189-99.
[1367] Stewart,EJ(2012)."Growing unculturable bacteria."J Bacteriol 194(16):4151-4160.van Nood,E.,A.Vrieze,M.Nieuwdorp,S.Fuentes,EGZoetendal,WMde Vos,CEVisser,EJKuijper,JFBartelsman,JGTijssen,P.Speelman,MGDijkgraaf and JJKeller(2013)."Duodenal infusion of donor feces forrecurrent Clostridium difficile."N Engl J Med 368(5):407-415.
[1368] Wang,Q.,GMGarrity,JMTiedje and JRCole(2007)."Naive Bayesianclassifier for rapid assignment of rRNA sequences into the new bacterialtaxonomy."Appl Environ Microbiol 73(16):5261-5267.
[1369] Xu et al.(2015).“Fecal microbiota transplantation broadening itsapplication beyond intestinal disorders”.World J Gastroenterol.21(1):102-111.
[1370] Ze,X.,F.Le Mougen,SHDuncan,P.Louis and HJFlint(2013)."Some aremore equal than others:the role of"keystone"species in the degradation ofrecalcitrant substrates."Gut Microbes 4(3):236-240。
Claims
1. A therapeutic composition comprising at least one isolated bacterium and a pharmaceutically acceptable excipient, wherein the bacterium comprises a gene encoding 16S ribosomal RNA (rRNA), and the gene comprises a sequence having at least 94% sequence identity to SEQ ID NO:40 or at least 93% sequence identity to SEQ ID NO:
34.
2. The therapeutic composition of claim 1, wherein the sequence identity is at least 95%.
3. The therapeutic composition of claim 1, wherein the sequence identity is at least 96%.
4. The therapeutic composition of claim 1, wherein the sequence identity is at least 97%.
5. The therapeutic composition of claim 1, wherein the sequence identity is at least 98%.
6. The therapeutic composition of claim 1, wherein the sequence identity is at least 98.7%.
7. The therapeutic composition of claim 1, wherein the sequence identity is at least 99%.
8. The therapeutic composition of claim 1, wherein the sequence identity is 100%.
9. The therapeutic composition according to any one of claims 1 to 8, wherein the isolated bacterium is a bacterium deposited at the Leibniz-Institut DSMZ under the following accession numbers: DSM32226 or DSM32219.
10. The therapeutic composition according to any one of claims 1 to 8, wherein the composition comprises at least two different isolated bacteria, wherein the at least two isolated bacteria are: a) SEQ ID NO:40 and SEQ ID NO:34; or b) SEQ ID NO: 40 or SEQ ID NO: 34 in combination with at least one bacterium selected from the group consisting of SEQ ID NOs: 1-33, 35-39 and 41-51.
11. The therapeutic composition of any one of claims 1 to 10, wherein the composition is for use in a method of treating gastrointestinal dysbiosis in a subject.
12. The therapeutic composition of claim 11, wherein the dysbiosis is dysbiosis associated with enteric bacterial infection.
13. The therapeutic composition of claim 12, wherein the enteric bacterial infection is a pathogenic bacterial infection.
14. The therapeutic composition of claim 13, wherein the pathogenic bacteria is resistant to treatment with one or more antibiotics.
15. The therapeutic composition of any one of claims 12 to 14, wherein the enteric bacterial infection is a pathogenic bacterial infection of the genus: Clostridium, Escherichia, Enterococcus, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Staphylococcus, Vibrio, Aeromonas, Campylobacter, Bacillus, Helicobacter, Listeria, Plesiomonas, or Yersinia.
16. The therapeutic composition of any one of claims 12 to 15, wherein the enteric bacterial infection is a pathogenic bacterial infection, and wherein the pathogenic bacteria is Clostridium difficile or Escherichia coli.
17. The therapeutic composition of claim 16, wherein the enteric bacterial infection is a pathogenic Clostridium difficile infection.
18. The therapeutic composition of any one of claims 12 to 17, wherein the enteric bacterial infection is a recurrent or chronic infection.
19. The therapeutic composition of claim 11, wherein the dysbiosis is dysbiosis associated with inflammatory bowel disease (IBD) or pimples.
20. The therapeutic composition of claim 19, wherein the IBD is ulcerative colitis (UC) or Crohn's disease.
21. The therapeutic composition of claim 11, wherein the dysbiosis is dysbiosis associated with irritable bowel syndrome (IBS).
22. The therapeutic composition of claim 11, wherein the dysbiosis is a dysbiosis associated with a metabolic disease, a neuropsychiatric disorder, an autoimmune disease, an allergic disease, or cancer.
23. The therapeutic composition of claim 22, wherein the metabolic disease is selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
24. The therapeutic composition of claim 22, wherein the neuropsychiatric disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, multiple sclerosis, myoclonic dystonia, autism and chronic fatigue syndrome.
25. The therapeutic composition of claim 22, wherein the autoimmune disease is selected from the group consisting of idiopathic thrombocytopenic purpura, arthritis, Sjögren's syndrome, systemic lupus erythematosus, and Hashimoto's thyroiditis.
26. The therapeutic composition of claim 22, wherein the allergic disease is selected from the group consisting of atopy and asthma.
27. The therapeutic composition of claim 22, wherein the cancer is selected from the group consisting of colorectal cancer, extraintestinal tumors, breast tumors, hepatocellular carcinoma, lymphoma, melanoma, and lung cancer.
28. The therapeutic composition of claim 11, wherein the dysbiosis is dysbiosis associated with hepatic encephalopathy.
29. The therapeutic composition of any one of claims 1 to 28, wherein the isolated bacteria is a spore-forming bacteria.
30. The therapeutic composition of any one of claims 1 to 29, wherein the isolated bacteria is susceptible to treatment with one or more antibiotics.
31. The therapeutic composition of claim 30, wherein the antibiotic is a beta-lactam, fusidic acid, an alphamycin, an aminoglycoside, fosfomycin and / or tunicamycin.
32. The therapeutic composition of any one of claims 1 to 31, wherein at least one bacterium in the composition has an antagonistic effect on pathogenic enteric bacteria, inhibits or prevents the growth of pathogenic enteric bacteria, or neutralizes or protects against toxins produced by enteric bacteria.
33. The therapeutic composition of claim 32, wherein the pathogenic bacteria is a pathogenic bacteria of the genus: Clostridium, Escherichia, Enterococcus, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Staphylococcus, Vibrio, Aeromonas, Campylobacter, Bacillus, Helicobacter, Listeria, Plesiomonas, or Yersinia.
34. The therapeutic composition of claim 33, wherein the pathogenic bacteria is Clostridium difficile or Escherichia coli.
35. The therapeutic composition of any one of claims 1 to 34, wherein at least one bacterium in the composition has immunomodulatory activity.
36. The therapeutic composition of any one of claims 1 to 35, wherein the composition further comprises a prebiotic.
37. The therapeutic composition of any one of claims 1 to 36, wherein the composition further comprises a carrier.
38. The therapeutic composition of any one of claims 1 to 37, wherein the composition further comprises insoluble fiber, a buffering agent, an osmotic agent, an anti-foaming agent and / or a preservative.
39. The therapeutic composition of any one of claims 1 to 38, wherein the composition is provided in a chemostat medium.
40. The therapeutic composition of any one of claims 1 to 39, wherein the composition is provided in saline, optionally in 0.9% saline.
41. The therapeutic composition of any one of claims 1 to 40, wherein the composition is provided under a reducing atmosphere.
42. The therapeutic composition of claim 41, wherein the composition is under N2, CO2, H2 or a mixture thereof.
43. The therapeutic composition of any one of claims 1 to 42, wherein the composition is for oral or rectal administration.
44. The therapeutic composition of any one of claims 1 to 43, wherein the composition is for oral administration and is lyophilized.
45. The therapeutic composition of claim 44, wherein the composition further comprises a stabilizer and / or a cryoprotectant.
46. The therapeutic composition of any one of claims 1 to 45, wherein the composition is in the form of a capsule, tablet or enema.
47. The therapeutic composition of claim 46, wherein the capsule or tablet is enteric-coated, pH-dependent, sustained-release and / or gastro-resistant.
48. A method for preparing a therapeutic composition according to any one of claims 1 to 10, wherein the method comprises the steps of: (i) culturing the isolated bacterium according to any one of claims 1 to 10; and (ii) mixing the bacteria obtained in (i) with a pharmaceutically acceptable excipient.
49. A method for preparing a therapeutic composition according to 48, wherein the method comprises the following steps: (i) culturing the first isolated bacterium of any one of claims 1 to 10; (i) culturing the second isolated bacterium of any one of claims 1 to 10; and (ii) mixing the bacteria obtained in (i) and (ii) with a pharmaceutically acceptable excipient, wherein the bacteria cultured in steps (i) and (ii) have different 16S rRNA sequences, and wherein steps (i) and (ii) are performed independently.
50. A therapeutic composition obtainable by the method of claim 48 or 49.
51. A therapeutic composition comprising at least one isolated bacterium from the Ruminococcaceae family and a pharmaceutically acceptable excipient, wherein the bacterium from the Ruminococcaceae family comprises a gene encoding 16S ribosomal RNA (rRNA), and the gene comprises a sequence having at least 90% sequence identity to the sequence shown in any one of SEQ ID NO: 12, 3, 4, 5, 6, 30, 35, 37, 44, 47, 48, 49, 50 or 51.
52. A therapeutic composition comprising at least one isolated bacterium from the family Lachnospiraceae and a pharmaceutically acceptable excipient, wherein the bacterium from the family Lachnospiraceae comprises a gene encoding 16S ribosomal RNA (rRNA), and the gene comprises a sequence having at least 90% sequence identity to any one of SEQ ID NO:7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 25, 26, 27, 28, 32, 33, 34, 36, 38, 40, 43, 45 or 46.
53. A therapeutic composition comprising at least one isolated bacterium and a pharmaceutically acceptable excipient, wherein the bacterium comprises a gene encoding 16S ribosomal RNA (rRNA), and the gene comprises a sequence having at least 92% sequence identity to the sequence shown in any one of SEQ ID Nos: 11 and 36; a sequence having at least 93% sequence identity to the sequence shown in any one of SEQ ID Nos: 15, 34, 38, and 43; a sequence having at least 94% sequence identity to the sequence shown in any one of SEQ ID Nos: 13, 17, 18, 27, 40, 45, and 46; a sequence having at least 95% sequence identity to the sequence shown in any one of SEQ ID Nos: 7, 32, and 33; a sequence having at least 96% sequence identity to the sequence shown in any one of SEQ ID Nos: 12 and 16; a sequence having at least 97% sequence identity to the sequence shown in any one of SEQ ID Nos: 8, or a sequence having at least 100% sequence identity to the sequence shown in any one of SEQ ID Nos: 14, 25, 26, and 28.
